Cbl-b inhibitor and use thereof

By developing specific compounds as Cbl-b inhibitors, the inefficiency and specificity problems in Cbl-b-mediated disease treatment are solved, and effective regulation of Cbl-b signaling pathways is achieved, and new therapeutic strategies are provided .

WO2024245264A1PCT designated stage expired Publication Date: 2024-12-05SIMCERE ZAIMING PHARMACEUTICAL CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/095934
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-02-06
Filing Date
2024-05-29
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Cbl-b inhibitors have problems of inefficiency and insufficient specificity in the treatment of Cbl-b-mediated diseases or conditions, and the prior art is difficult to effectively regulate the activity of Cbl-b to prevent or treat related immune and oncology diseases.

Method used

A new class of compounds, including compounds of formula (I), formula (II) and formula (III) and their stereoisomers or pharmaceutically acceptable salts, developed as Cbl-b inhibitors, through specific chemical structures Interact with Cbl-b to regulate its signaling pathway to prevent or treat diseases mediated by Cbl-b.

Benefits of technology

These compounds are able to effectively inhibit the activity of Cbl-b, improve immune regulation and anti-tumor effects, and provide new therapeutic strategies to prevent or treat diseases and disorders mediated by Cbl-b.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024095934_05122024_PF_FP_ABST
    Figure CN2024095934_05122024_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed are a compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof as a Cbl-b inhibitor, a preparation method therefor, and a pharmaceutical composition containing the compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and the use of the compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof or the pharmaceutical composition thereof in the preparation of a drug for preventing or treating diseases or conditions mediated by Cbl-b comprising tumors or autoimmune diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Cbl-b inhibitors and their applications

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of and priority to the following five Chinese invention patent applications, the entire contents of which are hereby incorporated by reference in their entirety:

[0003] Patent application No. 202310619310.0 filed with the State Intellectual Property Office of China on May 29, 2023;

[0004] Patent application No. 202310881975.9 filed with the State Intellectual Property Office of China on July 17, 2023;

[0005] Patent application No. 202311071639.4 filed with the State Intellectual Property Office of China on August 24, 2023;

[0006] Patent application No. 202311735773.X filed with the State Intellectual Property Office of China on December 15, 2023; and

[0007] Patent application No. 202410173764.4 submitted to the State Intellectual Property Office of China on February 6, 2024. Technical Field

[0008] The present application relates to a compound or stereoisomer or pharmaceutically acceptable salt thereof as a Cbl-b inhibitor, a preparation method thereof, a pharmaceutical composition containing the compound or stereoisomer or pharmaceutically acceptable salt thereof, and the use of the compound or stereoisomer or pharmaceutically acceptable salt thereof or the pharmaceutical composition in preventing or treating diseases or conditions mediated by Cbl-b. Background Art

[0009] Intracellular signaling cascades are typically regulated by protein phosphorylation, while gene expression and regulation are influenced by epigenetic factors. The proteins that regulate these signals are themselves regulated by the intracellular protein production-degradation balance to maintain cellular homeostasis. Currently, protein degradation is primarily through two pathways: lysosomal degradation and ubiquitin-mediated proteasomal degradation. The ubiquitin-mediated pathway is a specific protein degradation pathway that is strictly spatiotemporally regulated. The ubiquitin system is widely present in eukaryotes and serves as a precise regulatory system for intracellular protein degradation. Ubiquitin (Ub) is a highly conserved small protein present in most eukaryotic cells. Its primary function is to tag proteins for degradation and hydrolysis. The ubiquitin system consists of ubiquitin, the 26S proteasome, and multiple enzymes (E1, E2, E3, and deubiquitinases). Protein ubiquitination is completed through the E1-E2-E3 cascade reaction involving ubiquitin activating enzyme E1 (ubactivating enzyme, E1), ubiquitin conjugating enzyme E2 (Ub conjugating enzyme, E2), and ubiquitin ligase E3 (Ub ligase, E3). The ubiquitinated protein is then degraded by the 26S proteasome (A patent review of the ubiquitin ligase system: 2015-201 Expert Opin Ther Pat. 2018, 28(12): 919–937).

[0010] The human genome encodes approximately 35 E2 conjugating enzymes and over 500 E3 ligases. Casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) is an E3 ligase that negatively regulates T cell activation. Cbl-b belongs to the Cbl family, which includes c-Cbl, Cbl-b, and Cbl-3 (Cbl: many adaptations to regulate protein tyrosine kinases. Nat. Rev. Mol. Cell Biol. 2:294–307). Cbl proteins negatively regulate T cell activation, growth factors (e.g., epidermal growth factor receptor (EGFR), c-KIT, platelet-derived growth factor receptor (PDGFR), and non-receptor tyrosine kinase signaling (e.g., Src family kinases and Zap70) (Regulating the regulator: Negative regulation of Cbl ubiquitin ligases. Trends Biochem Sci 31:79–88; The Cbl family proteins: Ring leaders in regulation of cell signaling. J Cell Physiol. 209:21–43). Studies have found that functional inactivation of Cbl proteins is associated with human cancers (Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet 42:794–800). Of the three Cbl proteins, Cbl-b plays a key role in establishing the threshold for T cell activation and controlling peripheral T cell tolerance. Increasing evidence suggests that Cbl-b also regulates innate immune responses and plays a crucial role in host defense against pathogens. Cbl-b knockout mice display severe autoimmune diseases (Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403:211–216). Therefore, Cbl-b may serve as an important target for immune regulation therapy.

[0011] Summary of the Invention

[0012] The present application relates to a compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof,

[0013] in,

[0014] Ring A is selected from

[0015] Y1, Y2, Y3 and Y4 are independently selected from CR a or N;

[0016] R a is selected from H, halogen, OH, NH2, CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkyl-NH-, (C1-C6 alkyl)2-N-, C3-C6 cycloalkyl or 4-7 membered heterocyclyl;

[0017] k is selected from 0 or 1;

[0018] R1, R2, R3 and R4 are independently selected from H, F, CF3, CH3, cyclopropyl or oxetanyl; or R1 and R2 together with the C atom to which they are attached form a cyclobutyl group, which is optionally substituted with F, CN, CH3 or -OCH3; or R1, R2, R3 and R4 together with the atom to which they are attached form a phenyl group, which is optionally substituted with halogen, CH3 or CN;

[0019] R5 and R6 are independently selected from H, C1-C6 alkyl, C3-C6 cycloalkyl or 4-7 membered heterocyclic group, wherein the C1-C6 alkyl, C3-C6 cycloalkyl or 4-7 membered heterocyclic group is optionally replaced by R 5a or R5 and R6 together with the N atom to which they are attached form a 5-7 membered heterocyclic group, wherein the 5-7 membered heterocyclic group contains at least one N atom and one O atom, and the 5-7 membered heterocyclic group is optionally substituted by a C1-C6 alkyl group;

[0020] R 5a is selected from OH, C1-C6 alkyl, C3-C6 cycloalkyl, 4-7 membered heterocyclyl or -SO2CH3, wherein the OH, C1-C6 alkyl, C3-C6 cycloalkyl, 4-7 membered heterocyclyl or -SO2CH3 is optionally replaced by R 5b replace;

[0021] R 5b is selected from halogen, OH, CN, C1-C6 alkyl, C1-C6 alkoxy or C1-C6 haloalkyl;

[0022] R7 and R8 are independently selected from H, deuterium, C1-C6 alkyl or C1-C6 haloalkyl, or R7 and R8 together with the C atom to which they are attached form a C3-C6 cycloalkyl or a 4-7 membered heterocyclyl;

[0023] R9 and R 10 Independently selected from H, F, CH3, CF3 or cyclopropyl;

[0024] The conditions are: (i) R5 and R6 are not and (ii) when R5 and R6 together with the nitrogen atom to which they are attached form a 5-7 membered heterocyclic group, Not for

[0025] In some embodiments, the present application relates to a compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof,

[0026] in,

[0027] Ring A is selected from

[0028] Y1, Y2, Y3 and Y4 are independently selected from CR a or N;

[0029] R a is selected from H, halogen, OH, NH2, CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkyl-NH-, (C1-C6 alkyl)2-N-, C3-C6 cycloalkyl or 4-7 membered heterocyclyl;

[0030] k is selected from 0 or 1;

[0031] R1, R2, R3 and R4 are independently selected from H, F, CF3 or CH3; or R1 and R2 together with the C atom to which they are attached form a cyclobutyl group, which is optionally substituted with F, CN or CH3; or R1, R2, R3 and R4 together with the atom to which they are attached form a phenyl group, which is optionally substituted with F or CN;

[0032] R5 and R6 are independently selected from H, C1-C6 alkyl, C3-C6 cycloalkyl or 4-7 membered heterocyclic group, wherein the C1-C6 alkyl, C3-C6 cycloalkyl or 4-7 membered heterocyclic group is optionally replaced by R 5a replace;

[0033] R 5a is selected from OH, C1-C6 alkyl, C3-C6 cycloalkyl, 4-7 membered heterocyclyl or -SO2CH3, wherein the OH, C1-C6 alkyl, C3-C6 cycloalkyl, 4-7 membered heterocyclyl or -SO2CH3 is optionally replaced by R 5b replace;

[0034] R 5bis selected from halogen, OH, CN, C1-C6 alkyl, C1-C6 alkoxy or C1-C6 haloalkyl;

[0035] R7 and R8 are independently selected from H, deuterium, C1-C6 alkyl or C1-C6 haloalkyl, or R7 and R8 together with the C atom to which they are attached form a C3-C6 cycloalkyl or a 4-7 membered heterocyclyl;

[0036] R9 and R 10 Independently selected from H, F, CH3 or CF3;

[0037] The condition is: R5 and R6 are not

[0038] In some embodiments, the compound of formula (I) or its stereoisomer or its pharmaceutically acceptable salt is selected from the compound of formula (II) or its stereoisomer or its pharmaceutically acceptable salt,

[0039] Among them, Y1, Y2, Y3, Y4, R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10 and k are defined as in formula (I), with the following conditions: (i) R5 and R6 are not and (ii) when R5 and R6 together with the nitrogen atom to which they are attached form a 5-7 membered heterocyclic group, Not for

[0040] In some embodiments, the compound of formula (I) or its stereoisomer or its pharmaceutically acceptable salt is selected from the compound of formula (III) or its stereoisomer or its pharmaceutically acceptable salt,

[0041] Among them, Y1, Y2, Y3, Y4, R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10 and k are defined as in formula (I), provided that: (i) R5 and R6 are not and (ii) when R5 and R6 together with the nitrogen atom to which they are attached form a 5-7 membered heterocyclic group, Not for

[0042] In some embodiments of the compounds of formula (I) to formula (III), Y1, Y2, Y3, and Y4 are all selected from CH.

[0043] In some embodiments of the compounds of formula (I) to formula (III), Y1 is selected from N, Y2, Y3, and Y4 are independently selected from CR aIn some embodiments of the compounds of formula (I) to formula (III), Y1 is selected from N, Y2 and Y3 are both selected from CH, and Y4 is selected from CR a .

[0044] In some embodiments of the compounds of formula (I) to formula (III), Y4 is selected from N, Y1, Y2, and Y3 are independently selected from CR a In some embodiments of the compounds of formula (I) to formula (III), Y4 is selected from N, and Y1, Y2, and Y3 are all selected from CH.

[0045] In some embodiments of the compounds of Formula (I) to Formula (III), R a is selected from H, CN, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl. In some embodiments of the compounds of formula (I) to formula (III), R a Selected from H, CN, C1-C6 haloalkyl or C3-C6 cycloalkyl.

[0046] In some embodiments of the compounds of Formula (I) to Formula (III), R a is selected from H, CN, CHF2, CF3, OCH3 or cyclopropyl. In some embodiments of the compounds of formula (I) to formula (III), R a is selected from H, CN, CHF2, CF3 or cyclopropyl.

[0047] In some embodiments of the compounds of Formula (I) to Formula (III), R a is selected from H, CN, CHF2 or cyclopropyl; or, R a is selected from H, CN, CF3 or cyclopropyl; or, R a is selected from H, CF3 or cyclopropyl; or, R a is selected from H or cyclopropyl; or, R a Selected from cyclopropyl.

[0048] In some embodiments of the compounds of formula (I) to formula (III), Y1, Y2, Y3, and Y4 are all selected from CH; or Y1 is selected from N, Y2 and Y3 are all selected from CH, and Y4 is selected from CR a , and R a Selected from OCH3 or cyclopropyl, or R a It is cyclopropyl.

[0049] In some embodiments of the compounds of formula (I) to formula (III), R5 and R6 together with the N atom to which they are attached form described Optionally substituted with C1-C6 alkyl.

[0050] In some embodiments of the compounds of formula (I) to formula (III), R5 and R6 together with the N atom to which they are attached form described Optionally substituted with C1-C6 alkyl.

[0051] In some embodiments of the compounds of formula (I) to formula (III), R5 and R6 together with the N atom to which they are attached form described Optionally substituted with C1-C6 alkyl.

[0052] In some embodiments of the compounds of formula (I) to formula (III), R5 and R6 together with the N atom to which they are attached form or

[0053] In some embodiments of the compounds of formula (I) to formula (III), R5 and R6 together with the N atom to which they are attached form

[0054] In some embodiments of the compounds of formula (I) to formula (III), R5 and R6 together with the N atom to which they are attached form

[0055] In some embodiments of the compounds of formula (I) to formula (III), R5 and R6 together with the N atom to which they are attached form

[0056] In some embodiments of the compounds of formula (I) to formula (III), R5 is selected from C1-C6 alkyl, C3-C6 cycloalkyl or 4-7 membered heterocyclyl, and the C1-C6 alkyl, C3-C6 cycloalkyl or 4-7 membered heterocyclyl is optionally replaced by R 5a replace.

[0057] In some embodiments of the compounds of formula (I) to formula (III), R5 is selected from CH3, CH2CH3, cyclopropyl, cyclobutyl or oxetanyl, and the CH3, CH2CH3, cyclopropyl, cyclobutyl or oxetanyl is optionally replaced by R 5a replace.

[0058] In some embodiments of the compounds of Formula (I) to Formula (III), R 5a is selected from OH, C1-C6 alkyl, C3-C6 cycloalkyl or SO2CH3, wherein the OH, C1-C6 alkyl, C3-C6 cycloalkyl or -SO2CH3 is optionally replaced by R 5b replace.

[0059] In some embodiments of the compounds of Formula (I) to Formula (III), R5a is selected from OH, CH3, CH2CH3, cyclopropyl, cyclobutyl or SO2CH3, wherein the OH, CH3, cyclopropyl, cyclobutyl, CH2CH3 or SO2CH3 is optionally replaced by R 5b replace.

[0060] In some embodiments of the compounds of Formula (I) to Formula (III), R 5a is selected from OH, CH3, cyclopropyl or cyclobutyl, wherein the OH, CH3, cyclopropyl or cyclobutyl is optionally replaced by R 5b replace.

[0061] In some embodiments of the compounds of Formula (I) to Formula (III), R 5b Selected from F, OH, CN, CH3, OCH3, CF3 or CHF2.

[0062] In some embodiments of the compounds of Formula (I) to Formula (III), R 5b Selected from F, OH, CN, CH3, OCH3 or CF3.

[0063] In some embodiments of the compounds of Formula (I) to Formula (III), R 5b Selected from CH3, OH, OCH3 or CHF2.

[0064] In some embodiments of the compounds of formula (I) to formula (III), R6 is selected from H, R5 is selected from C1-C6 alkyl, C3-C6 cycloalkyl or 4-7 membered heterocyclyl, and the C1-C6 alkyl, C3-C6 cycloalkyl or 4-7 membered heterocyclyl is optionally replaced by R 5a replace.

[0065] In some embodiments of the compounds of formula (I) to formula (III), R6 is selected from H, and R5 is selected from CH3, CH2CH3, cyclopropyl, cyclobutyl or oxetanyl, wherein the CH3, CH2CH3, cyclopropyl, cyclobutyl or oxetanyl is optionally replaced by R 5a replace.

[0066] In some embodiments of the compounds of formula (I) to formula (III), R6 is selected from H, and R5 is selected from CH3, CH2CH3 or cyclobutyl, wherein CH3, CH2CH3 or cyclobutyl is optionally replaced by R 5a replace.

[0067] In some embodiments of the compounds of formula (I) to formula (III), R6 is selected from H, and R5 is selected from CH3, CH2CH3, cyclopropyl, cyclobutyl or oxetanyl, wherein the CH3, CH2CH3, cyclopropyl, cyclobutyl or oxetanyl is optionally replaced by R 5aReplacement, R 5a is selected from OH, C1-C6 alkyl, C3-C6 cycloalkyl or SO2CH3, wherein the OH, C1-C6 alkyl, C3-C6 cycloalkyl or -SO2CH3 is optionally replaced by R 5b Replace, and R 5b Selected from F, OH, CN, CH3, OCH3, CF3 or CHF2.

[0068] In some embodiments of the compounds of formula (I) to formula (III), R6 is selected from H, and R5 is selected from CH3, CH2CH3, cyclopropyl, cyclobutyl or oxetanyl, wherein the CH3, CH2CH3, cyclopropyl, cyclobutyl or oxetanyl is optionally replaced by R 5a Replacement, R 5a is selected from OH, CH3, CH2CH3, cyclopropyl, cyclobutyl or SO2CH3, wherein the OH, CH3, CH2CH3, cyclopropyl, cyclobutyl or SO2CH3 is optionally replaced by R 5b Replace, and R 5b Selected from F, OH, CN, CH3, OCH3, CF3 or CHF2.

[0069] In some embodiments of the compounds of formula (I) to formula (III), R5 is selected from CH3, CH2CH3, cyclopropyl, cyclobutyl or oxetanyl, and the CH3, CH2CH3, cyclopropyl, cyclobutyl or oxetanyl is optionally replaced by R 5a Substitution, R6 is selected from H; or R5 and R6 and the nitrogen atom to which they are connected together form described Optionally substituted with C1-C6 alkyl.

[0070] In some embodiments of the compounds of formula (I) to formula (III), R5 is selected from CH3, CH2CH3, cyclopropyl, cyclobutyl or oxetanyl, and the CH3, CH2CH3, cyclopropyl, cyclobutyl or oxetanyl is optionally replaced by R 5a Substitution, R6 is selected from H; or R5 and R6 and the nitrogen atom to which they are connected together form described Optionally substituted with C1-C6 alkyl.

[0071] In some embodiments of the compounds of formula (I) to formula (III), R5 is selected from CH3, CH2CH3 or cyclobutyl, and the CH3, CH2CH3 or cyclobutyl is optionally replaced by R 5a Replacement, R 5a is selected from OH, CH3, cyclopropyl or cyclobutyl, wherein the OH, CH3, cyclopropyl or cyclobutyl is optionally replaced by R 5bReplace, and R 5b is selected from CH3, OH, OCH3 or CHF2, and R6 is selected from H; or R5 and R6 and the N atom to which they are connected together form described Optionally substituted with C1-C6 alkyl.

[0072] In some embodiments of the compounds of Formula (I) to Formula (III), R5 is selected from and R6 is H; or R5 and R6 and the N atom to which they are connected together form

[0073] In some embodiments of the compounds of formula (I) to formula (III), R5 and R6 together with the N atom to which they are attached form described Optionally substituted with C1-C6 alkyl.

[0074] In some embodiments of the compounds of Formula (I) to Formula (III), R5 is selected from and R6 is H; or R5 and R6 and the N atom to which they are connected together form

[0075] In some embodiments of the compounds of Formula (I) to Formula (III), R5 is selected from

[0076] In some embodiments of the compounds of Formula (I) to Formula (III), R5 is selected from

[0077] In some embodiments of the compounds of Formula (I) to Formula (III), R5 is selected from

[0078] In some embodiments of the compounds of Formula (I) to Formula (III), R6 is selected from H.

[0079] In some embodiments of the compounds of formula (I) to formula (III), k=0, R1 and R2 are independently selected from H, F, CF3, cyclopropyl or Or R1 and R2 together with the C atom to which they are connected form

[0080] In some embodiments of the compounds of Formula (I) to Formula (III), k=0, R1 is selected from H or F, and R2 is selected from H, F, CH3, CF3, cyclopropyl or In some embodiments of the compounds of formula (I) to formula (III), k=0, R1 is selected from H or F, and R2 is selected from F, CH3, CF3, cyclopropyl or

[0081] In some embodiments of the compounds of formula (I) to formula (III), k=0 and the C atom to which R1 and R2 are attached together form

[0082] In some embodiments of the compounds of formula (I) to formula (III), k=0 and the C atom to which R1 and R2 are attached together form

[0083] In some embodiments of the compounds of formula (I) to formula (III), k=0, R1 is selected from H or F, and R2 is selected from CF3, cyclopropyl or or k=0, R1 is selected from H or F, and R2 is selected from CF3 or cyclopropyl; or k=0, R1 is F and R2 is selected from CF3 or cyclopropyl; or k=0, R1 is H and R2 is selected from cyclopropyl or Or k=0, R1 is H and R2 is cyclopropyl; or k=0, R1 and R2 together with the C atom to which they are connected form Alternatively, k = 0, R1 and R2 together with the C atom to which they are connected form

[0084] In some embodiments of the compounds of Formula (I) to Formula (III), k=1, and R3 and R4 are independently selected from H or F, or R3 is H and R4 is F.

[0085] In some embodiments of the compounds of formula (I) to formula (III), k=1 and the C atom to which R1, R2, R3 and R4 are attached together form

[0086] In some embodiments of the compounds of formula (I) to formula (III), k=1 and the C atom to which R1, R2, R3 and R4 are attached together form

[0087] In some embodiments of the compounds of formula (I) to formula (III), k=1, R3 is H and R4 is F, or k=1, R1, R2, R3 and R4 together with the C atom to which they are attached form Or k=1, R1, R2, R3 and R4 together with the C atom to which they are connected form

[0088] In some embodiments of the compounds of Formula (I) to Formula (III), R7 or R8 are independently selected from H, deuterium, CH3 or CF3, or R7 and R8 together with the C atom to which they are attached form a cyclopropyl group.

[0089] In some embodiments of the compounds of formula (I) to (III), R7 and R8 are independently selected from H or CH3. In some embodiments of the compounds of formula (I) to (III), R7 and R8 are both H, or R7 is H and R8 is CH3.

[0090] In some embodiments of the compounds of formula (I) to formula (III), R9 and R 10 Independently selected from H, F, CH3 or CF3.

[0091] In some embodiments of the compounds of Formula (I) to Formula (III), R9 is selected from H or F; or R9 is H.

[0092] In some embodiments of the compounds of Formula (I) to Formula (III), R 10 Selected from H, CH3, CF3 or cyclopropyl.

[0093] In some embodiments of the compounds of Formula (I) to Formula (III), R 10 is selected from H, CH3 or CF3, or R 10 Selected from CH3 or CF3.

[0094] In some embodiments of the compounds of Formula (I) to Formula (III), R9 is H, and R 10 is selected from H, CH3, CF3 or cyclopropyl; or R9 is H, and R 10 is selected from CH3 or CF3; or R9 is F, and R 10 For CH3.

[0095] In some embodiments, the compound of the present application is selected from the following compounds or stereoisomers or pharmaceutically acceptable salts thereof:

[0096] On the other hand, the present application provides a pharmaceutical composition comprising a compound of formula (I), a compound of formula (II), a compound of formula (III) or the above-mentioned specific compounds or their stereoisomers or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable excipient.

[0097] In another aspect, the present application provides a method for treating or preventing a disease or condition mediated by Cbl-b in a mammal, comprising administering to a mammal, preferably a human, in need of such treatment or prevention, a therapeutically effective amount of a compound of formula (I), a compound of formula (II), a compound of formula (III), or the aforementioned specific compounds or stereoisomers thereof or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.

[0098] On the other hand, the present application provides a method for treating or preventing tumors or autoimmune diseases in mammals, comprising administering a therapeutically effective amount of a compound of formula (I), a compound of formula (II), a compound of formula (III) or the above-mentioned specific compounds or their stereoisomers or pharmaceutically acceptable salts, or pharmaceutical compositions thereof to a mammal, preferably a human, in need of such treatment or prevention.

[0099] On the other hand, the present application provides the use of a compound of formula (I), a compound of formula (II), a compound of formula (III), or the above-mentioned specific compounds or stereoisomers or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, in the preparation of a medicament for preventing or treating a disease or condition mediated by Cbl-b in a mammal, preferably a human.

[0100] On the other hand, the present application provides the use of a compound of formula (I), a compound of formula (II), a compound of formula (III) or the above-mentioned specific compounds or their stereoisomers or pharmaceutically acceptable salts, or their pharmaceutical compositions in the preparation of a drug for preventing or treating tumors or autoimmune diseases in mammals, preferably humans.

[0101] On the other hand, the present application provides the use of a compound of formula (I), a compound of formula (II), a compound of formula (III), or the above-mentioned specific compounds or stereoisomers or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, in preventing or treating diseases or conditions mediated by Cbl-b in mammals, preferably humans.

[0102] On the other hand, the present application provides the use of a compound of formula (I), a compound of formula (II), a compound of formula (III) or the above-mentioned specific compounds or their stereoisomers or pharmaceutically acceptable salts, or their pharmaceutical compositions in preventing or treating tumors or autoimmune diseases in mammals, preferably humans.

[0103] On the other hand, the present application provides a compound of formula (I), a compound of formula (II), a compound of formula (III) or the above-mentioned specific compounds or stereoisomers or pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof for preventing or treating a disease or condition mediated by Cbl-b in a mammal, preferably a human.

[0104] On the other hand, the present application provides a compound of formula (I), a compound of formula (II), a compound of formula (III) or the above-mentioned specific compounds or their stereoisomers or pharmaceutically acceptable salts, or pharmaceutical compositions thereof for preventing or treating tumors or autoimmune diseases in mammals, preferably humans.

[0105] In some embodiments, the disease or condition mediated by Cbl-b is selected from a tumor or an autoimmune disease.

[0106] Definitions and Explanations of Terms

[0107] Unless otherwise indicated, the terms used in this application have the following meanings. The definitions of groups and terms described in this application, including their definitions as examples, exemplary definitions, preferred definitions, definitions described in tables, and definitions of specific compounds in the examples, may be combined and coupled with each other in any manner. A specific term should not be considered as undefined or unclear unless specifically defined, but should be understood according to its common meaning in the art. When a trade name appears in this document, it is intended to refer to the corresponding commercial product or its active ingredient.

[0108] In this article Indicates the junction site.

[0109] The diagrammatic representations of racemates or enantiomerically pure compounds herein are from Maehr, J. Chem. Ed. 1985, 62: 114-120. Unless otherwise indicated, wedge and dotted wedge keys are used. To indicate the absolute configuration of a stereocenter, use black real and imaginary bonds. Indicates the relative configuration of a stereocenter (such as the cis-trans configuration of an alicyclic compound).

[0110] In this document, a carbon atom marked with "*" represents a chiral carbon atom, which means that its absolute configuration is one of (S)-configuration and (R)-configuration.

[0111] The term "tautomer" refers to functional group isomers resulting from the rapid movement of an atom in a molecule between two positions. The compounds of the present application may exhibit tautomerism. Tautomeric compounds may exist as two or more interconvertible species. Tautomers generally exist in equilibrium, and attempts to separate a single tautomer usually produce a mixture whose physical and chemical properties are consistent with the mixture of compounds. The position of equilibrium depends on the chemical characteristics within the molecule. For example, in many aliphatic aldehydes and ketones such as acetaldehyde, the keto form predominates; whereas in phenols, the enol form predominates. The present application encompasses all tautomeric forms of the compounds.

[0112] The term "stereoisomer" refers to isomers resulting from different spatial arrangements of atoms in a molecule, including cis-trans isomers, enantiomers and diastereomers.

[0113] The compounds of the present application may have asymmetric atoms such as carbon atoms, sulfur atoms, nitrogen atoms, phosphorus atoms or asymmetric double bonds, and therefore the compounds of the present application may exist in specific geometric or stereoisomeric forms. Specific geometric or stereoisomeric forms may be cis and trans isomers, E-type and Z-type geometric isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic mixtures or other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, all of which are within the definition of the compounds of the present application and mixtures thereof. Additional asymmetric carbon atoms, asymmetric sulfur atoms, asymmetric nitrogen atoms or asymmetric phosphorus atoms may be present in substituents such as alkyl groups, and all of these isomers and mixtures thereof involved in the substituents are also within the definition of the compounds of the present application. The compounds of the present invention containing an asymmetric atom can be isolated in optically pure or racemic forms. Optically pure forms can be resolved from racemic mixtures or synthesized by using chiral starting materials or chiral reagents.

[0114] The term "substituted" refers to the replacement of any one or more hydrogen atoms on a particular atom by a substituent, as long as the valence state of the particular atom is normal and the substituted compound is stable. When the substituent is an oxo (i.e., =O), it means that two hydrogen atoms are replaced. Oxo does not occur on aromatic groups.

[0115] The term "optional" or "optionally" refers to that the event or situation described subsequently may or may not occur, and the description includes that the event or situation occurs and that the event or situation does not occur. For example, an ethyl group is "optionally" substituted with halogen, meaning that the ethyl group may be unsubstituted (CH2CH3), monosubstituted (CH2CH2F, CH2CH2Cl, etc.), polysubstituted (CHFCH2F, CH2CHF2, CHFCH2Cl, CH2CHCl2, etc.), or fully substituted (CF2CF3, CF2CCl3, CCl2CCl3, etc.). It will be appreciated by those skilled in the art that for any group comprising one or more substituents, any sterically impossible and / or incomposable replacement or substitution pattern will not be introduced.

[0116] When any variable (such as R 1a 、R 2a ) appears more than once in the composition or structure of a compound, its definition is independent in each case. For example, if a group is represented by two R 1a is replaced, then each R1a There are independent options.

[0117] When the number of a linking group is 0, such as -(CR3R4)0-, it means that the linking group is a bond.

[0118] In this article, C m -C n For example, "C1-C6" means that the group may have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms.

[0119] The term "halo" or "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I).

[0120] The term "hydroxy" refers to an -OH group.

[0121] The term "cyano" refers to a -CN group.

[0122] The term "amino" refers to a -NH2 group.

[0123] The term "alkyl" refers to a group of the formula C n H 2n+1 The term "C1-C6 alkyl" is understood to mean a straight or branched saturated monovalent hydrocarbon group having 1, 2, 3, 4, 5 or 6 carbon atoms. Specific examples of the alkyl group include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1,3-dimethylbutyl or 1,2-dimethylbutyl. The term "C1-C3 alkyl" is understood to mean a linear or branched saturated monovalent hydrocarbon group having 1, 2 or 3 carbon atoms. The "C1-C6 alkyl" may include a "C1-C3 alkyl".

[0124] The term "haloalkyl" refers to an alkyl group as defined above that is substituted with one or more halogen atoms.

[0125] The term "alkoxy" refers to a monovalent group derived from a straight-chain or branched alcohol by the loss of a hydrogen atom from a hydroxyl group, and can be understood as "alkyloxy" or "alkyl-O-." The term "C1-C6 alkoxy" can be understood as "C1-C6 alkyloxy" or "C1-C6 alkyl-O-," and the term "C1-C3 alkoxy" can be understood as "C1-C3 alkyloxy" or "C1-C3 alkyl-O-." The "C1-C6 alkoxy" group may further include a "C1-C3 alkoxy group."

[0126] The term "haloalkoxy" refers to an alkoxy group as defined above substituted with one or more halogen atoms.

[0127] The term "cycloalkyl" refers to a fully saturated carbon ring that exists in the form of a monocyclic, fused, bridged, or spirocyclic ring. Unless otherwise indicated, the carbon ring is typically a 3- to 10-membered ring. The term "C3-C 10 "Cycloalkyl" is understood to mean a saturated monovalent monocyclic, bicyclic, spirocyclic or bridged ring having 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms. Specific examples of such cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, norbornyl (bicyclo[2.2.1]heptyl), bicyclo[2.2.2]octyl, adamantyl, spiro[4.5]decyl and the like. The term "C3-C 10 "Cycloalkyl" may include "C3-C8 cycloalkyl", "C3-C8 cycloalkyl" may include "C3-C6 cycloalkyl", and "C3-C6 cycloalkyl" may include "C3-C4 cycloalkyl". The term "C3-C6 cycloalkyl" may be understood to mean a saturated monovalent monocyclic or bicyclic hydrocarbon ring having 3, 4, 5 or 6 carbon atoms, specific examples of which include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

[0128] The term "heterocyclyl" refers to a fully saturated or partially saturated (heteroaromatic as a whole that is not aromatic) monovalent monocyclic, fused, spirocyclic or bridged ring group containing 1, 2, 3, 4 or 5 heteroatoms or heteroatomic groups (i.e., atomic groups containing heteroatoms) in the ring atoms, wherein the "heteroatoms or heteroatomic groups" include but are not limited to nitrogen atom (N), oxygen atom (O), sulfur atom (S), phosphorus atom (P), boron atom (B), -S(=O)2-, -S(=O)- and optionally substituted -NH-, -S(=O)(=NH)-, -C(=O)NH-, -C(=NH)-, -S(=O)2NH-, S(=O)NH- or -NHC(=O)NH-, etc. The term "4-10 membered heterocyclyl" refers to a heterocyclyl group having 4, 5, 6, 7, 8, 9 or 10 ring atoms, and containing 1, 2, 3, 4 or 5 heteroatoms or heteroatom groups independently selected from the above-mentioned heteroatoms in the ring atoms. The term "4-10 membered nitrogen-containing heterocyclyl" refers to a 4, 5, 6, 7, 8, 9 or 10 membered heterocyclyl group containing at least 1 nitrogen atom in the ring atoms. The term "4-7 membered heterocyclyl" refers to a heterocyclyl group having 4, 5, 6 or 7 ring atoms, and containing 1, 2, 3 or 4 heteroatoms or heteroatom groups independently selected from the above-mentioned heteroatoms in the ring atoms. The term "4-7 membered monocyclic nitrogen-containing heterocyclyl" refers to a 4, 5, 6 or 7 membered heterocyclyl group in the form of a monocyclic ring and containing at least 1 nitrogen atom in the ring atoms. “4-10 membered heterocyclyl” includes “6-10 membered heterocyclyl”, and “6-10 membered heterocyclyl” further includes “6-7 membered heterocyclyl”, wherein specific examples of 4 membered heterocyclyl include but are not limited to azetidinyl, thietanyl or oxetanyl; specific examples of 5 membered heterocyclyl include but are not limited to tetrahydrofuranyl, dioxolyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, pyrrolinyl, 4,5-dihydrooxazolyl or 2,5-dihydro-1H-pyrrolyl; specific examples of 6 membered heterocyclyl include but are not limited to tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, trithianyl, tetrahydropyridinyl or 4H-[1,3,4]thiadiazinyl; specific examples of 7 membered heterocyclyl include but are not limited to diazepanyl. The heterocyclic group may also be a bicyclic group, wherein specific examples of 5,5-membered bicyclic groups include but are not limited to hexahydrocyclopenta[c]pyrrol-2(1H)-yl; specific examples of 5,6-membered bicyclic groups include but are not limited to hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl or 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazinyl. Optionally, the heterocyclic group may be a benzo-fused ring group of the above-mentioned 4-7-membered heterocyclic groups, specific examples of which include but are not limited to dihydroisoquinolinyl and the like."4-10 membered heterocyclyl" may include "5-10 membered heterocyclyl", "4-7 membered heterocyclyl", "5-6 membered heterocyclyl", "6-8 membered heterocyclyl", "4-10 membered heterocycloalkyl", "5-10 membered heterocycloalkyl", "4-7 membered heterocycloalkyl", "5-6 membered heterocycloalkyl", "6-8 membered heterocycloalkyl", etc., and "4-7 membered heterocyclyl" may further include "4-6 membered heterocyclyl", "5-6 membered heterocyclyl", "4-7 membered heterocycloalkyl", "4-6 membered heterocycloalkyl", "5-6 membered heterocycloalkyl", etc. In the present application, although some bicyclic heterocyclyl groups partially contain a benzene ring or a heteroaromatic ring, the heterocyclyl group as a whole is still non-aromatic.

[0129] The term "therapeutically effective amount" means an amount of a compound of the present invention that (i) treats a specific disease, condition, or disorder, (ii) alleviates, ameliorates, or eliminates one or more symptoms of a specific disease, condition, or disorder, or (iii) delays the onset of one or more symptoms of a specific disease, condition, or disorder described herein. The amount of a compound of the present invention that constitutes a "therapeutically effective amount" varies depending on the compound, the disease state and its severity, the mode of administration, and the age of the mammal to be treated, but can be routinely determined by those skilled in the art based on their own knowledge and this disclosure.

[0130] The term "pharmaceutically acceptable" refers to those compounds, materials, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0131] The term "pharmaceutically acceptable salt" refers to a salt of a pharmaceutically acceptable acid or base, including a salt formed between a compound and an inorganic acid or organic acid, and a salt formed between a compound and an inorganic base or an organic base.

[0132] The term "pharmaceutical composition" refers to a mixture of one or more compounds of the present application, or their stereoisomers, or salts thereof, and pharmaceutically acceptable excipients. The purpose of a pharmaceutical composition is to facilitate administration of the compounds of the present disclosure to an organism.

[0133] The term "pharmaceutically acceptable excipient" refers to an excipient that is non-irritating to organisms and does not impair the biological activity and properties of the active compound. Suitable excipients are well known to those skilled in the art and include, for example, carbohydrates, waxes, water-soluble and / or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, and the like.

[0134] The word "comprise" or "comprises" and its English variations such as comprises or comprising should be understood as having an open and non-exclusive meaning, ie, "including but not limited to".

[0135] The present application also includes isotopically labeled compounds of the present application that are identical to those described herein, but in which one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into the compounds of the present application include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as 2 H. 3 H. 11 C. 13 C. 14 C. 13 N. 15 N. 15 O. 17 O. 18 O. 31 P. 32 P. 35 S. 18 F. 123 I. 125 I and 36 Cl et al.

[0136] Certain isotope-labeled compounds of the present application (e.g. 3 H and 14 C-labeled) can be used in compound and / or substrate tissue distribution assays. 3 H) and carbon-14 (i.e. 14 C) isotopes are particularly preferred due to their ease of preparation and detectability. Positron emitting isotopes, such as 15 O. 13 N. 11 C and 18 F can be used in positron emission tomography (PET) studies to determine substrate occupancy. Isotopically labeled compounds of the present application can generally be prepared by following procedures analogous to those disclosed in the Schemes and / or Examples below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.

[0137] The pharmaceutical compositions of the present application can be prepared by combining the compounds of the present application with suitable pharmaceutically acceptable excipients, and can be formulated into solid, semi-solid, liquid or gaseous preparations, such as tablets, pills, capsules, powders, granules, ointments, emulsions, suspensions, suppositories, injections, inhalants, gels, microspheres and aerosols, etc.

[0138] Typical routes of administration of the compounds of the present invention, or their stereoisomers, or their pharmaceutically acceptable salts, or their pharmaceutical compositions include, but are not limited to, oral, rectal, topical, inhalation, parenteral, sublingual, vaginal, intranasal, intraocular, intraperitoneal, intramuscular, subcutaneous, and intravenous administration.

[0139] The pharmaceutical composition of the present application can be manufactured by methods well known in the art, such as conventional mixing methods, dissolution methods, granulation methods, emulsification methods, freeze-drying methods, etc.

[0140] In some embodiments, the pharmaceutical composition is in oral form. For oral administration, the pharmaceutical composition can be formulated by mixing the active compound with pharmaceutically acceptable excipients well known in the art. These excipients enable the compounds of the present application to be formulated into tablets, pills, lozenges, dragees, capsules, liquids, gels, slurries, suspensions, and the like for oral administration to a patient.

[0141] Solid oral compositions can be prepared by conventional mixing, filling, or tableting methods. For example, they can be prepared by mixing the active compound with a solid excipient, optionally grinding the resulting mixture, adding other suitable excipients as needed, and then granulating the mixture to obtain a tablet or dragee core. Suitable excipients include, but are not limited to, binders, diluents, disintegrants, lubricants, glidants, or flavoring agents.

[0142] The pharmaceutical composition may also be suitable for parenteral administration, such as sterile solutions, suspensions or lyophilized products in appropriate unit dosage forms.

[0143] In all methods of administration of the compound of formula (I) or (II) or (III) or the above-mentioned specific compounds described herein, the daily dosage is 0.01 mg / kg to 200 mg / kg body weight, preferably 0.05 mg / kg to 50 mg / kg body weight, more preferably 0.1 mg / kg to 30 mg / kg body weight, in the form of single or divided doses.

[0144] The compounds of the present application can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific examples listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent replacement methods well known to those skilled in the art. Preferred embodiments include but are not limited to the examples of the present application.

[0145] The chemical reactions of the specific examples of this application are carried out in a suitable solvent that is compatible with the chemical transformations of this application and the reagents and materials required. In order to obtain the compounds of this application, it is sometimes necessary for those skilled in the art to modify or select synthetic steps or reaction schemes based on existing examples. Example

[0146] The invention is described in detail below by way of examples, but this is not intended to limit the present invention in any way. While the present invention has been described in detail herein, and specific embodiments thereof have been disclosed, it will be apparent to those skilled in the art that various changes and modifications can be made to the specific embodiments herein without departing from the spirit and scope of the present invention. All reagents used herein were commercially available and used without further purification.

[0147] Unless otherwise specified, the ratios expressed for mixed solvents are volume ratios. Unless otherwise specified, % refers to wt%.

[0148] Compounds are manually or Software naming, commercially available compounds use supplier catalog names.

[0149] The structures of the compounds were determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). The units of NMR shifts are 10 - 6 (ppm). The solvents for NMR determination are deuterated dimethyl sulfoxide, deuterated chloroform, deuterated methanol, etc., and the internal standard is tetramethylsilane (TMS); "IC 50 ” refers to the half-maximal inhibitory concentration, which is the concentration at which half of the maximum inhibitory effect is achieved.

[0150] Explanation of terms or abbreviations:

[0151] ACN or MeCN: acetonitrile; p-TSA or TsOH: p-toluenesulfonic acid; TEA: triethylamine; Pd(dppf)Cl2: [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride; HATU: 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate; DIEA or DIPEA: N,N-diisopropylethylamine; DMF: N,N-dimethylformamide; Xphos Pd G2: chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II); Xphos: 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl; THF: tetrahydrofuran; DCM: dichloromethane; AcOH: acetic acid; DAST: diethylaminosulfur trifluoride; Py: pyridine; dioxane: 1,4-dioxane; DCE: dichloroethane; DME: ethylene glycol dimethyl ether; n-BuLi: n-butyllithium; DMP: dimethyl phthalate; SOCl2: dichlorothionyl; TFA: trifluoroacetic acid; DIABL-H: diisobutylaluminum hydride; B2Pin2: diboronic acid pinacol ester; LHMDS or LiH MDS: lithium bis(trimethylsilyl)amide; (Ph3P)2Pd(II)Cl2: bis(triphenylphosphine)palladium dichloride; Ti(Oi-Pr)4 or Ti(i-PrO)4: tetraisopropyl titanate or titanium tetraisopropoxide; Pd(PPh3)4: tetrakis(triphenylphosphine)palladium; CAN: cerium ammonium nitrate; Pd(dba)2: bisdibenzylideneacetonate palladium; Pcy3: tricyclohexylphosphine; DMF-DMA: N,N-dimethylformamide dimethyl acetal; NBS: N-bromosuccinimide; Ms2O: methanesulfonic anhydride; DMSO: dimethyl sulfoxide; BINAP: 1,1'-binaphthyl-2,2'-bis(diphenylphosphine); cPrMgBr: cyclopropylmagnesium bromide; Fe(acac)2: ferrous acetylacetonate; Ruppert's reagent: (trifluoromethyl)trimethylsilane; Pd(Pt-Bu3)2: bis(tri-tert-butylphosphine)palladium; TFAA: trifluoroacetic anhydride; Dess-Martin reagent: 1,1,1-triacetoxy-1,1-dihydro-1,2-benzidoxyl-3(1H)-one; DMAP: 4-dimethylaminopyridine; TMSOK: potassium trimethylsilanolate; NIS: N-iodosuccinimide; Pd(dtbpf)Cl2: [1,1'-bis(di-tert-butylphosphino)ferrocene]dichloropalladium; DEA: diethylamine; ABPR: automatic back pressure regulator; NMP: N-methylpyrrolidone; PEG 400: polyethylene glycol 400; solutol: polyethylene glycol-15 hydroxystearate; VETPGS: vitamin E polyethylene glycol succinate.

[0152] The eluent mentioned below can be a mixed eluent formed by two or more solvents, and the ratio is the volume ratio of each solvent. For example, "0-10% methanol / dichloromethane" means that during the gradient elution process, the volume ratio of methanol to dichloromethane in the mixed eluent is 0:100 to 10:90.

[0153] Example 1: Preparation of 3-(3-(3,3-difluoro-1-(fluoro-(4-methyl-4H-1,2,4-triazol-3-yl)methyl)cyclobutyl)phenyl)-8-methyl-6-(((S)-3-methylpiperidin-1-yl)methyl)-4H-chromen-4-one (Compound 1)

[0154] Step 1: Preparation of 1-(3-bromophenyl)-3,3-dimethoxycyclobutane-1-carbonitrile (1B)

[0155] Under an argon atmosphere, a mixture of compound 1A (2.0 g, 10.2 mmol) and 1,3-dibromo-2,2-dimethoxypropane (2.67 g, 10.2 mmol) in DMF (10.0 mL) was added dropwise to an ice-bath solution of sodium hydride (732.0 mg, 18.3 mmol, 60% purity) in DMF (20.0 mL). After the addition was complete, the reaction solution was heated to 60°C and stirred for 18 hours. After completion of the reaction, the solution was cooled to room temperature and added dropwise to an ice-cold saturated aqueous ammonium chloride solution. The mixture was extracted three times with ethyl acetate (60.0 mL). The organic phase was dried and concentrated. The crude product was purified by normal phase column chromatography (petroleum ether:ethyl acetate = 10:1) to afford the title compound 1B (2.0 g).

[0156] 1 H NMR (400MHz, CDCl3) δ7.63(q,J=1.9Hz,1H),7.48(d,J=7.9Hz,1H),7.43(d,J=7.9Hz,1H),7.30(dd,J=7.9, 1.3Hz,1H),3.29(d,J=1.4Hz,3H),3.20(d,J=1.4Hz,3H),3.13–3.07(m,2H),2.71(dt,J=11.5,1.6Hz,2H).

[0157] Step 2: Preparation of 1-(3-bromophenyl)-3-oxocyclobutane-1-carbonitrile (Compound 1C)

[0158] Compound 1B (2.0 g, 6.75 mmol) and p-toluenesulfonic acid monohydrate (2.57 g, 13.51 mmol) were added to a mixture of water (10.0 mL) and acetone (10.0 mL). The mixture was heated to 75°C and stirred for 5.0 hours. After TLC monitoring of the reaction, the reaction solution was cooled to room temperature, saturated brine (100.0 mL) was added, and the mixture was extracted three times with ethyl acetate (60.0 mL). The organic phase was dried and concentrated, and the crude product was purified by normal phase column chromatography (petroleum ether:ethyl acetate = 5:1) to obtain the title compound 1C (1.6 g).

[0159] Step 3: Preparation of 1-(3-bromophenyl)-3,3-difluorocyclobutane-1-carbonitrile (1D)

[0160] Compound 1C (1.7 g, 6.75 mmol) was dissolved in DCM (16.0 mL). The reaction solution was cooled to 0°C in an ice bath, and DAST (2.27 g, 14.07 mmol) was added dropwise. After the addition was complete, the temperature was slowly raised to room temperature and stirred for 12 hours. After TLC monitoring of the reaction, the reaction solution was added dropwise to an ice-cold saturated aqueous sodium bicarbonate solution and extracted three times with dichloromethane (60.0 mL). The organic phase was dried and concentrated, and the crude product was purified by normal phase column chromatography (petroleum ether:ethyl acetate = 20:1) to obtain the title compound 1D (1.1 g).

[0161] Step 4: Preparation of 1-(3-bromophenyl)-3,3-difluorocyclobutane-1-carbaldehyde (Compound 1E)

[0162] Compound 1D (1.8 g, 6.62 mmol) was dissolved in toluene (18.0 mL). The reaction mixture was cooled to -78°C, and a toluene solution of diisobutylaluminum hydride (1 M, 10.0 mL, 10.0 mmol) was added dropwise. After the addition was complete, the mixture was stirred at -78°C for 2 hours. After the reaction was complete, the reaction mixture was added dropwise to ice water, followed by dilute hydrochloric acid (1 M, 50.0 mL) and stirred for 0.5 hours. After stirring, the mixture was extracted three times with dichloromethane (60.0 mL). The organic phase was dried and concentrated, and the crude product was purified by normal phase column chromatography (petroleum ether:ethyl acetate = 10:1) to obtain the title compound 1E (1.4 g).

[0163] Step 5: Preparation of (1-(3-bromophenyl)-3,3-difluorocyclobutyl)-(4-methyl-4H-1,2,4-triazol-3-yl)methanol (Compound 1F)

[0164] 4-Methyl-4H-1,2,4-triazole (392.67 mg, 4.73 mmol) was dissolved in DME (20.0 mL). The reaction mixture was cooled to -60°C, and a 2.5 M solution of n-butyllithium in n-hexane (1.89 mL, 4.72 mmol) was added dropwise. After the addition was complete, the mixture was stirred at -60°C for 1.0 hour. A solution of compound 1E (1.0 g, 3.64 mmol) in DME (1.5 mL) was then added dropwise. After the addition was complete, the reaction mixture was brought to room temperature and allowed to react for 0.5 hours. After the reaction was complete, the reaction mixture was cooled to 0°C in an ice bath, and saturated aqueous ammonium chloride was added and stirred for 10 minutes. After stirring, the mixture was extracted three times with ethyl acetate (60.0 mL). The organic phase was dried and concentrated, and the crude product was washed twice with petroleum ether (60.0 mL) to obtain the title compound 1F (820.0 mg).

[0165] MS m / z(ESI):358.3 / 360.3[M+H] + .

[0166] Step 6: Preparation of 3-((1-(3-bromophenyl)-3,3-difluorocyclobutyl)fluoromethyl)-4-methyl-4H-1,2,4-triazole (Compound 1G)

[0167] Compound 1F (200.0 mg, 0.56 mmol) was dissolved in DCM (5.0 mL). The reaction mixture was cooled to 0°C, and diethylaminosulfur trifluoride (0.15 mL, 1.12 mmol) was added dropwise. After the addition was complete, the reaction mixture was brought to room temperature and allowed to react for 0.5 hours. After the reaction, the reaction mixture was cooled to 0°C in an ice bath, and saturated sodium bicarbonate solution was added and stirred for 10 minutes. After stirring, the mixture was extracted three times with dichloromethane (30.0 mL). The organic phase was dried and concentrated, and the crude product was purified by normal phase column chromatography (dichloromethane:methanol = 95:5) to obtain the title compound 1G (185.0 mg).

[0168] MS m / z(ESI):360.3 / 362.3[M+H] + .

[0169] Step 7: Preparation of 3-((3,3-difluoro-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclobutyl)fluoromethyl)-4-methyl-4H-1,2,4-triazole (Compound 1H)

[0170] To a mixture of compound 1G (50.0 mg, 138.82 μmol), B2Pin2 (52.89 mg, 208.23 μmol), potassium acetate (27.21 mg, 277.65 μmol), and anhydrous dioxane (2.0 mL) was added Pd(dppf)Cl2 (10.16 mg, 13.88 μmol). The resulting mixture was heated to 100°C under nitrogen and stirred for 1 hour. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure. The residue was purified by normal phase column chromatography (petroleum ether:ethyl acetate = 0:1) to afford the title compound 1H (50.0 mg).

[0171] MS m / z(ESI):408.3[M+H] + .

[0172] Step 8: Preparation of 3-(3-(3,3-difluoro-1-(fluoro-(4-methyl-4H-1,2,4-triazol-3-yl)methyl)cyclobutyl)phenyl)-8-methyl-6-(((S)-3-methylpiperidin-1-yl)methyl)-4H-chromen-4-one (Compound 1)

[0173] Compound 1H (20.5 mg, 50.35 μmol), 1I (20.0 mg, 50.35 μmol), and potassium carbonate (13.9 mg, 100.69 μmol) were added to a mixture of water (0.2 mL) and 1,4-dioxane (1.0 mL), and the atmosphere was replaced with nitrogen. Pd(dppf)Cl2 (3.69 mg, 5.03 μmol) was added under a nitrogen atmosphere, and the resulting mixture was heated to 100°C under nitrogen and stirred for 1.0 hour. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain a crude product, which was separated by preparative HPLC (column: Welch Xtimate C18, column length: 150 mm, inner diameter: 30 mm, particle size: 5 μm; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 1 (9.0 mg).

[0174] MS m / z(ESI):551.38[M+H] + .

[0175] 1H NMR (400MHz, DMSO-d6) δ8.53(s,1H),8.35(s,1H),7.88(d,J=2.0Hz,1H),7.64(t,J=1.4Hz,1H),7.58–7.50(m,1H),7.42–7.34(m,2H ),7.15(d,J=7.9Hz,1H),6.10(d,J=44.8Hz,1H),3.68–3.55(m,1H),3.52(s,2H),3.46(dd,J=15.7,13.2Hz,1H),3.31–3.21(m,1H), 3.18–3.05(m,1H),2.99(s,3H),2.73(t,J=10.4Hz,2H),1.89(dd,J=12.5,9.9Hz,1H),1.64(dd,J=2 7.3,10.4Hz,4H),1.48(d,J=12.2Hz,1H),1.25(s,2H),0.86(d,J=7.0Hz,1H),0.82(d,J=5.3Hz,3H).

[0176] Example 2: Preparation of 8-methyl-6-(((S)-3-methylpiperidin-1-yl)methyl)-3-(3-(1,2,2,2-tetrafluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)phenyl)-4H-chromen-4-one (Compound 2)

[0177] Step 1: Preparation of 1-(3-bromophenyl)-2,2,2-trifluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethan-1-ol (Compound 2B)

[0178] 4-Methyl-4H-1,2,4-triazole (102.46 mg, 1.23 mmol) was dissolved in ethylene glycol dimethyl ether (10.0 mL). The reaction mixture was cooled to -60°C, and a 2.5 M solution of n-butyllithium in n-hexane (0.492 mL, 1.23 mmol) was added dropwise. After the addition was complete, the reaction mixture was stirred at -60°C for 1.0 hour. A solution of compound 2A (312.0 mg, 1.23 mmol) in ethylene glycol dimethyl ether (1.5 mL) was then added dropwise. After the addition was complete, the reaction mixture was transferred to room temperature and reacted for 0.5 hours. After the reaction was completed, the reaction mixture was cooled to 0°C in an ice bath, and saturated aqueous ammonium chloride was added and stirred for 10 minutes. After stirring, the mixture was extracted three times with ethyl acetate (60.0 mL). The organic phase was dried and concentrated, and the crude product was washed twice with petroleum ether (60.0 mL) to obtain the title compound 2B (250.0 mg).

[0179] MS m / z(ESI):336.0 / 338.0[M+H] + .

[0180] Step 2: Preparation of 3-(1-(3-bromophenyl)-1,2,2,2-tetrafluoroethyl)-4-methyl-4H-1,2,4-triazole (Compound 2C)

[0181] Compound 2B (100.0 mg, 0.3 mmol) was dissolved in dichloromethane (3.0 mL). The reaction mixture was cooled to 0°C, and DAST (0.079 mL, 0.6 mmol) was added dropwise. After the addition was complete, the reaction mixture was brought to room temperature and allowed to react for 0.5 hours. After the reaction was completed, the reaction mixture was cooled to 0°C in an ice bath, and saturated aqueous sodium bicarbonate solution was added and stirred for 10 minutes. After stirring, the mixture was extracted three times with dichloromethane (30.0 mL). The organic phase was dried and concentrated. The crude product was purified by normal phase column chromatography (dichloromethane:methanol = 95:5) to obtain the title compound 2C (60.0 mg).

[0182] MS m / z(ESI):338.0 / 340.0[M+H] + .

[0183] Step 3: Preparation of 4-methyl-3-(1,2,2,2-tetrafluoro-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-4H-1,2,4-triazole (Compound 2D)

[0184] To a mixture of compound 2C (60.0 mg, 177.46 μmol), B2Pin2 (67.61 mg, 266.19 μmol), potassium acetate (52.17 mg, 532.39 μmol), and anhydrous dioxane (2.0 mL) was added Pd(dppf)Cl2 (12.99 mg, 17.75 μmol). The resulting mixture was heated to 100°C under nitrogen and stirred for 1 hour. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure. The residue was purified by normal phase column chromatography (petroleum ether:ethyl acetate = 0:1) to afford the title compound 2D (60.0 mg).

[0185] MS m / z(ESI):386.1[M+H] + .

[0186] Step 4: Preparation of 8-methyl-6-(((S)-3-methylpiperidin-1-yl)methyl)-3-(3-(1,2,2,2-tetrafluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)phenyl)-4H-chromen-4-one (Compound 2)

[0187] Compound 2D (60.0 mg, 155.78 μmol), 1I (41.26 mg, 103.85 μmol), and potassium carbonate (28.66 mg, 207.7 μmol) were added to a mixture of water (0.2 mL) and 1,4-dioxane (1.0 mL). The atmosphere was replaced with nitrogen. Pd(dppf)Cl2 (7.6 mg, 10.39 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen and stirred for 1.0 hour. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was separated by preparative HPLC (column: Welch Xtimate C18, column length: 150 mm, inner diameter: 30 mm, particle size: 5 μm; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% in 18 minutes) to obtain the title compound 2 (25.0 mg).

[0188] MS m / z(ESI):529.3[M+H] + .

[0189] 1 H NMR (400MHz, DMSO-d6) δ8.78(s,1H),8.71(s,1H),7.87(s,1H),7.81(d,J=7. 7Hz,1H),7.66(t,J=8.5Hz,3H),7.41(d,J=7.8Hz,1H),3.52(s,2H),3.40(s,3 H),2.73(t,J=11.0Hz,2H),2.50(s,3H),1.89(t,J=10.7Hz,1H),1.63(dd,J=2 9.5,10.5Hz,4H),1.48(q,J=12.2Hz,1H),0.87(s,1H),0.82(d,J=5.0Hz,3H).

[0190] Example 3: Preparation of 3-(3-(1-fluoro-2-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)propan-2-yl)phenyl)-8-methyl-6-(((S)-3-methylpiperidin-1-yl)methyl)-4H-chromen-4-one (Compound 3)

[0191] Step 1: Preparation of 2-(3-bromophenyl)-2-methylpropionitrile (3A)

[0192] Under an argon atmosphere, compound 1A (1.0 g, 5.1 mmol) was dissolved in tetrahydrofuran (10.0 mL) and cooled to 0°C in an ice bath. Lithium bis(trimethylsilyl)amide (5.1 mL, 5.1 mmol) was added dropwise. After stirring for 1 hour, iodomethane (1.45 g, 10.2 mmol) was added. The mixture was transferred to room temperature and stirred for another 1 hour. After TLC monitoring, the starting material disappeared. The reaction solution was cooled to 0°C again, lithium bis(trimethylsilyl)amide (5.1 mL, 5.1 mmol) was added dropwise, stirred for 1 hour, and iodomethane (1.45 g, 10.2 mmol) was added. The mixture was transferred to room temperature and stirred for another 1 hour. After completion of the reaction, the reaction solution was cooled to room temperature and added dropwise to an ice-cold saturated aqueous ammonium chloride solution. The mixture was extracted three times with ethyl acetate (60.0 mL). The organic phase was dried and concentrated. The crude product was purified by normal phase column chromatography (petroleum ether:ethyl acetate = 20:1) to give the title compound 3A (600.0 mg).

[0193] MS m / z(ESI):224.0 / 226.0[M+H] + .

[0194] Step 2: Preparation of 2-(3-bromophenyl)-2-methylpropanal (Compound 3B)

[0195] Compound 3A (600.0 mg, 2.68 mmol) was dissolved in toluene (10.0 mL). The reaction mixture was cooled to -78°C, and a toluene solution of diisobutylaluminum hydride (1 M, 4.02 mL, 4.02 mmol) was added dropwise. After the addition was complete, the reaction mixture was stirred at -78°C for 2.0 hours. After the reaction was completed, the reaction mixture was added dropwise to ice water, followed by dilute aqueous hydrochloric acid (1 M, 50.0 mL) and stirred for 0.5 hours. After stirring, the mixture was extracted three times with dichloromethane (60.0 mL). The organic phase was dried and concentrated, and the crude product was purified by normal phase column chromatography (petroleum ether:ethyl acetate = 10:1) to obtain the title compound 3B (520.0 mg).

[0196] MS m / z(ESI):227.0 / 229.0[M+H] + .

[0197] Step 3: Preparation of 2-(3-bromophenyl)-2-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)propanol (Compound 3C)

[0198] 4-Methyl-4H-1,2,4-triazole (247.34 mg, 2.98 mmol) was dissolved in ethylene glycol dimethyl ether (10.0 mL). The reaction mixture was cooled to -60°C, and a 2.5 M solution of n-butyllithium in n-hexane (1.20 mL, 2.98 mmol) was added dropwise. After the addition was complete, the reaction mixture was stirred at -60°C for 1.0 hour. A solution of compound 3B (520 mg, 2.29 mmol) in ethylene glycol dimethyl ether (1.5 mL) was then added dropwise. After the addition was complete, the reaction mixture was transferred to room temperature and reacted for 0.5 hours. After the reaction was completed, the reaction mixture was cooled to 0°C in an ice bath, and saturated aqueous ammonium chloride was added and stirred for 10 minutes. After stirring, the mixture was extracted three times with ethyl acetate (60.0 mL). The organic phase was dried and concentrated, and the crude product was washed twice with petroleum ether (60.0 mL) to obtain the title compound 3C (202.0 mg).

[0199] MS m / z(ESI):310.05 / 312.05[M+H] + .

[0200] Step 4: Preparation of 3-(2-(3-bromophenyl)-1-fluoro-2-methylpropyl)-4-methyl-4H-1,2,4-triazole (Compound 3D)

[0201] Compound 3C (202.0 mg, 0.65 mmol) was dissolved in dichloromethane (2.0 mL). After the reaction mixture was cooled to 0°C, diethylaminosulfur trifluoride (0.17 mL, 1.30 mmol) was added dropwise. After the addition was complete, the reaction mixture was brought to room temperature and allowed to react for 0.5 hours. After the reaction was completed, the reaction mixture was cooled to 0°C in an ice bath, and saturated aqueous sodium bicarbonate solution was added and stirred for 10 minutes. After stirring, the mixture was extracted three times with dichloromethane (30.0 mL). The organic phase was dried and concentrated. The crude product was purified by normal phase column chromatography (dichloromethane:methanol = 95:5) to obtain the title compound 3D (60.0 mg).

[0202] MS m / z(ESI):312.04 / 314.04[M+H] + .

[0203] Step 5: Preparation of 3-(1-fluoro-2-methyl-2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propyl)-4-methyl-4H-1,2,4-triazole (3E)

[0204] To a mixture of compound 3D (20 mg, 0.068 mmol), B2Pin2 (25.9 mg, 0.101 mmol), potassium acetate (20 mg, 0.204 mmol), and anhydrous dioxane (2.0 mL) was added Pd(dppf)Cl2 (5.1 mg, 0.007 mmol). The resulting mixture was heated to 100°C under nitrogen and stirred for 1 hour. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure. The residue was purified by normal phase column chromatography (petroleum ether:ethyl acetate = 0:1) to afford the title compound 3E (23.0 mg).

[0205] MS m / z(ESI):360.2[M+H] + .

[0206] Step 6: Preparation of 3-(3-(1-fluoro-2-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)propan-2-yl)phenyl)-8-methyl-6-(((S)-3-methylpiperidin-1-yl)methyl)-4H-chromen-4-one (Compound 3)

[0207] Compound 3E (48.83 mg, 135.93 μmol), 1I (36.0 mg, 90.62 μmol), and potassium carbonate (25.01 mg, 181.25 μmol) were added to a mixture of water (0.4 mL) and 1,4-dioxane (2.0 mL). The atmosphere was replaced with nitrogen. Pd(dppf)Cl2 (6.64 mg, 9.06 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen and stirred for 1.0 hour. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain a crude product, which was then separated by preparative HPLC (column: Welch Xtimate C18, column length: 150 mm, inner diameter: 30 mm, particle size: 5 μm; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% in 18 minutes) to obtain the title compound 3 (10.0 mg).

[0208] MS m / z(ESI):503.45[M+H] + .

[0209] 1H NMR (400MHz, DMSO-d6) δ8.71–8.44(m,1H),8.45–8.01(m,1H),7.89(d,J=5.2Hz,1 H),7.72–7.15(m,5H),6.13–4.37(m,1H),3.63(s,1H),3.19(d,J=26.4Hz,2H),2.7 5(d,J=14.3Hz,2H),2.50(s,2H),2.21–1.74(m,5H),1.68(d,J=19.7Hz,3H),1.60( d,J=10.8Hz,4H),1.53–1.35(m,2H),0.89(t,J=6.5Hz,1H),0.82(d,J=5.1Hz,3H).

[0210] Example 4: Preparation of cis-6-(((2-methoxyethyl)amino)methyl)-8-methyl-3-(3-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4H-chromen-4-one (Compound 4)

[0211] Step 1: Preparation of 6-(hydroxymethyl)-8-methyl-4H-chromen-4-one (4B)

[0212] Compound 4A (1.0 g, 4.18 mmol) and (tributyltin)methanol (2.01 g, 6.27 mmol) were added to 1,4-dioxane (10.0 mL), and the nitrogen atmosphere was replaced. Tetrakis(triphenylphosphine)palladium (241.78 mg, 209.15 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen protection and stirred for 16.0 hours. The crude product was purified by reverse phase column chromatography (chromatographic column: The title compound 4B (640.0 mg) was obtained after purification using a flash silica gel column; mobile phase: acetonitrile / water = 70:30).

[0213] MS m / z(ESI):191.20[M+H] + .

[0214] Step 2: Preparation of 6-(bromomethyl)-8-methyl-4H-chromen-4-one (4C)

[0215] Compound 4B (640.0 mg, 3.36 mmol) was dissolved in dichloromethane (7.0 mL), cooled to 0°C, and phosphorus tribromide (0.7 mL) was added. The reaction mixture was slowly warmed to room temperature and stirred for 1.0 hour. After completion of the reaction, saturated aqueous sodium bicarbonate was added to the reaction mixture to quench the reaction. The mixture was then extracted three times with dichloromethane (30.0 mL). The organic phase was dried and concentrated to obtain the crude product, title compound 4C (800.0 mg), without further purification.

[0216] MS m / z(ESI):252.98 / 254.98[M+H] + .

[0217] Step 3: Preparation of 6-(((2-methoxyethyl)amino)methyl)-8-methyl-4H-chromen-4-one (Compound 4D)

[0218] Compound 4C (200.0 mg, 790.23 μmol), 2-methoxyethane-1-amine (178.06 mg, 2.37 mmol) and potassium iodide (131.18 mg, 790.23 μmol) were added to DMF (5.0 mL) in sequence. The mixture was stirred at room temperature for 1.0 hour. After the reaction was completed, the crude product was purified by reverse phase column chromatography (chromatographic column: The title compound 4D (110.0 mg) was obtained after purification using a flash silica gel column; mobile phase: acetonitrile / water = 70:30.

[0219] MS m / z(ESI):248.29[M+H] + .

[0220] Step 4: Preparation of 3-iodo-6-(((2-methoxyethyl)amino)methyl)-8-methyl-4H-chromen-4-one (Compound 4E)

[0221] Compound 4D (110.0 mg, 445 μmol) and tetrahydropyrrole (63.27 mg, 0.89 mmol) were added to methanol (2.0 mL), and the reaction mixture was stirred at 60°C for 1 hour. After TLC monitoring of the disappearance of the starting material, the reaction mixture was concentrated, and the crude product was added to dichloromethane (3.0 mL), followed by pyridine (0.1 mL) and iodine (225.8 mg, 0.89 mmol), and stirred at room temperature for 1 hour. After the reaction was completed, the reaction mixture was thoroughly concentrated to dryness, and the crude product was purified by reverse phase column chromatography (chromatographic column: Flash silica gel column; mobile phase: acetonitrile / water = 70:30) to give the title compound 4E (90.0 mg).

[0222] MS m / z(ESI):374.19[M+H]+.

[0223] Step 5: Preparation of cis-6-(((2-methoxyethyl)amino)methyl)-8-methyl-3-(3-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4H-chromen-4-one (Compound 4)

[0224] Compound 4E (66.0 mg, 176.86 μmol), 4F (74.97 mg, 212.23 μmol), and potassium carbonate (48.81 mg, 353.71 μmol) were added to a mixture of water (0.4 mL) and 1,4-dioxane (2.0 mL), and the atmosphere was replaced with nitrogen. Pd(dppf)Cl2 (12.95 mg, 17.69 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen and stirred for 1.0 hour. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain a crude product, which was then purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 50:50) to give the title compound 4 (20.00 mg).

[0225] MS m / z(ESI):473.47[M+H] + .

[0226] 1 H NMR (400MHz, DMSO-d6) δ8.63 (s, 1H), 8.31 (s, 1H), 7.94 (d, J = 2.1Hz, 1H), 7.66 ( dt,J=11.0,1.4Hz,2H),7.50–7.43(m,2H),7.31(dt,J=7.2,1.9Hz,1H),3.82(s ,2H),3.44(d,J=5.7Hz,2H),3.26(s,3H),3.25(s,3H),2.90(d,J=3.7Hz,2H),2 .66(t,J=5.7Hz,2H),2.56(d,J=7.1Hz,3H),2.50(s,3H),1.10(d,J=5.2Hz,3H).

[0227] Example 5: Preparation of cis-6-((((1-hydroxycyclobutyl)methyl)amino)methyl)-8-methyl-3-(3-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4H-chromen-4-one (Compound 5)

[0228] Step 1: Preparation of 6-((((1-hydroxycyclobutyl)methyl)amino)methyl)-8-methyl-4H-chromen-4-one (Compound 5A)

[0229] Compound 4C (150.0 mg, 592.67 μmol), 1-(aminomethyl)cyclobutane-1-ol (119.89 mg, 1.19 mmol) and potassium iodide (98.38 mg, 592.67 μmol) were added to DMF (5.0 mL) in sequence and stirred at room temperature for 1.0 hour. After the reaction, the crude product was purified by reverse phase column chromatography (chromatographic column: The title compound 5A (100.0 mg) was obtained after purification using a flash silica gel column; mobile phase: acetonitrile / water = 70:30).

[0230] MS m / z(ESI):274.33[M+H] + .

[0231] Step 2: Preparation of 3-iodo-6-((((1-hydroxycyclobutyl)methyl)amino)methyl)-8-methyl-4H-chromen-4-one (Compound 5B)

[0232] Compound 5A (100.0 mg, 366 μmol) and tetrahydropyrrole (52.0 mg, 733.0 μmol) were added to methanol (2.0 mL), and the reaction mixture was stirred at 60°C for 1 hour. After TLC monitoring of the disappearance of the starting material, the reaction mixture was concentrated, and the crude product was added to dichloromethane (3.0 mL), followed by pyridine (0.1 mL) and iodine (185.72 mg, 0.73 mmol), and stirred at room temperature for 1 hour. After the reaction was completed, the reaction mixture was thoroughly concentrated to dryness, and the resulting crude product was purified by reverse phase column chromatography (chromatographic column: Flash silica gel column; mobile phase: acetonitrile / water = 70:30) to give the title compound 5B (80.0 mg).

[0233] MS m / z(ESI):400.23[M+H] + .

[0234] Step 3: Preparation of cis-6-((((1-hydroxycyclobutyl)methyl)amino)methyl)-8-methyl-3-(3-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4H-chromen-4-one (Compound 5)

[0235] Compound 5B (80.0 mg, 200.39 μmol), 4F (70.79 mg, 200.39 μmol), and potassium carbonate (55.31 mg, 400.78 μmol) were added to a mixture of water (0.4 mL) and 1,4-dioxane (2.0 mL), and the atmosphere was replaced with nitrogen. Pd(dppf)Cl2 (14.67 mg, 20.04 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen and stirred for 1.0 hour. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain a crude product, which was then purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 70:30) to give the title compound 5 (20.00 mg).

[0236] MS m / z(ESI):499.48[M+H] + .

[0237] 1 H NMR (400MHz, DMSO-d6) δ8.61(d,J=6.3Hz,1H),8.29(d,J=1.9Hz,1H),7.94(s,1H),7.66(d,J =17.9Hz,2H),7.50–7.40(m,2H),7.27(dd,J=16.4,7.4Hz,1H),4.73(d,J=159.0Hz,1H),3.84 (s,2H),3.24(d,J=4.5Hz,3H),2.93–2.82(m,2H),2.55(d,J=4.7Hz,4H),2.48(d,J=7.2Hz,3H ),1.96(dt,J=36.4,9.8Hz,4H),1.81–1.56(m,2H),1.47–1.33(m,1H),1.09(d,J=5.2Hz,3H).

[0238] Example 6: Preparation of cis-3-(3-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-7-(1-((1-methylcyclobutyl)amino)ethyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 6)

[0239] Step 1: Preparation of 1-(6-amino-5-(trifluoromethyl)pyridin-3-yl)ethan-1-one (Compound 6B)

[0240] Compound 6A (300.0 mg, 1.24 mmol) and tri-n-butyl(1-ethoxyvinyl)tin (674.32 mg, 1.87 mmol) were added to toluene (10.0 mL) and the nitrogen atmosphere was replaced. Bis(triphenylphosphine)palladium dichloride (87.37 mg, 124.48 μmol) was added and the resulting mixture was heated to 100°C under nitrogen protection and stirred for 16.0 hours. The crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 70:30) and concentrated to obtain the intermediate, which was stirred with dioxane hydrochloride solution (4.0 M, 5.0 mL) at room temperature for 1.0 hour. The reaction solution was concentrated to obtain the title compound 6B (180.0 mg).

[0241] MS m / z(ESI):205.15[M+H] + .

[0242] Step 2: Preparation of 5-(1-((1-methylcyclobutyl)amino)ethyl)-3-(trifluoromethyl)pyridin-2-amine (Compound 6C)

[0243] Compound 6B (180.0 mg, 0.88 mmol), 1-methylcyclobutylamine hydrochloride (321.67 mg, 2.65 mmol) and tetraisopropyl titanate (1.0 g, 3.53 mmol) were added to DCE (4.0 mL), followed by triethylamine (446.1 mg, 4.41 mmol). The mixture was heated to 80°C and stirred for 16.0 hours. After TLC monitoring of the disappearance of the starting material, methanol (4.0 mL) was added to the reaction solution, followed by sodium borohydride (166.8 mg, 4.41 mmol), and the mixture was stirred at room temperature for 3.0 hours. After the reaction was completed, the crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 65:35) to give the title compound 6C (180.0 mg).

[0244] MS m / z(ESI):274.3[M+H] + .

[0245] Step 3: Preparation of 7-[1-[(1-methylcyclobutyl)amino]ethyl]-9-(trifluoromethyl)pyrido[1,2-a]pyrimidin-4-one (Compound 6D)

[0246] Compound 6C (180.0 mg, 658.63 μmol) and 5-(methoxymethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione (122.61 mg, 658.63 μmol) were added to diphenyl ether (3.0 mL), and the reaction was heated to 120°C and stirred for 1.0 hour. After TLC monitoring of the disappearance of the starting material, the reaction was heated to 210°C and stirred for 1.0 hour. The reaction was cooled to room temperature, and the crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 60:40) to give the title compound 6D (20.0 mg).

[0247] MS m / z(ESI):326.33[M+H] + .

[0248] Step 4: Preparation of 3-iodo-7-[1-[(1-methylcyclobutyl)amino]ethyl]-9-(trifluoromethyl)pyrido[1,2-a]pyrimidin-4-one (Compound 6E)

[0249] At room temperature, compound 6D (20.0 mg, 61.48 μmol), cerium ammonium nitrate (32.58 mg, 61.48 μmol) and iodine (15.6 mg, 61.48 μmol) were added to an acetonitrile solution (3.0 mL) in sequence. The reaction solution was then stirred for 6 hours. After the reaction was completed, saturated aqueous sodium sulfite solution (10 mL) was added to quench the reaction and extracted with dichloromethane (50 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain a crude product. The crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 50:50) to give the title compound 6E (10.0 mg).

[0250] MS m / z(ESI):452.22[M+H] + .

[0251] Step 5: Preparation of cis-3-(3-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-7-(1-((1-methylcyclobutyl)amino)ethyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 6)

[0252] Compound 6E (10.0 mg, 22.16 μmol), 4F (11.74 mg, 33.24 μmol), and potassium carbonate (6.12 mg, 44.32 μmol) were added to a mixture of water (0.4 mL) and 1,4-dioxane (2.0 mL), and the atmosphere was replaced with nitrogen. Pd(dppf)Cl2 (1.62 mg, 2.22 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen and stirred for 1.0 hour. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain a crude product, which was then purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 50:50) to give the title compound 6 (2.4 mg).

[0253] MS m / z(ESI):551.64[M+H] + .

[0254] 1 H NMR(400MHz,DMSO-d6)δ9.29(s,1H),8.68(s,1H),8.61(s,1H),8.31(s,1H),7.93(s,1H),7. 69(d,J=7.7Hz,1H),7.48(t,J=7.8Hz,1H),7.30(d,J=7.8Hz,1H),4.18(d,J=6.2Hz,1H),3.2 5(s,3H),2.90(s,2H),2.57(d,J=6.5Hz,3H),1.91(t,J=9.7Hz,1H),1.77(t,J=9.4Hz,2H),1 .59(d,J=6.9Hz,2H),1.50(s,1H),1.34(d,J=6.7Hz,3H),1.15(s,3H),1.11(d,J=4.7Hz,3H).

[0255] Example 7: Preparation of cis-7-(1-((2-methoxyethyl)amino)ethyl)-3-(3-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 7)

[0256] Step 1: Preparation of 7-acetyl-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 7B)

[0257] Compound 7A (1.85 g, 5.12 mmol) and tri-n-butyl(1-ethoxyvinyl)tin (2.77 g, 7.68 mmol) were added to 1,4-dioxane (10.0 mL), and the nitrogen atmosphere was replaced. Tetrakis(triphenylphosphine)palladium (197.24 mg, 170.63 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen protection and stirred for 16.0 hours. The crude product was purified by reverse phase column chromatography (chromatographic column: The reaction mixture was purified by flash silica gel column; mobile phase: acetonitrile / water = 70:30) and concentrated to obtain the intermediate, which was added to dichloromethane (6.0 mL) and trifluoroacetic acid (2.0 mL) and stirred at room temperature for 1.0 hour. The reaction mixture was concentrated to obtain the title compound 7B (650.0 mg).

[0258] MS m / z(ESI):257.18[M+H] + .

[0259] Step 2: Preparation of 7-(1-((2-methoxyethyl)amino)ethyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 7C)

[0260] Compound 7B (86.0 mg, 0.36 mmol), 2-methoxyethane-1-amine (50.43 mg, 0.67 mmol) and tetraisopropyl titanate (381.64 mg, 1.34 mmol) were added to 1,2-dichloroethane (2.0 mL). The resulting mixture was heated to 60°C and stirred for 2.0 hours. After TLC monitoring of the disappearance of the starting material, acetic acid (0.1 mL) was added to the reaction solution, followed by sodium triacetoxyborohydride (284.59 mg, 1.34 mmol), and the mixture was stirred at room temperature for 16.0 hours. After the reaction was completed, the crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 65:35) to give the title compound 7C (40.0 mg).

[0261] MS m / z(ESI):316.12[M+H] + .

[0262] Step 3: Preparation of 3-iodo-7-(1-((2-methoxyethyl)amino)ethyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 7D)

[0263] At room temperature, compound 7C (160.0 mg, 507.47 μmol), cerium ammonium nitrate (538.1 mg, 1.01 mmol), and iodine (257.6 mg, 1.01 mmol) were added to an acetonitrile solution (4.0 mL) in sequence and stirred for 3 hours. After the reaction was completed, saturated aqueous sodium sulfite solution (10 mL) was added to quench the reaction, and the mixture was extracted with dichloromethane (50 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure to obtain a crude product. The crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 50:50) to give the title compound 7D (140.0 mg).

[0264] MS m / z(ESI):442.02[M+H] + .

[0265] Step 4: Preparation of cis-7-(1-((2-methoxyethyl)amino)ethyl)-3-(3-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 7)

[0266] Compound 7D (42.46 mg, 96.25 μmol), 4F (34.0 mg, 96.25 μmol), and potassium carbonate (26.56 mg, 192.49 μmol) were added to a mixture of water (0.4 mL) and 1,4-dioxane (2.0 mL), and the atmosphere was replaced with nitrogen. Pd(dppf)Cl2 (7.05 mg, 9.62 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen and stirred for 1.0 hour. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain a crude product, which was then purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 50:50) to give the title compound 7 (11.88 mg).

[0267] MS m / z(ESI):541.46[M+H] + .

[0268] 1H NMR(400MHz,DMSO-d6)δ9.20(d,J=1.8Hz,1H),8.67(s,1H),8.49(d,J=1.9Hz,1H),8.29 (s,1H),7.91(d,J=2.0Hz,1H),7.68(d,J=7.7Hz,1H),7.46(t,J=7.8Hz,1H),7.29(d,J= 7.8Hz,1H),4.02(d,J=6.7Hz,1H),3.42–3.38(m,1H),3.23(s,3H),3.22(s,3H),2.88(d,J =3.6Hz,2H),2.64–2.53(m,4H),1.34(d,J=6.6Hz,3H),1.24(s,1H),1.09(d,J=5.0Hz,3H).

[0269] Example 8: 4-[2-cyclopropyl-6-[7-[(2-methoxyethylamino)methyl]-4-oxo-pyrido[1,2-a]pyrimidin-3-yl]-4-pyridinyl]-3-(4-methyl-1,2,4-triazol-3-yl)benzonitrile (Compound 8)

[0270] Step 1: Preparation of 7-bromopyrido[1,2-a]pyrimidin-4-one (Compound 8B)

[0271] Compound 8A (500 mg, 2.89 mmol) and 5-(methoxymethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione (538 mg, 2.89 mmol) were dissolved in diphenyl ether (5 mL) and heated to 120°C for 1 hour, then to 240°C for 30 minutes. After completion of the reaction, the mixture was cooled to room temperature, and the crude product was purified on a normal phase silica gel column (PE:EA = 1:0 to 0:1) to obtain the title compound 8B (340 mg).

[0272] MS M / z(ESI):225 / 227[M+H] + ;

[0273] Step 2: Preparation of 7-(hydroxymethyl)pyrido[1,2-a]pyrimidin-4-one (Compound 8C)

[0274] A mixture of compound 8B (340 mg, 1.51 mmol), tetrakis(triphenylphosphine)palladium (174.59 mg, 151.08 μmol), (tributyltin)methanol (970.22 mg, 3.02 mmol) and 1,4-dioxane (5 mL) was added to a reaction tube, evacuated and replaced with argon, and heated to 100 ° C for overnight reaction. Cooled to room temperature, and then analyzed by reverse phase chromatography ( The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 5:95) to give the title compound 8C (230 mg).

[0275] MS M / z(ESI):177[M+H] + ;

[0276] Step 3: Preparation of 7-(chloromethyl)pyrido[1,2-a]pyrimidin-4-one (Compound 8D)

[0277] Compound 8C (230 mg, 1.31 mmol) was dissolved in DCM (3 mL), and thionyl chloride (776.60 mg, 6.53 mmol) was added. The mixture was heated to 50°C and reacted for 5 hours. After completion of the reaction, the mixture was cooled to room temperature and concentrated to afford crude compound 8D (254 mg), which was carried on to the next step without purification.

[0278] MS M / z(ESI):195[M+H] + ;

[0279] Step 4: Preparation of 7-[(2-methoxyethylamino)methyl]pyrido[1,2-a]pyrimidin-4-one (Compound 8E)

[0280] Compound 8D (230 mg, 1.18 mmol) was dissolved in DMF (3 mL), potassium carbonate (490.00 mg, 3.55 mmol) and 2-methoxyethylamine (266.30 mg, 3.55 mmol) were added, and stirred overnight. After the reaction was completed, the mixture was purified by reverse phase chromatography ( The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 25:75) to give the title compound 8E (275 mg).

[0281] MS M / z(ESI):234[M+H] + ;

[0282] Step 5: Preparation of tert-butyl N-(2-methoxyethyl)-N-[(4-oxopyrido[1,2-a]pyrimidin-7-yl)methyl]carbamate (Compound 8F)

[0283] Compound 8E (275.67 mg, 1.18 mmol) was dissolved in DMF (3 mL), and DMAP (14.44 mg, 118.18 μmol) and Boc2O (257.92 mg, 1.18 mmol) were added and stirred overnight. After the reaction was completed, the mixture was purified by reverse phase chromatography ( The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 30:70) to give the title compound 8F (150 mg).

[0284] MS M / z(ESI):334[M+H] + ;

[0285] Step 6: Preparation of tert-butyl N-[(3-iodo-4-oxo-pyrido[1,2-a]pyrimidin-7-yl)methyl]-N-(2-methoxyethyl)carbamate (Compound 8G)

[0286] Compound 8F (150 mg, 449.94 μmol) was dissolved in acetonitrile (5 mL), and cerium ammonium nitrate (238.55 mg, 449.94 μmol) and iodine (228.39 mg, 899.87 μmol) were added and stirred overnight. After the reaction was completed, saturated aqueous sodium sulfite solution (10 mL) was added to quench the reaction, and the mixture was extracted with dichloromethane (50 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure to obtain a crude product. The crude product was purified by reverse phase chromatography ( The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 30:70) to obtain the title compound 8G (145 mg).

[0287] MS M / z(ESI):460[M+H] + ;

[0288] Step 7: Preparation of tert-butyl N-[[3-[4-[4-cyano-2-(4-methyl-1,2,4-triazol-3-yl)phenyl]-6-cyclopropyl-2-pyridyl]-4-oxo-pyrido[1,2-a]pyrimidin-7-yl]methyl]-N-(2-methoxyethyl)carbamate (Compound 8H)

[0289] 19B (20.21 mg, 43.55 μmol), compound 8G (10 mg, 21.77 μmol), and tetrakis(triphenylphosphine)palladium (2.52 mg, 2.18 μmol) were added to DMF (1 mL), the argon atmosphere was replaced, and then heated to 130°C and stirred for 1 hour. After the reaction was completed, the mixture was cooled to room temperature and subjected to reverse phase chromatography ( The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 20:80) to give the title compound 8H (5 mg).

[0290] MS M / z(ESI):633[M+H] + ;

[0291] Step 8: Preparation of 4-[2-cyclopropyl-6-[7-[(2-methoxyethylamino)methyl]-4-oxo-pyrido[1,2-a]pyrimidin-3-yl]-4-pyridinyl]-3-(4-methyl-1,2,4-triazol-3-yl)benzonitrile (Compound 8)

[0292] Compound 8H (40 mg, 63.22 μmol) was dissolved in DCM (3 mL), TFA (36.04 mg, 316.10 μmol) was added, and stirred for 2 hours. After the reaction was completed, the reaction solution was concentrated and the crude product was purified by reverse phase chromatography ( The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 40:60) to obtain the title compound 8 (9 mg).

[0293] MS M / z(ESI):533[M+H] + ;

[0294] 1 H NMR(400MHz, DMSO-d6)δ9.26(s,1H),9.10(s,1H),8.51(s,1H),8.25–8.19(m,2H),8.12–8.03(m,2H),7.89(d,J=8.0Hz,1H),7.80(d ,J=9.0Hz,1H),6.94(s,1H),3.91(s,2H),3.49-3.38(m,5H),3.25(s,3H),2.75-2.68(m,2H),2.15-2.05(m,1H),1.03–0.90(m,5H).

[0295] Example 9: Preparation of cis-7-(((2-methoxyethyl)amino)methyl)-3-(3-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 9)

[0296] Step 1: Preparation of 7-(tert-butoxymethyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 9A)

[0297] Compound 7A (1.3 g, 4.44 mmol), potassium tert-butyloxymethyltrifluoroborate (1.7 g, 8.87 mmol), and potassium carbonate (1.84 g, 13.3 mmol) were added to 1,4-dioxane (100.0 mL) and water (15.0 mL), and the atmosphere was replaced with nitrogen. Under a nitrogen atmosphere, Xphos Pd G2 (348.6 mg, 443.63 μmol) and Xphos (422.97 mg, 887.25 μmol) were added. The resulting mixture was heated to 100°C under nitrogen and stirred for 4.0 hours. After the reaction, the crude product was purified by normal phase column chromatography (petroleum ether:ethyl acetate = 1:1) to obtain the title compound 9A (430.0 mg).

[0298] MS m / z(ESI):301.1[M+H] + .

[0299] Step 2: Preparation of 7-(tert-butoxymethyl)-3-iodo-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 9B)

[0300] Compound 9A (400.0 mg, 1.33 mmol), cerium ammonium nitrate (706.3 mg, 1.33 mmol), and iodine (405.7 mg, 1.60 mmol) were added to an acetonitrile solution (25.0 mL). The reaction mixture was then stirred for 3 hours. After completion of the reaction, saturated aqueous sodium sulfite solution (10 mL) was added to quench the reaction, and the mixture was extracted with dichloromethane (50 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure to yield the crude product, title compound 9B (550.0 mg).

[0301] MS m / z(ESI):427.2[M+H] + .

[0302] Step 3: Preparation of cis-7-(tert-butoxymethyl)-3-(3-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 9C)

[0303] Compound 9B (300.0 mg, 703.9 μmol), 4F (248.7 mg, 703.9 μmol), and potassium carbonate (291.9 mg, 2.11 mmol) were added to a mixture of water (2 mL) and 1,4-dioxane (10 mL), and the atmosphere was replaced with nitrogen. Pd(dppf)Cl2 (51.5 mg, 70.4 μmol) was added under a nitrogen atmosphere, and the resulting mixture was heated to 100°C under nitrogen protection and stirred for 1.0 hour. The crude product was purified by reverse phase column chromatography (chromatographic column: The title compound 9C (280 mg) was purified by flash silica gel column; mobile phase: acetonitrile / water = 60:40.

[0304] MS m / z(ESI):526.2[M+H]+.

[0305] Step 4: Preparation of cis-7-(chloromethyl)-3-(3-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (9D)

[0306] Compound 9C (280 mg, 532.8 μmol) was dissolved in DCM (10 mL), and TFA (5 mL) was added. The mixture was stirred at room temperature for 5 hours. After completion of the reaction, the reaction solution was concentrated and dissolved in DCM (10 mL). Dichlorothionyl (2 mL) was added under ice-bath, and the mixture was stirred for 2 hours. The mixture was concentrated to give the title compound 9D (240 mg).

[0307] MS m / z(ESI):488.2[M+H] + .

[0308] Step 5: Preparation of cis-7-(((2-methoxyethyl)amino)methyl)-3-(3-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 9)

[0309] Compound 9D (25 mg, 51.2 μmol) was dissolved in acetonitrile (2 mL), and then 2-methoxyethane-1-amine (22.5 mg, 204.8 μmol) and DIEA (19.9 mg, 153.7 μmol) were added. The mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated and the residue was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 60:40) to give the title compound 9 (6.0 mg).

[0310] MS m / z(ESI):527.1[M+H] + .

[0311] 1 H NMR(400MHz,DMSO-d6)δ9.20(d,J=1.8Hz,1H),8.67(s,1H),8.49(d,J=1.9Hz,1H ),8.29(s,1H),7.91(d,J=2.0Hz,1H),7.68(d,J=7.7Hz,1H),7.46(t,J=7.8Hz,1H ),7.29(d,J=7.8Hz,1H),4.02(d,J=6.7Hz,1H),3.23(s,3H),3.22(s,3H),2.88( d,J=3.6Hz,2H),2.64–2.53(m,4H),1.34(d,J=6.6Hz,3H),1.09(d,J=5.0Hz,3H).

[0312] Example 10: Preparation of cis-7-((((S)-1-methoxypropan-2-yl)amino)methyl)-3-(3-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 10)

[0313] Compound 9D (25 mg, 51.2 μmol) was dissolved in acetonitrile (2 mL), and then (S)-1-methoxy-2-propylamine hydrochloride (19.2 mg, 153.7 μmol) and DIEA (19.9 mg, 153.7 μmol) were added. The resulting solution was stirred at room temperature for 1 hour. The reaction solution was concentrated and the residue was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 60:40) to give the title compound 10 (5.9 mg).

[0314] MS m / z(ESI):541.1[M+H] + .

[0315] Example 11: Preparation of cis-7-((((S)-2-methoxypropyl)amino)methyl)-3-(3-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 11)

[0316] Compound 9D (25 mg, 51.2 μmol) was dissolved in acetonitrile (2 mL), and then (S)-2-methoxypropane-1-amine hydrochloride (19.2 mg, 153.7 μmol) and DIEA (19.9 mg, 153.7 μmol) were added. The resulting solution was stirred at room temperature for 1 hour, and the solvent was removed by rotary evaporation. The residue was purified by reverse phase column chromatography (chromatographic column: Flash silica gel column; mobile phase: acetonitrile / water = 60:40) to give the title compound 11 (5.0 mg).

[0317] MS m / z(ESI):541.1[M+H] + .

[0318] Example 12: Preparation of cis-7-((((1-hydroxycyclobutyl)methyl)amino)methyl)-3-(3-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 12)

[0319] Compound 9D (25 mg, 51.2 μmol) was dissolved in acetonitrile (2 mL), and then 1-(aminomethyl)cyclobutane-1-ol hydrochloride (21.1 mg, 153.7 μmol) and DIEA (19.9 mg, 153.7 μmol) were added. The resulting solution was stirred at room temperature for 1 hour, and the solvent was removed by rotary evaporation. The residue was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 60:40) to give the title compound 12 (7.0 mg).

[0320] MS m / z(ESI):553.1[M+H] + .

[0321] Example 13: Preparation of 3-[7-[1-[(1-methylcyclobutyl)amino]ethyl]-4-oxo-9-(trifluoromethyl)pyrido[1,2-a]pyrimidin-3-yl]-5-[3-methyl-1-(4-methyl-1,2,4-triazol-3-yl)cyclobutyl]benzonitrile (Compound 13)

[0322] Step 1: Preparation of 2-(3-bromo-5-chloro-phenyl)acetic acid (Compound 13B)

[0323] Compound 13A (1 g, 4.34 mmol) was dissolved in ethanol (5 mL) and water (5 mL), and NaOH (1.74 g, 43.39 mmol) was added to the mixture, and the mixture was heated under reflux for 8 hours. The mixture was cooled to room temperature, concentrated to remove ethanol, and the pH was adjusted to 1 with concentrated HCl. Ethyl acetate (50 mL) was added for extraction, and the organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product of compound 13B without further purification.

[0324] MS M / z(ESI):247 / 249[MH] + ;

[0325] Step 2: Preparation of methyl 2-(3-bromo-5-chloro-phenyl)acetate (Compound 13C)

[0326] Compound 13B (900 mg, 3.61 mmol) was dissolved in methanol (10 mL), and thionyl chloride (42.92 mg, 360.74 μmol) was added. The mixture was heated under reflux for 1 hour. After cooling to room temperature, the reaction solution was concentrated and diluted with ethyl acetate (50 mL). The mixture was washed with saturated aqueous NaHCO₃ (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product. The crude product was purified by silica gel column chromatography (100% PE) to give the title compound 13C (930 mg).

[0327] MS M / z(ESI):263 / 265[M+H] + ;

[0328] Step 3: Preparation of 1-(3-bromo-5-chloro-phenyl)-3-methyl-cyclobutanecarboxylic acid methyl ester (Compound 13D)

[0329] NaH (282.34 mg, 7.06 mmol, purity 60%) was added to a dry three-necked flask, the argon atmosphere was replaced, DMF (40 mL) was added, and the mixture was cooled in an ice-water bath. A solution of 1,3-dibromo-2-methyl-propane (914.41 mg, 4.24 mmol) and compound 13C (930 mg, 3.53 mmol) in DMF (10 mL) was slowly added dropwise to the mixture, and the mixture was warmed to room temperature and stirred for 1 hour. The mixture became clear. After the reaction was completed, the mixture was added dropwise to a saturated NH4Cl solution, the liquid was separated, and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was then chromatographed on a reverse phase column (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 5%-98%, 15 min) to give the title compound 13D (1.12 g).

[0330] MS M / z(ESI):317 / 319[M+H] + ;

[0331] Step 4: Preparation of 1-(3-bromo-5-chloro-phenyl)-3-methyl-cyclobutanecarboxylic acid (Compound 13E)

[0332] Compound 13D (1.12 g, 3.53 mmol) was dissolved in water (7.5 mL) and ethanol (10 mL), and NaOH (564.22 mg, 14.11 mmol) was added. The mixture was then heated to 70°C for 2 hours. After cooling to room temperature, the reaction solution was concentrated and the pH was adjusted to 1 with concentrated HCl. The solution was extracted with ethyl acetate (50 mL), and the organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to afford crude product 13E (1.07 g), which was carried on to the next step without purification.

[0333] MS M / z(ESI):301 / 303[MH] + ;

[0334] Step 5: Preparation of 1-[[1-(3-bromo-5-chloro-phenyl)-3-methyl-cyclobutanecarbonyl]amino]-3-methyl-thiourea (Compound 13F)

[0335] 1-Amino-3-methyl-thiourea (444.79 mg, 4.23 mmol), compound 13E (1.07 g, 3.52 mmol) and HATU (1.73 g, 4.58 mmol) were added to a dry flask, the argon atmosphere was replaced, DMF (10 mL) and DIEA (1.37 g, 10.57 mmol) were added via syringe, and the mixture was stirred for 1 h. EA (50 mL) was added for extraction, the mixture was washed with water (100 mL), dried over anhydrous sodium sulfate, filtered, concentrated and subjected to reverse phase column chromatography (chromatographic column: The title compound 13F (910 mg) was purified by flash silica gel column; mobile phase: acetonitrile / water = 5%-98%, 15 min).

[0336] MS M / z(ESI):390 / 392[M+H] + ;

[0337] Step 6: Preparation of 5-[1-(3-bromo-5-chloro-phenyl)-3-methyl-cyclobutyl]-4-methyl-1,2,4-triazole-3-thiol (Compound 13G)

[0338] Compound 13F was dissolved in a mixture of NaOH (1.86 g, 46.58 mmol) and THF / H2O (15 mL / 25 mL), and then heated under reflux for 6 hours. The mixture was cooled to room temperature, extracted with DCM, dried over anhydrous sodium sulfate, filtered, concentrated, and the crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 5%-98%, 15 min) to obtain compound 13G (550 mg).

[0339] MS M / z(ESI):372 / 374[M+H] + ;

[0340] Step 7: Preparation of 3-[1-(3-bromo-5-chloro-phenyl)-3-methyl-cyclobutyl]-4-methyl-1,2,4-triazole (Compound 13H)

[0341] Compound 13G (550 mg, 1.48 mmol) was dissolved in AcOH (2 mL) and DCM (20 mL), cooled in an ice bath, and H2O2 (250.94 mg, 7.38 mmol) was added and stirred for 1 h. Reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 5%-98%, 15 min) to give compound 13H (370 mg).

[0342] MS M / z(ESI):340 / 342[M+H] + ;

[0343] Step 8: Preparation of 3-chloro-5-[3-methyl-1-(4-methyl-1,2,4-triazol-3-yl)cyclobutyl]benzonitrile (Compound 13I)

[0344] Compound 13H (120 mg, 352.27 μmol), tetrakis(triphenylphosphine)palladium (81.41 mg, 70.45 μmol) and Zn(CN)2 (124.47 mg, 1.06 mmol) were mixed and argon was replaced. DMF (2 mL) was then added using a syringe and heated to 130°C for 3 hours. The mixture was cooled to room temperature and subjected to reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 5%-98%, 15 min) to give compound 13I (81 mg).

[0345] MS M / z(ESI):287.1[M+H] + ;

[0346] Step 9: Preparation of 3-[3-methyl-1-(4-methyl-1,2,4-triazol-3-yl)cyclobutyl]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (Compound 13J)

[0347] Compound 13I (10 mg, 34.87 μmol), potassium acetate (6.84 mg, 69.75 μmol), PCy3 (2.93 mg, 10.46 μmol), B2Pin2 (17.71 mg, 69.75 μmol), and Pd(dba)2 (1.98 mg, 3.49 μmol) were mixed and the argon atmosphere was replaced. 1,4-dioxane (1 mL) was then added and heated to 100°C overnight. The mixture was cooled to room temperature and filtered to obtain the crude product of compound 13J, which was directly carried out to the next step without purification.

[0348] MS M / z(ESI):379[M+H] + ;

[0349] Step 10: Preparation of 3-[7-[1-[(1-methylcyclobutyl)amino]ethyl]-4-oxo-9-(trifluoromethyl)pyrido[1,2-a]pyrimidin-3-yl]-5-[3-methyl-1-(4-methyl-1,2,4-triazol-3-yl)cyclobutyl]benzonitrile (Compound 13)

[0350] Compound 13J (12.57 mg, 33.24 μmol), compound 6E (13.49 mg, 29.92 μmol), Pd(dppf)Cl2 (2.43 mg, 3.32 μmol) and K2CO3 (9.19 mg, 66.49 μmol) were added to the reaction tube, and the argon atmosphere was replaced. Water (0.2 mL) and 1,4-dioxane (1 mL) were then added via syringe. The mixture was heated to 100°C for 1 hour. The mixture was cooled to room temperature and the crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 5%-98%, 15 min) to give compound 13 (4.5 mg).

[0351] MS M / z(ESI):576.3[M+H] + ;

[0352] 1 H NMR (400MHz, DMSO-d6) δ9.28(s,1H),8.75(s,1H),8.63(s,1H),8.32(s,1H),8.17(d,J=5.5Hz,2H),7.80(s,1H),4.18(s,1H),3.24(s,3H) ,2.94(s,2H),2.58(s,2H),2.34(s,1H),2.04–1.87(m,2H),1.64–1.40(m,4H),1.32(d,J=6.7Hz,3H),1.13(s,3H),1.09(d,J=5.0Hz,3H).

[0353] Example 14: Preparation of 4-[2-cyclopropyl-6-[6-[(2-methoxyethylamino)methyl]-8-methyl-4-oxo-chromen-3-yl]-4-pyridinyl]-3-(4-methyl-1,2,4-triazol-3-yl)benzonitrile (Compound 14)

[0354] Step 1: Preparation of 1-(5-bromo-2-hydroxy-3-methyl-phenyl)ethanone (Compound 14B)

[0355] Compound 14A (1 g, 6.66 mmol) was dissolved in dichloromethane (20 mL) and cooled in an ice bath. A solution of bromine (1.92 g, 11.99 mmol) in dichloromethane (5 mL) was slowly added dropwise to the mixture. The mixture was stirred for 1 hour, warmed to room temperature, and quenched with a saturated aqueous sodium sulfite solution (5 mL). The organic phase was separated, and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to afford the crude title compound 14B (1.3 g), which was used directly in the next step without purification.

[0356] MS M / z(ESI):227 / 229[MH] + ;

[0357] Step 2: Preparation of 1-(5-bromo-2-hydroxy-3-methyl-phenyl)-3-(dimethylamino)prop-2-en-1-one (Compound 14C)

[0358] Compound 14B (1.3 g, 5.68 mmol) was dissolved in DMF-DMA (5 mL), heated to 100°C, and stirred for 5 h. The mixture was cooled to room temperature and concentrated to give crude compound 14C (1.6 g), which was used in the next step without purification.

[0359] MS M / z(ESI):284 / 286[M+H] + ;

[0360] Step 3: Preparation of 6-bromo-8-methyl-chromen-4-one (Compound 14D)

[0361] Compound 14C (1.6 g, 5.63 mmol) was dissolved in DCM (10 mL) and concentrated HCl (1 mL) was added under ice-cooling. The mixture was stirred for 1 h. The mixture was diluted with ethyl acetate (100 mL), washed with saturated aqueous NaHCO₃, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (PE:EA = 1:3) to afford the title compound 14D (700 mg).

[0362] MS M / z(ESI):239 / 241[M+H] + ;

[0363] Step 4: Preparation of 6-(hydroxymethyl)-8-methyl-chromen-4-one (Compound 14E)

[0364] Compound 14D (700 mg, 2.93 mmol) and tetrakis(triphenylphosphine)palladium (169.77 mg, 146.40 μmol) were mixed and argon was replaced. 1,4-dioxane (5 mL) and (tri-n-butyltin)methanol (1.41 g, 4.39 mmol) were added and heated to 100°C for 18 h. The reaction was cooled to room temperature and the crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 5%-98% (15 min) to give the title compound 14E (470 mg).

[0365] MS M / z(ESI):191[M+H] + ;

[0366] Step 5: Preparation of 6-(chloromethyl)-8-methyl-chromen-4-one (Compound 14F)

[0367] Compound 14E (470 mg, 2.47 mmol) was dissolved in DCM (5 mL), and thionyl chloride (1.47 g, 12.36 mmol) was added, and the mixture was heated to 50° C. for 5 hours. The mixture was cooled to room temperature and concentrated to give crude compound 14F (515 mg), which was used in the next step without purification.

[0368] MS M / z(ESI):209[M+H] + ;

[0369] Step 6: Preparation of 6-[(2-methoxyethylamino)methyl]-8-methyl-chromen-4-one (Compound 14G)

[0370] Compound 14F (515 mg, 2.47 mmol) was dissolved in DMF (3 mL), potassium carbonate (1.02 g, 7.41 mmol), KI (410 mg, 2.47 mmol) and 2-methoxyethylamine (556.20 mg, 7.41 mmol) were added, and stirred overnight. The crude product was purified by reverse phase column chromatography (chromatographic column: The title compound 14G (330 mg) was purified by flash silica gel column; mobile phase: acetonitrile / water = 5%-98% (15 min).

[0371] MS M / z(ESI):248[M+H] + ;

[0372] Step 7: Preparation of 1-[2-hydroxy-5-[(2-methoxyethylamino)methyl]-3-methyl-phenyl]-3-pyrrolidin-1-yl-prop-2-en-1-one (Compound 14H)

[0373] Compound 14G (330 mg, 1.33 mmol) was dissolved in MeOH (5 mL), pyrrolidine (1 mL) was added to the mixture, and the mixture was stirred at 50° C. for 2 h. After cooling to room temperature, the mixture was concentrated to give crude compound 14H (424 mg), which was used directly in the next step.

[0374] MS M / z(ESI):319.2[M+H] + ;

[0375] Step 8: Preparation of 3-iodo-6-[(2-methoxyethylamino)methyl]-8-methyl-chromen-4-one (Compound 14I)

[0376] Compound 14H (424 mg, 1.33 mmol) was dissolved in DCM (5 mL), and then pyridine (211.11 mg, 2.67 mmol, 215.00 μL) and iodine (677.40 mg, 2.67 mmol) were added to the mixture and stirred for 1 h. The crude product was purified by reverse phase column chromatography (chromatographic column: The title compound 14I (170 mg) was purified by flash silica gel column; mobile phase: acetonitrile / water = 5%-98%, 15 min).

[0377] MS M / z(ESI):374[M+H] + ;

[0378] Step 9: Preparation of 4-[2-cyclopropyl-6-[6-[(2-methoxyethylamino)methyl]-8-methyl-4-oxo-chromen-3-yl]-4-pyridinyl]-3-(4-methyl-1,2,4-triazol-3-yl)benzonitrile (Compound 14)

[0379] Compound 19B (41.04 mg, 88.43 μmol), compound 14I (30 mg, 80.39 μmol), and tetrakis(triphenylphosphine)palladium (9.29 mg, 8.04 μmol) were added to DMF (1 mL) and the argon atmosphere was replaced. The mixture was then heated to 130°C and stirred for 1 hour. The mixture was cooled to room temperature and the crude product was purified by reverse phase chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 5%-98%, 15 min) to give the title compound 14 (3 mg).

[0380] MS M / z(ESI):547.2[M+H] + ;

[0381] 1 H NMR(400MHz,DMSO-d6)δ9.05(s,1H),8.52(s,1H),8.24-8.18(m,2H),7.99(s,1H),7.91–7.84(m,2H),7.71(s,1H),7.04(s,1H),3.8 6(s,2H),3.45-3.4(m,5H),3.25(s,3H),2.70(t,J=5.8Hz,2H),2.38(s,3H),2.10–1.96(m,2H),0.96(s,2H),0.86(t,J=6.7Hz,2H).

[0382] Example 15: Preparation of cis-3-[3-[3-methyl-1-(4-methyl-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-7-[1-[(3-methyloxetane-3-yl)amino]ethyl]-9-(trifluoromethyl)pyrido[1,2-a]pyrimidin-4-one (Compound 15)

[0383] Step 1: Preparation of 7-acetyl-9-(trifluoromethyl)pyrido[1,2-a]pyrimidin-4-one (Compound 15A)

[0384] Compound 7A (1 g, 3.41 mmol), tetrakis(triphenylphosphine)palladium (394.34 mg, 341.25 μmol), tributyl(1-ethoxyvinyl)tin (3.70 g, 10.24 mmol), and 1,4-dioxane (2 mL) were mixed and replaced with argon. The mixture was heated to 100°C overnight. The mixture was cooled to room temperature, and aqueous HCl (1 M, 1 mL) was added and stirred for 1 hour. The mixture was extracted with ethyl acetate (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 5%-98%, 15 min) to give compound 15A (470 mg).

[0385] MS M / z(ESI):257[M+H] + ;

[0386] Step 2: Preparation of 7-[1-[(3-methyloxetan-3-yl)amino]ethyl]-9-(trifluoromethyl)pyrido[1,2-a]pyrimidin-4-one (Compound 15B)

[0387] A mixture of compound 15A (50 mg, 195.17 μmol), 3-methyloxetane-3-amine (34.01 mg, 390.35 μmol), titanium tetraisopropoxide (221.88 mg, 780.70 μmol), triethylamine (98.75 mg, 975.87 μmol, 136.11 μL) and DCE (2 mL) was heated to 80°C overnight. The mixture was cooled to room temperature and then cooled in an ice bath. AcOH (1 mL) and sodium triacetoxyborohydride (206.83 mg, 975.87 μmol) were added and stirred for 2 hours. The mixture was quenched with water, filtered through celite, and purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 5%-98%, 15 min) to give compound 15B (15 mg).

[0388] MS M / z(ESI):328[M+H] + ;

[0389] Step 3: Preparation of 3-iodo-7-[1-[(3-methyloxetan-3-yl)amino]ethyl]-9-(trifluoromethyl)pyrido[1,2-a]pyrimidin-4-one (Compound 15C)

[0390] Compound 15B (15 mg, 45.83 μmol) was dissolved in acetonitrile (5 mL), and iodine (23.26 mg, 91.66 μmol) and cerium ammonium nitrate (48.60 mg, 91.66 μmol) were added to the mixture and stirred for 8 h. The mixture was quenched with saturated aqueous Na2SO3 solution, extracted with ethyl acetate (50 mL), dried over anhydrous sodium sulfate, and purified by reverse phase column chromatography (chromatographic column: Fast silica gel column; mobile phase:

[0391] The residue was purified by filtration with 5% to 98% acetonitrile / water (15 min) to afford compound 15C (6 mg).

[0392] MS M / z(ESI):454[M+H] + ;

[0393] Step 4: Preparation of cis-3-[3-[3-methyl-1-(4-methyl-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-7-[1-[(3-methyloxetan-3-yl)amino]ethyl]-9-(trifluoromethyl)pyrido[1,2-a]pyrimidin-4-one (Compound 15)

[0394] Compound 15C (6 mg, 13.24 μmol), 4F (4.68 mg, 13.24 μmol), Pd(dppf)Cl2 (960.72 μg, 1.32 μmol), and K2CO3 (3.66 mg, 26.48 μmol) were added to the reaction tube, and the argon atmosphere was replaced. Water (0.2 mL) and 1,4-dioxane (1 mL) were then added via syringe. The mixture was heated to 100°C for 1 hour. The mixture was cooled to room temperature and subjected to reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 5%-98%, 15 min) to give compound 15 (1.8 mg).

[0395] MS M / z(ESI):553.3[M+H] + ;

[0396] 1H NMR(400MHz, DMSO-d6)δ9.26(s,1H),8.62(d,J=26.7Hz,2H),8.29(s,1H),7.91(s,1H),7.67(s,1H),7.48(s,1H),7.30(s,1H),5.3 3(s,1H),4.42(s,1H),4.20(d,J=26.3Hz,2H),3.94(s,1H),3.22(s,3H),2.88(s,2H),2.0(s,1H),1.49–1.18(m,9H),1.09(s,3H).

[0397] Example 16: Preparation of cis-6-(1-((2-methoxyethyl)amino)ethyl)-8-methyl-3-(3-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4H-chromen-4-one (Compound 16)

[0398] Step 1: Preparation of 4-(1-((2-methoxyethyl)amino)ethyl)-2-methylphenol (Compound 16B)

[0399] Compound 16A (2 g, 13.32 mmol), 2-methoxyethylamine (1.50 g, 19.98 mmol), and tetraisopropyl titanate (7.57 g, 26.64 mmol) were added to tetrahydrofuran (30 ml) and stirred at 25°C for 1 hour. NaBH4 (1.52 g, 40.00 mmol) was then added and stirred for 1 hour. After the reaction was complete, the reaction was slowly quenched with methanol (1 mL) and concentrated to obtain a residue. The residue was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 50:50) to give the title compound 16B (2.79 g).

[0400] MS m / z(ESI):210.12[M+H] + .

[0401] Step 2: Preparation of 2-bromo-4-(1-((2-methoxyethyl)amino)ethyl)-6-methylphenol (Compound 16C)

[0402] To a solution of compound 16B (600 mg, 2.87 mmol) and DIEA (741 mg, 5.73 mmol) in dichloromethane (10 mL) was added NBS (765.40 mg, 4.30 mmol) and stirred at 25°C for 4 hours. The reaction mixture was concentrated to obtain a residue. The residue was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 50:50) to give the title compound 16C (350 mg).

[0403] MS m / z(ESI):288.03[M+H] + .

[0404] Step 3: Preparation of 2-(1-ethoxyvinyl)-4-(1-((2-methoxyethyl)amino)ethyl)-6-methylphenol (Compound 16D)

[0405] Compound 16C (260 mg, 902.21 μmol) solution, tri-n-butyl(1-ethoxyvinyl)tin (652 mg, 1.8 mmol), and tetrakis(triphenylphosphine)palladium (312.77 mg, 270.66 μmol) were added to 1,4-dioxane (2 mL) and stirred at 100°C for 2 hours. The mixture was concentrated to obtain a residue. The residue was purified by reverse phase column chromatography (column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 50:50) to obtain the title compound 16D (252 mg).

[0406] MS m / z(ESI):280.15[M+H] + .

[0407] Step 4: Preparation of 1-(2-hydroxy-5-(1-((2-methoxyethyl)amino)ethyl)-3-methylphenyl)ethan-1-one (Compound 16E)

[0408] Aqueous HCl (4M, 5 mL) was added to a solution of compound 16D (252 mg, 902.02 μmol) in 1,4-dioxane (5 mL), and the mixture was stirred at 25°C for 1 h. After the reaction was completed, the reaction solution was concentrated to obtain a residue, which was then purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 50:50) to give the title compound 16E (80 mg).

[0409] MS m / z(ESI):252.13[M+H] + .

[0410] Step 5: Preparation of (E)-3-(dimethylamino)-1-(2-hydroxy-5-(1-((2-methoxyethyl)amino)ethyl)-3-methylphenyl)prop-2-en-1-one (Compound 16F)

[0411] N,N-dimethylformamide dimethyl acetal was added to compound 16E (80 mg, 318.32 μmol) and stirred at 80°C for 1 hour. After the reaction was completed, the reaction solution was concentrated to obtain a residue, which was then purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 50:50) to give the title compound 16F (97 mg).

[0412] MS m / z(ESI):307.18[M+H] + .

[0413] Step 6: Preparation of 3-iodo-6-(1-((2-methoxyethyl)amino)ethyl)-8-methyl-4H-chromen-4-one (Compound 16G)

[0414] Iodine (149.10 mg, 587.47 μmol), pyridine (46.47 mg, 587.47 μmol), and compound 16F (90 mg, 293.73 μmol) were added to dichloromethane (1 mL) and stirred at 80°C for 1 hour. After the reaction was completed, the reaction solution was concentrated to obtain a residue, which was then purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 50:50) to obtain the title compound 16G (20 mg).

[0415] MS m / z(ESI):388.02[M+H] + .

[0416] Step 7: Preparation of cis-6-(1-((2-methoxyethyl)amino)ethyl)-8-methyl-3-(3-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4H-chromen-4-one (Compound 16)

[0417] To a mixture of compound 4F (20 mg, 56.61 μmol) and compound 16G (21.92 mg, 56.61 μmol) in 1,4-dioxane (3 ml) / water (1 mL) were added Pd(dppf)Cl2 (20.71 mg, 28.31 μmol) and K2CO3 (15.65 mg, 113.23 μmol) and stirred at 80°C for 1 hour. After completion of the reaction, the reaction mixture was concentrated to obtain a residue. The residue was purified by reverse phase column chromatography (column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 50:50) to give the title compound 16 (1 mg).

[0418] MS m / z(ESI):487.37[M+H] + .

[0419] Example 17: Preparation of 7-((((1-methoxycyclopropyl)methyl)amino)methyl)-3-(3-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 17)

[0420] Steps 1-2: Preparation of 7-(chloromethyl)-3-(3-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 17C)

[0421] The preparation method of this compound 17C refers to the synthesis method of compound 9B to compound 9D. Starting from 200 mg of the starting material of 9B, compound 17C (300 mg) was synthesized in two steps.

[0422] MS m / z(ESI):488.2[M+H] + .

[0423] Step 3: Preparation of 7-((((1-methoxycyclopropyl)methyl)amino)methyl)-3-(3-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 17)

[0424] Compound 17C (30.00 mg, 61.49 μmol) was dissolved in acetonitrile (3 mL), and DIEA (79.47 mg, 614.88 μmol) and (1-methoxycyclopropyl)methylamine (31.00 mg, 30.7 μmol) were added. The mixture was stirred at 25°C for 1 hour. After the reaction was completed, the reaction solution was concentrated to obtain a residue, which was then purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 50:50) to give the title compound 17 (5 mg).

[0425] MS m / z(ESI):553.42[M+H] + .

[0426] 1H NMR (400MHz, Methanol-d4) δ9.25 (s, 1H), 8.54 (d, J = 4.7Hz, 1H), 8.38 (s, 1H), 8. 31(s,1H),7.91(s,1H),7.67(t,J=8.1Hz,1H),7.50(d,J=7.7Hz,1H),7.40(d,J=7 .8Hz,1H),4.05(s,3H),3.45(s,3H),3.40(s,2H),3.35(s,2H),2.98(d,J=9.4Hz, 2H),2.88(m,1H),2.62(d,J=10.4Hz,2H),1.16(d,3H),0.70(s,2H),0.59(s,2H).

[0427] Example 18: Preparation of 7-(((1-(methoxymethyl)cyclopropyl)amino)methyl)-3-(3-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 18)

[0428] Compound 17C (30.00 mg, 61.49 μmol) was dissolved in acetonitrile (3 mL), and DIEA (79.47 mg, 614.88 μmol) and 1-(methoxymethyl)cyclopropane-1-amine (31.10 mg, 307.44 μmol) were added. The mixture was stirred at 25°C for 1 hour. After the reaction was completed, the reaction solution was concentrated to obtain a residue, which was then purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 50:50) to give the title compound 18 (8 mg).

[0429] MS m / z(ESI):553.42[M+H] + .

[0430] 1H NMR (400MHz, Methanol-d4) δ9.25 (s, 1H), 8.54 (d, J = 4.7Hz, 1H), 8.38 (s, 1H), 8. 31(s,1H),7.91(s,1H),7.67(t,J=8.1Hz,1H),7.50(d,J=7.7Hz,1H),7.40(d,J=7 .8Hz,1H),4.05(s,3H),3.45(s,3H),3.40(s,2H),3.35(s,2H),2.98(d,J=9.4Hz, 2H),2.88(m,1H),2.62(d,J=10.4Hz,2H),1.16(d,3H),0.70(s,2H),0.59(s,2H).

[0431] Example 19: Preparation of 4-[2-cyclopropyl-6-[7-[(2-methoxyethylamino)methyl]-4-oxo-9-(trifluoromethyl)pyrido[1,2-a]pyrimidin-3-yl]-4-pyridinyl]-3-(4-methyl-1,2,4-triazol-3-yl)benzonitrile (Compound 19)

[0432] Step 1: Preparation of 4-(2-cyclopropyl-6-trimethyltin-4-pyridyl)-3-(4-methyl-1,2,4-triazol-3-yl)benzonitrile (Compound 19B)

[0433] Compound 19A (300 mg, 893.42 μmol), tetrakis(triphenylphosphine)palladium (79.42 mg, 68.72 μmol), hexamethyltin (337.74 mg, 1.03 mmol), and toluene (5 mL) were mixed, the atmosphere replaced with argon, and heated to 100°C for 1 hour. After completion of the reaction, the mixture was cooled to room temperature and concentrated to afford product 19B (319 mg).

[0434] MS M / z(ESI):466[M+H] + ;

[0435] Step 2: Synthesis of 7-(hydroxymethyl)-9-(trifluoromethyl)pyrido[1,2-a]pyrimidin-4-one (19C)

[0436] 7A (1 g, 3.41 mmol), tetrakis(triphenylphosphine)palladium (394.34 mg, 341.25 μmol), (tributyltin)methanol (2.19 g, 6.83 mmol) and 1,4-dioxane (5 mL) were mixed and replaced with argon. The mixture was heated to 100°C for 2 hours. After the reaction was completed, it was cooled to room temperature and the mixture was purified by reverse phase chromatography ( The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 5%-98%) to give the title compound 19C (450 mg).

[0437] MS M / z(ESI):245[M+H] + ;

[0438] Step 3: Synthesis of 7-(chloromethyl)-9-(trifluoromethyl)pyrido[1,2-a]pyrimidin-4-one (19D)

[0439] Compound 19C (450 mg, 1.84 mmol) was dissolved in dichloromethane (2.80 mL), and thionyl chloride (1.10 g, 9.21 mmol, 669.29 μL) was added. The mixture was heated to 50°C and allowed to react for 5 hours. After completion of the reaction, the mixture was cooled to room temperature and concentrated to afford crude compound 19D (484 mg), which was carried on to the next step without purification.

[0440] MS M / z(ESI):263[M+H] + ;

[0441] Step 4: Synthesis of 7-[(2-methoxyethylamino)methyl]-9-(trifluoromethyl)pyrido[1,2-a]pyrimidin-4-one (19E)

[0442] Compound 19D (484 mg, 1.84 mmol) was dissolved in DMF (3 mL), potassium carbonate (509.43 mg, 3.69 mmol) and 2-methoxyethylamine (415.28 mg, 5.53 mmol) were added, and stirred overnight. The mixture was purified by reverse phase chromatography ( The title compound 19E (351 mg) was purified by flash silica gel column; mobile phase: acetonitrile / water = 5%-98%).

[0443] MS M / z(ESI):302[M+H] + ;

[0444] Step 5: Synthesis of 3-iodo-7-[(2-methoxyethylamino)methyl]-9-(trifluoromethyl)pyrido[1,2-a]pyrimidin-4-one (19F)

[0445] Compound 19E (351 mg, 1.17 mmol) was dissolved in acetonitrile (10 mL), and cerium ammonium nitrate (1.28 g, 2.34 mmol) and iodine (593.9 mg, 2.34 mmol) were added. The reaction was allowed to proceed overnight at room temperature. After the reaction was completed, saturated aqueous sodium sulfite solution was added to quench the reaction, and the mixture was extracted with ethyl acetate (50 ml). The crude product was concentrated and purified by reverse phase chromatography (HPLC). The product was purified by flash silica gel column; mobile phase: acetonitrile / water = 5%-98%) to obtain the title compound 19F (351 mg).

[0446] MS M / z(ESI):428[M+H] + ;

[0447] Step 7: Preparation of 4-[2-cyclopropyl-6-[7-[(2-methoxyethylamino)methyl]-4-oxo-9-(trifluoromethyl)pyrido[1,2-a]pyrimidin-3-yl]-4-pyridinyl]-3-(4-methyl-1,2,4-triazol-3-yl)benzonitrile (Compound 19)

[0448] Compound 19B (21.73 mg, 46.82 μmol), 19F (10 mg, 23.41 μmol), tetrakis(triphenylphosphine)palladium (2.71 mg, 2.34 μmol) and DMF (1 mL) were mixed and replaced with argon. The mixture was heated to 130°C for 1 hour. After the reaction was completed, the mixture was cooled to room temperature and purified by reverse phase chromatography ( The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 95:5) to obtain compound 19 (1.8 mg).

[0449] MS M / z(ESI):601[M+H] + ;

[0450] 1 H NMR (400MHz, DMSO-d6) δ9.24(d,J=9.0Hz,2H),8.51(s,2H),8.23(d,J=10.2Hz,2H),8.03(s,1H),7.89(d,J=7.9Hz,1H ),7.03(s,1H),3.91(s,2H),3.49-3.38(m,5H),3.25(s,3H),2.75-2.68(m,2H),2.15-2.05(m,1H),1.03–0.90(m,5H).

[0451] Example 20: Preparation of cis-7-fluoro-6-[(2-methoxyethylamino)methyl]-8-methyl-3-[3-[3-methyl-1-(4-methyl-1,2,4-triazol-3-yl)cyclobutyl]phenyl]chromen-4-one (Compound 20)

[0452] Step 1: Preparation of 5-fluoro-6-(hydroxymethyl)-8-methyl-chromen-4-one (Compound 20B)

[0453] Compound 20A (1.5 g, 5.84 mmol), tributyltin carbinol (6.00 g, 18.69 mmol), and dioxane (15 mL) were mixed and the atmosphere was replaced with nitrogen. Tetrakis(triphenylphosphine)palladium (673.98 mg, 583.53 μmol) was added to the mixture under nitrogen protection. The mixture was heated to 100°C and stirred for 12 hours. After completion, the reaction was quenched with saturated potassium fluoride solution and extracted with ethyl acetate (100 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was separated by preparative HPLC (column: Welch Xtimate C18, column length: 150 mm, inner diameter: 30 mm, particle size: 5 μm; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B: 5% to 95% over 18 minutes) to obtain the title compound 20B (550 mg).

[0454] MS m / z(ESI):209.1[M+H] + .

[0455] Step 2: Preparation of 6-(chloromethyl)-5-fluoro-8-methyl-chromen-4-one (Compound 20C)

[0456] Thionyl chloride (1.76 g, 14.75 mmol, 1.07 mL) was added to a solution of compound 20B (150 mg, 720.51 μmol) in dichloromethane (5.0 mL). The mixture was heated to 50°C and stirred for 2.0 hours. After completion of the reaction, the reaction mixture was concentrated to afford the crude title compound 20C (160 mg), which was used directly in the next reaction without purification.

[0457] MS m / z(ESI):227.0[M+H] + .

[0458] Step 3: Preparation of 7-fluoro-6-[(2-methoxyethylamino)methyl]-8-methyl-chromen-4-one (Compound 20D)

[0459] Compound 20C (160 mg, 705.99 μmol) was dissolved in DMF (3.0 mL). 2-Methoxyethylamine (79.54 mg, 1.06 mmol) was added to the reaction mixture, and the reaction mixture was stirred at room temperature for 3.0 hours. After TLC monitoring of the reaction completion, the crude product was separated by preparative HPLC (column: Welch Xtimate C18, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 20D (170 mg).

[0460] MS m / z(ESI):266.1[M+H] + .

[0461] Step 4: Preparation of 1-[4-fluoro-2-hydroxy-5-[(2-methoxyethylamino)methyl]-3-methyl-phenyl]-3-pyrrolidin-1-yl-prop-2-en-1-one (Compound 20E)

[0462] Compound 20D (170 mg, 640.83 μmol) and tetrahydropyrrole (227.88 mg, 3.20 mmol) were added to methanol (2 mL), heated to 50°C, and stirred for 1 hour. After completion of the reaction, the mixture was cooled to room temperature and concentrated under reduced pressure to afford the crude title compound 20E (210 mg), which was used directly in the next step without purification.

[0463] MS m / z(ESI):337.2[M+H] + .

[0464] Step 5: Preparation of 7-fluoro-3-iodo-6-[(2-methoxyethylamino)methyl]-8-methyl-chromen-4-one (Compound 20F)

[0465] Compound 20E (210 mg, 624.26 μmol), iodine (316.88 mg, 1.25 mmol), and pyridine (49.38 mg, 624.26 μmol, 50.29 μL) were added to chloroform (2 mL) and stirred at room temperature for 1 hour. After completion of the reaction, the mixture was cooled to room temperature and concentrated under reduced pressure to obtain a crude product. The crude product was separated by preparative HPLC (column: Welch Xtimate C18, column length: 150 mm, inner diameter: 30 mm, particle size: 5 μm; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B: 5% to 95% over 18 minutes) to obtain the title compound 20F (75 mg).

[0466] MS m / z(ESI):392.0[M+H] + .

[0467] Step 6: Preparation of cis-7-fluoro-6-[(2-methoxyethylamino)methyl]-8-methyl-3-[3-[3-methyl-1-(4-methyl-1,2,4-triazol-3-yl)cyclobutyl]phenyl]chromen-4-one (Compound 20)

[0468] Compound 20F (15 mg, 38.35 μmol), cis-4-methyl-3-((1s,3s)-3-methyl-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclobutyl)-4H-1,2,4-triazole (15.59 mg, 57.52 μmol), Pd(dppf)Cl2 (5.61 mg, 7.67 μmol), and potassium carbonate (10.58 mg, 76.69 μmol) were added to a mixture of water (0.4 mL) and 1,4-dioxane (2.0 mL), and the atmosphere was replaced with nitrogen. The mixture was heated to 90°C under nitrogen and stirred for 2.0 hours. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain a crude product, which was separated by preparative HPLC (column: Welch Xtimate C18, column length: 150 mm, inner diameter: 30 mm, particle size: 5 μm; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% in 18 minutes) to obtain the title compound 20 (11 mg).

[0469] MS m / z(ESI):491.3[M+H] + .

[0470] 1 H NMR (400MHz, DMSO-d6) δ8.64(s,1H),8.29(s,1H),8.11(d,J=8.0Hz,1H),7.62(s,1H),7.45(s,2H),7.30(s,1H),3.8 9(s,2H),3.24(d,J=6.8Hz,7H),2.94–2.83(m,2H),2.73(s,2H),2.55(s,3H),2.37(s,3H),1.23(s,2H),1.08(s,3H).

[0471] Example 21: Preparation of 4-[2-cyclopropyl-6-[7-fluoro-6-[(2-methoxyethylamino)methyl]-8-methyl-4-oxo-chromen-3-yl]-4-pyridinyl]-3-(4-methyl-1,2,4-triazol-3-yl)benzonitrile (Compound 21)

[0472] Compound 19B (23.73 mg, 51.13 μmol), 20F (10 mg, 25.56 μmol), tetrakis(triphenylphosphine)palladium (2.95 mg, 2.56 μmol) and DMF (1 mL) were mixed and replaced with argon, heated to 130°C and stirred for 1 hour. After cooling to room temperature, the mixture was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 5%-98%, 15 min) to give the title compound 21 (2.6 mg).

[0473] MS M / z(ESI):565.2[M+H] + ;

[0474] 1 H NMR (400MHz, DMSO-d6) δ9.05(s,1H),8.53(s,1H),8.22(d,J=8.8Hz,2H),8.10(d,J=8.2Hz,1H),7.97–7.76(m,2H),7.03(d,J=1.6Hz,1H) ,3.86(s,2H),3.45-3.4(m,5H),3.25(s,3H),2.70(t,J=5.8Hz,2H),2.38(s,3H),2.10–1.96(m,2H),0.96(s,2H),0.86(t,J=6.7Hz,2H).

[0475] Example 22: Preparation of trans-3-[3-[3-fluoro-1-(4-methyl-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-6-[(2-methoxyethylamino)methyl]-8-methyl-chromen-4-one (Compound 22)

[0476] Step 1: Preparation of trans-3-[1-(3-bromophenyl)-3-fluoro-cyclobutyl]-4-methyl-1,2,4-triazole (Compound 22B)

[0477] To a solution of compound 22A (100 mg, 324.49 μmol) in dichloromethane (5 mL) at 0°C was added DAST (104.61 mg, 648.99 μmol) dropwise, and the mixture was brought to room temperature and stirred for 1 hour. The reaction mixture was concentrated under reduced pressure to obtain a crude product, which was then separated by preparative HPLC (column: Welch Xtimate C18, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to afford the title compound 22B (50 mg).

[0478] MS m / z(ESI):310.1[M+H] + .

[0479] Step 2: Preparation of trans-3-[3-fluoro-1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclobutyl]-4-methyl-1,2,4-triazole (Compound 22C)

[0480] Compound 22B (50 mg, 161.20 μmol), B2Pin2 (61.40 mg, 241.81 μmol), potassium acetate (31.64 mg, 322.41 μmol), and anhydrous dioxane (3.0 mL) were mixed and the atmosphere was replaced with nitrogen. Pd(dppf)Cl2 (11.80 mg, 16.12 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen and stirred for 1 hour. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was separated by preparative HPLC (column: Welch Xtimate C18, column length: 150 mm, ID: 30 mm, particle size: 5 μm; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B: 5% to 95% over 18 minutes) to obtain the title compound 22C (18 mg).

[0481] MS m / z(ESI):358.2[M+H] + .

[0482] Step 3: Preparation of trans-3-[3-[3-fluoro-1-(4-methyl-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-6-[(2-methoxyethylamino)methyl]-8-methyl-chromen-4-one (Compound 22)

[0483] 14I (10 mg, 26.80 μmol), 22C (9.57 mg, 26.80 μmol), Pd(dppf)Cl2 (1.96 mg, 2.68 μmol), and potassium carbonate (7.40 mg, 53.59 μmol) were added to a mixture of water (0.4 mL) and 1,4-dioxane (2.0 mL), and the atmosphere was replaced with nitrogen. The resulting mixture was heated to 90°C under nitrogen and stirred for 2.0 hours. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was separated by preparative HPLC (column: Welch Xtimate C18, column length: 150 mm, inner diameter: 30 mm, particle size: 5 μm; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B: 5% to 95% over 18 minutes) to obtain the title compound 22 (8 mg).

[0484] MS m / z(ESI):477.2[M+H] + .

[0485] 1H NMR(400MHz,DMSO-d6)δ8.64(s,1H),8.41(s,1H),7.95(s,1H),7.68(s,1H),7.50–7.48(m,2H),7.48–7.43(m,1H),7.22–7.18(m,1H),3.8 6(s,2H),3.51(ddd,J=9.7,6.0,2.9Hz,3H),3.44(s,2H),3.28(s,3H),3.25(s,3H),2.92–2.78(m,3H),2.70(t,J=5.6Hz,2H),2.48(s,3H).

[0486] Example 23: Preparation of 3-[3-[6-[(2-methoxyethylamino)methyl]-8-methyl-4-oxo-chromen-3-yl]phenyl]-3-(4-methyl-1,2,4-triazol-3-yl)cyclobutanecarbonitrile (Compound 23)

[0487] Step 1: Preparation of cis-[3-(3-bromophenyl)-3-(4-methyl-1,2,4-triazol-3-yl)cyclobutyl]methanesulfonate (Compound 23A)

[0488] Compound 22A (260 mg, 843.68 μmol) and triethylamine (170.74 mg, 1.69 mmol, 235.35 μL) were added to dichloromethane (5 mL), followed by the addition of methanesulfonic anhydride (176.36 mg, 1.01 mmol) in portions, and the mixture was stirred at room temperature for 12 hours. After completion of the reaction, the reaction solution was concentrated to obtain a crude product, which was then separated by preparative HPLC (column: Welch Xtimate C18, column length: 150 mm, inner diameter: 30 mm, particle size: 5 μm; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 23A (270 mg).

[0489] MS m / z(ESI):386.0[M+H]+.

[0490] Step 2: Preparation of 3-(3-bromophenyl)-3-(4-methyl-1,2,4-triazol-3-yl)cyclobutanecarbonitrile (Compound 23B)

[0491] Compound 23A (270 mg, 699.00 μmol), NaCN (68.51 mg, 1.40 mmol), and potassium carbonate (192.93 mg, 1.40 mmol) were added to DMSO (5.0 mL), heated to 120°C, and stirred for 16 hours. After completion of the reaction, the reaction solution was separated by preparative HPLC (column: Welch Xtimate C18, column length: 150 mm, inner diameter: 30 mm, particle size: 5 μm; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B: 5% to 95% over 18 minutes) to obtain the title compound 23B (60 mg).

[0492] MS m / z(ESI):317.0[M+H] + .

[0493] Step 3: Preparation of 3-(4-methyl-1,2,4-triazol-3-yl)-3-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclobutanecarbonitrile (Compound 23C)

[0494] Compound 23B (60 mg, 189.17 μmol), B2Pin2 (72.05 mg, 283.75 μmol), potassium acetate (37.13 mg, 378.33 μmol), and anhydrous dioxane (3.0 mL) were mixed and the atmosphere was replaced with nitrogen. Pd(dppf)Cl2 (13.83 mg, 18.92 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen and stirred for 1 hour. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was separated by preparative HPLC (column: Welch Xtimate C18, column length: 150 mm, inner diameter: 30 mm, particle size: 5 μm; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 23C (45 mg).

[0495] MS m / z(ESI):365.2[M+H] + .

[0496] Step 4: Preparation of 3-[3-[6-[(2-methoxyethylamino)methyl]-8-methyl-4-oxo-chromen-3-yl]phenyl]-3-(4-methyl-1,2,4-triazol-3-yl)cyclobutanecarbonitrile (Compound 23)

[0497] Compound 14I (15 mg, 40.19 μmol), 23C (14.64 mg, 40.19 μmol), Pd(dppf)Cl2 (2.94 mg, 4.02 μmol), and potassium carbonate (11.09 mg, 80.39 μmol) were added to a mixture of water (0.4 mL) and 1,4-dioxane (2.0 mL), and the atmosphere was replaced with nitrogen. The resulting mixture was heated to 90°C under nitrogen and stirred for 2.0 hours. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was separated by preparative HPLC (column: Welch Xtimate C18, column length: 150 mm, inner diameter: 30 mm, particle size: 5 μm; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B: 5% to 95% over 18 minutes) to obtain the title compound 23 (5 mg).

[0498] MS m / z(ESI):484.3[M+H] + .

[0499] 1 H NMR (400MHz, DMSO-d6) δ8.65(s,1H),8.43(s,1H),7.92(s,1H),7.66(s,1H),7.53(d,J=7.6Hz,1H),7.46(t,J=7.7Hz,1H), 7.27–7.18(m,2H),3.80(s,2H),3.26(s,3H),3.24(s,3H),3.07–3.01(m,4H),2.68–2.67(m,2H),2.65(s,4H),2.48(s,3H).

[0500] Example 24: Preparation of 7-[1-[(1-methylcyclobutyl)amino]ethyl]-3-[3-[(4-methyl-4H-1,2,4-triazol-3-yl)-(oxetane-3-yl)methyl]phenyl]-9-(trifluoromethyl)pyrido[1,2-a]pyrimidin-4-one (Compound 24)

[0501] Step 1: Preparation of 1-[[2-(3-bromophenyl)acetyl]amino]-3-methylthiourea (Compound 24B)

[0502] Compound 24A (10 g, 46.50 mmol), 4-methylthiosemicarbazide (7.34 g, 69.75 mmol), HATU (26.32 g, 69.75 mmol), and DIEA (12.02 g, 93.00 mmol) were added to DMF (100 mL) and reacted at room temperature for 2 hours. After the reaction, water (100 mL) and dichloromethane (200 mL x 3) were added for extraction. The organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure to afford the title compound 24B (14 g), which was used directly in the next step without further purification.

[0503] MS m / z(ESI):302.0[M+H] + .

[0504] Step 2: Preparation of 5-[(3-bromophenyl)methyl]-4-methyl-1,2,4-triazole-3-thiol (Compound 24C)

[0505] Compound 24B (14 g, 46.33 mmol) was added to a 3.0 M sodium hydroxide solution (100 mL) and reacted at 80°C for 3 hours. After the reaction, the temperature was lowered to 0°C, and the pH was adjusted to acidic by adding a saturated aqueous citric acid solution. The mixture was extracted with dichloromethane, and the organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure to afford the title compound 24C (13 g), which was used directly in the next step without further purification.

[0506] MS m / z(ESI):284.0[M+H] + .

[0507] Step 3: Preparation of 3-[(3-bromophenyl)methyl]-4-methyl-4H-1,2,4-triazole (Compound 24D)

[0508] Compound 24C (13 g, 45.75 mmol) was dissolved in dichloromethane (100 mL) at 0°C. Acetic acid (15 mL) and hydrogen peroxide (15 mL) were slowly added dropwise to the reaction mixture. The reaction was allowed to react at room temperature for 1 hour. After completion of the reaction, water (50.0 mL) and dichloromethane (60 mL x 3) were added for extraction. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was separated on a preparative HPLC column (Welch Xtimate C18, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 24D (7 g), which was used directly in the next step without further purification.

[0509] MS m / z(ESI):252.0[M+H]+ .

[0510] Step 4: Preparation of 3-[(3-bromophenyl)-(oxetan-3-yl)methyl]-4-methyl-4H-1,2,4-triazole (Compound 24E)

[0511] Compound 24D (300 mg, 1.19 mmol) was dissolved in DME (5 mL). 3-Iodooxetane (328.38 mg, 1.78 mmol) and LiHMDS (1 M, 1.80 mL, in THF) were added sequentially at -10°C under a nitrogen atmosphere. The resulting mixture was stirred at room temperature for 48 h. LiHMDS (1 M, 1.80 mL) was then added and stirred at room temperature for 2 h. After completion of the reaction, saturated aqueous ammonium chloride was added for quenching. The mixture was extracted with dichloromethane and concentrated under reduced pressure to afford the crude product. The crude product was separated on a preparative HPLC column (Welch Xtimate C18, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to afford the title compound 24E (90 mg).

[0512] MS m / z(ESI):308.0[M+H] + .

[0513] Step 5: Preparation of 4-methyl-3-[oxetan-3-yl-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]-1,2,4-triazole (Compound 24F)

[0514] To a mixture of compound 24E (110 mg, 356.94 μmol), B2Pin2 (135.96 mg, 535.41 μmol), potassium acetate (70.06 mg, 713.88 μmol), and anhydrous dioxane (3.0 mL) was added Pd(dppf)Cl2 (26.11 mg, 35.69 μmol). The mixture was heated to 100°C under nitrogen and stirred for 1 hour. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure. The residue was purified by normal phase column chromatography (petroleum ether:ethyl acetate = 0:1) to obtain the title compound 24F (90.0 mg).

[0515] MS m / z(ESI):356.2[M+H] + .

[0516] Step 6: Preparation of 7-[1-[(1-methylcyclobutyl)amino]ethyl]-3-[3-[(4-methyl-4H-1,2,4-triazol-3-yl)-(oxetan-3-yl)methyl]phenyl]-9-(trifluoromethyl)pyrido[1,2-a]pyrimidin-4-one (Compound 24)

[0517] 24F (20 mg, 44.32 μmol), 6E (20.47 mg, 57.62 μmol), Pd(dppf)Cl2 (3.24 mg, 4.43 μmol), and K2CO3 (12.23 mg, 88.65 μmol) were added to a mixture of 1,4-dioxane (2 mL) and water (0.4 mL), and the atmosphere was replaced with nitrogen. The mixture was heated to 100°C under nitrogen and stirred for 2.0 hours. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was separated on a preparative HPLC column (Welch Xtimate C18, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 24 (15 mg).

[0518] MS m / z(ESI):553.3[M+H] + .

[0519] 1 H NMR(400MHz,DMSO-d6)δ9.14(s,1H),8.51(s,1H),8.46(s,1H),8.26(s,1H),7.66(s,1H ),7.59(d,J=7.8Hz,1H),7.32(t,J=7.7Hz,1H),7.11(d,J=7.7Hz,1H),4.69–4.61(m,2H) ,4.44–4.36(m,2H),4.18(t,J=6.2Hz,1H),4.04(q,J=6.4,6.0Hz,1H),3.84–3.76(m,1H) ,3.28(s,3H),2.58–2.45(m,1H),1.81–1.34(m,6H),1.21(d,J=6.7Hz,3H),1.01(s,3H).

[0520] Example 25: Preparation of (R)-4-(2-(difluoromethyl)-6-(8-methyl-6-((2-methylmorpholinyl)methyl)-4-oxo-4H-chromen-3-yl)pyridin-4-yl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)benzonitrile (Compound 25)

[0521] Step 1: Preparation of 4-(2-chloro-6-vinylpyridin-4-yl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)benzonitrile (25B)

[0522] Compound 25A (270 mg, 817.76 μmol) and potassium vinyl trifluoroborate (109.54 mg, 817.76 μmol) were dissolved in dioxane (5.0 mL). Pd(PPh3)4 (94.50 mg, 81.78 μmol) and cesium carbonate (531.54 mg, 1.64 mmol) were added. The mixture was heated to 90°C under nitrogen and stirred for 2 hours. After the reaction, the reactants were dried and concentrated. The crude product was separated by preparative HPLC (Welch Xtimate C18 column, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 25B (200 mg).

[0523] MS m / z(ESI):322.1[M+H] + .

[0524] Step 2: Preparation of 4-(2-chloro-6-formylpyridin-4-yl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)benzonitrile (25C)

[0525] Compound 25B (200 mg, 621.58 μmol) was dissolved in water (2 mL) and tetrahydrofuran (8 mL). Sodium periodate (664.75 mg, 3.11 mmol) and potassium osmate dihydrate (38.66 mg, 124.32 μmol) were added sequentially at 0°C, and the mixture was stirred at 0°C for 1 hour. After completion, the reaction was quenched with saturated aqueous sodium sulfite solution, extracted with dichloromethane, and concentrated under reduced pressure to obtain a crude product. The crude product was separated by preparative HPLC (Welch Xtimate C18 column, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 25C (90 mg).

[0526] MS m / z(ESI):324.1[M+H] + .

[0527] Step 3: Preparation of 4-[2-chloro-6-difluoromethylpyridin-4-yl]-3-(4-methyl-4H-1,2,4-triazol-3-yl)benzonitrile (25D)

[0528] Compound 25C (90 mg, 278.00 μmol) was dissolved in dichloromethane (5 mL), and DAST (89.62 mg, 556.01 μmol) was added at 0°C, and the mixture was stirred at 0°C for 1 hour. After completion, the reaction was quenched with saturated aqueous sodium bicarbonate solution, extracted with dichloromethane, and concentrated under reduced pressure to obtain a crude product. The crude product was separated by preparative HPLC (Welch Xtimate C18 column, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 25D (20 mg).

[0529] MS m / z(ESI):346.1[M+H] + .

[0530] Step 4: Preparation of (R)-8-methyl-6-((2-methylmorpholinyl)methyl)-4H-chromen-4-one (25F)

[0531] Compound 4A (400.0 mg, 1.67 mmol), 25E ​​(369.9 mg, 1.67 mmol) and potassium carbonate (461.8 mg, 3.35 mmol) were added to a mixture of water (2.0 mL) and 1,4-dioxane (10.0 mL), and the nitrogen atmosphere was replaced. Under a nitrogen atmosphere, Xphos Pd G2 (131.7 mg, 167.7 μmol) and Xphos (159.62 mg, 334.6 μmol) were added. The resulting mixture was heated to 100°C under nitrogen protection and stirred for 12.0 hours. The crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 80:20) to obtain the title compound 25F (415.0 mg).

[0532] MS m / z(ESI):274.14[M+H] + .

[0533] Step 5: Preparation of (R)-3-iodo-8-methyl-6-((2-methylmorpholinyl)methyl)-4H-chromen-4-one (25G)

[0534] Compound 25F (200.0 mg, 731.7 μmol) and tetrahydropyrrole (104.1 mg, 1.46 mmol) were added to methanol (4.0 mL), and the reaction mixture was stirred at 60°C for 1 hour. After TLC monitoring of the disappearance of the starting material, the reaction mixture was concentrated, and the crude product was added to dichloromethane (4.0 mL), followed by pyridine (0.5 mL) and iodine (371.4 mg, 1.46 mmol), and stirred at room temperature for another 1 hour. After the reaction was completed, the reaction mixture was concentrated, and the crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 85:15) to obtain the title compound 25G (210.0 mg).

[0535] MS m / z(ESI):400.03[M+H] + .

[0536] Step 6: Preparation of (R)-8-methyl-6-((2-methylmorpholinyl)methyl)-3-(trimethylstannyl)-4H-chromen-4-one (25H)

[0537] Compound 25G (110.0 mg, 275.5 μmol) and hexamethyltin (902.7 mg, 2.76 mmol) were added to 1,4-dioxane (2.0 mL), and the nitrogen atmosphere was replaced. Pd(PPh3)4 (31.9 mg, 27.6 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen protection and stirred for 1.0 hour. The crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 90:10) to give the title compound 25H (105.0 mg).

[0538] MS m / z(ESI):438.1[M+H] + .

[0539] Step 7: Preparation of (R)-4-(2-(difluoromethyl)-6-(8-methyl-6-((2-methylmorpholinyl)methyl)-4-oxo-4H-chromen-3-yl)pyridin-4-yl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)benzonitrile (Compound 25)

[0540] Compound 25H (37.4 mg, 86.77 μmol), 25D (20.0 mg, 57.8 μmol) and cuprous iodide (11.0 mg, 57.9 μmol) were added to 1,4-dioxane (2.0 mL) and the nitrogen atmosphere was replaced. Under a nitrogen atmosphere, Pd(dppf)Cl2·DCM (9.38 mg, 11.6 μmol) and 1,1'-binaphthyl-2,2'-bis(diphenylphosphine) (14.4 mg, 23.1 μmol) were added. The resulting mixture was heated to 100°C under nitrogen protection and stirred for 7.0 hours. The crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 70:30) to give the title compound 25 (5.0 mg).

[0541] MS m / z(ESI):583.38[M+H] + .

[0542] 1 H NMR (400MHz, DMSO-d6) δ9.06 (s, 1H), 8.56 (s, 1H), 8.26 (d, J = 9.3Hz, 3H), 8.00–7.86 (m, 2H),7.67(s,1H),7.38(s,1H),6.95(t,J=54.6Hz,1H),3.81–3.69(m,2H),3.56(s,3H), 2.73–2.61(m,3H),2.60(s,3H),2.17–1.91(m,2H),1.78(d,J=11.6Hz,1H),1.46(s,1H),1.02(d,J=6.2Hz,3H).

[0543] Example 26: Preparation of 3-[3-[3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-7-fluoro-6-[(2-methoxyethylamino)methyl]-8-methyl-chromen-4-one (Compound 26)

[0544] Step 1: Preparation of 3-(3-bromophenyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanone (26B)

[0545] Compound 26A (1.5 g, 4.87 mmol) was added to DCM (10 mL), followed by DMP (4.13 g, 9.73 mmol), and the reaction was allowed to proceed at room temperature for 1 hour. After completion of the reaction, a saturated aqueous sodium sulfite solution (10.0 mL) was added and the mixture was extracted with dichloromethane (20.0 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure. The crude product was separated on a preparative HPLC column (Welch Xtimate C18, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to yield the title compound 26B (1 g).

[0546] MS m / z(ESI):306.1[M+H] + .

[0547] Step 2: Preparation of 3-[1-(3-bromophenyl)-3,3-difluoro-cyclobutyl]-4-methyl-4H-1,2,4-triazole (26C)

[0548] Compound 26B (0.4 g, 1.31 mmol) was added to a DCM solution (10 mL), followed by DAST (210.60 mg, 1.31 mmol), and the mixture was allowed to react at room temperature for 12 hours. After completion of the reaction, saturated aqueous sodium bicarbonate (10.0 mL) was added and the mixture was extracted with dichloromethane (20.0 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure. The crude product was separated by preparative HPLC (Welch Xtimate C18 column, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 26C (50 mg).

[0549] MS m / z(ESI):328.1[M+H] + .

[0550] Step 3: Preparation of 3-[3,3-difluoro-1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclobutyl]-4-methyl-4H-1,2,4-triazole (26D)

[0551] To a mixture of compound 26C (50 mg, 152.37 μmol), B2Pin2 (58.04 mg, 228.55 μmol), potassium acetate (29.91 mg, 304.73 μmol), and anhydrous dioxane (3.0 mL) was added Pd(dppf)Cl2 (11.15 mg, 15.24 μmol). The resulting mixture was heated to 100°C under nitrogen and stirred for 1 hour. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure. The residue was separated by normal phase column chromatography (petroleum ether:ethyl acetate = 0:1) to obtain the title compound 26D (22.0 mg).

[0552] MS m / z(ESI):376.2[M+H] + .

[0553] Step 4: Preparation of 3-[3-[3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-7-fluoro-6-[(2-methoxyethylamino)methyl]-8-methyl-chromen-4-one (Compound 26)

[0554] Compound 20F (10 mg, 25.56 μmol), 26D (11.51 mg, 30.68 μmol), Pd(dppf)Cl2 (1.87 mg, 2.56 μmol), and K2CO3 (7.06 mg, 51.13 μmol) were added to a mixture of 1,4-dioxane (2 mL) and water (0.4 mL), and the atmosphere was replaced with nitrogen. The mixture was heated to 100°C under nitrogen and stirred for 2.0 hours. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was separated on a preparative HPLC column (Welch Xtimate C18, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 26 (2 mg).

[0555] MS m / z(ESI):513.2[M+H] + .

[0556] 1H NMR (400MHz, DMSO-d6) δ8.64(s,1H),8.41(s,1H),8.11–8.05(m,1H),7.56(s,1H),7.53–7.46(m,2H),7.32(d,J=7.4 Hz,1H),3.85(s,2H),3.74(q,J=13.2Hz,3H),3.47(s,4H),3.34(s,3H),3.24(s,3H),2.70–2.65(m,2H),2.37(s,3H).

[0557] Example 27: Preparation of 7-fluoro-3-[3-[3-[3-fluoro-3-methyl-1-(4-methyl-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-6-[(2-methoxyethylamino)methyl]-8-methyl-chromen-4-one (Compound 27)

[0558] Step 1: Preparation of 3-(3-bromophenyl)-1-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanol (27A)

[0559] Compound 26B (500 mg, 1.63 mmol) was added to THF (10 mL) at 0°C, and methylmagnesium bromide (3 M, 2.18 mL in THF) was slowly added. The reaction was allowed to react at room temperature for 12 hours. After completion of the reaction, water was added to quench the reaction and the mixture was extracted with dichloromethane (20.0 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure. The crude product was separated by preparative HPLC (Welch Xtimate C18 column, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 27A (300 mg).

[0560] MS m / z(ESI):322.1[M+H] + .

[0561] Step 2: Preparation of 3-[1-(3-bromophenyl)-3-fluoro-3-methyl-cyclobutyl]-4-methyl-4H-1,2,4-triazole (27B)

[0562] Compound 27A (300 mg, 931.10 μmol) was added to DCM (5 mL) at 0°C, followed by DAST (300.17 mg, 1.86 mmol), and the mixture was allowed to react at 0°C for 1 hour. After completion of the reaction, saturated aqueous sodium bicarbonate (10.0 mL) was added and the mixture was extracted with dichloromethane (20.0 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure. The crude product was separated by preparative HPLC (Welch Xtimate C18 column, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 27B (20 mg).

[0563] MS m / z(ESI):324.1[M+H] + .

[0564] Step 3: Preparation of 3-[3-fluoro-3-methyl-1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclobutyl]-4-methyl-4H-1,2,4-triazole (27C)

[0565] To a mixture of compound 27B (20 mg, 61.69 μmol), B2Pin2 (23.50 mg, 92.54 μmol), potassium acetate (12.09 mg, 123.38 μmol), and anhydrous dioxane (2.0 mL) was added Pd(dppf)Cl2 (4.51 mg, 6.17 μmol). The mixture was heated to 100°C under nitrogen and stirred for 1 hour. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure. The residue was purified by normal phase column chromatography (petroleum ether:ethyl acetate = 0:1) to afford the title compound 27C (10.0 mg).

[0566] MS m / z(ESI):372.2[M+H] + .

[0567] Step 4: Preparation of 7-fluoro-3-[3-[3-[3-fluoro-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-6-[(2-methoxyethylamino)methyl]-8-methyl-chromen-4-one (Compound 27)

[0568] Compound 20F (15 mg, 38.35 μmol), 27C (17.08 mg, 46.02 μmol), Pd(dppf)Cl2 (2.80 mg, 3.83 μmol), and K2CO3 (10.58 mg, 76.69 μmol) were added to a mixture of 1,4-dioxane (2 mL) and water (0.4 mL), and the atmosphere was replaced with nitrogen. The mixture was heated to 100°C under nitrogen and stirred for 2.0 hours. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was separated on a preparative HPLC column (Welch Xtimate C18, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 27 (5 mg).

[0569] MS m / z(ESI):509.2[M+H] + .

[0570] 1 H NMR (400MHz, DMSO-d6) δ8.64(s,1H),8.30(s,1H),8.20(s,1H),8.10(d,J=8 .3Hz,1H),7.67(s,1H),7.48–7.44(m,2H),7.34(dt,J=6.2,2.2Hz,1H),3.8 7(s,2H),3.44(s,2H),3.34(s,2H),3.32(s,3H),3.25(s,3H),3.11(d,J=12 .7Hz,2H),2.70(t,J=5.6Hz,2H),2.39–2.37(m,3H),1.40(d,J=22.7Hz,3H).

[0571] Example 28: Preparation of 3-[3-[3-[3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-7-[1-[(1-methylcyclobutyl)amino]ethyl]-9-(trifluoromethyl)pyrido[1,2-a]pyrimidin-4-one (Compound 28)

[0572] Step 1: Preparation of 3-[1-(3-bromophenyl)-3-methoxy-cyclobutyl]-4-methyl-4H-1,2,4-triazole (28A)

[0573] Compound 26A (150 mg, 486.74 μmol) was dissolved in DMF (5 mL). Sodium hydride (58.40 mg, 1.46 mmol, 60% purity) and iodomethane (138.17 mg, 973.48 μmol, 60.60 μL) were added sequentially at 0°C and allowed to react at room temperature for 12 hours. After completion of the reaction, water (10.0 mL) and dichloromethane (20.0 mL x 3) were added for extraction. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by normal phase column chromatography (dichloromethane:methanol = 10:1) to obtain the title compound 28A (90.0 mg).

[0574] MS m / z(ESI):322.1[M+H] + .

[0575] Step 2: Preparation of 3-[3-methoxy-1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclobutyl]-4-methyl-4H-1,2,4-triazole (28B)

[0576] To a mixture of compound 28A (90 mg, 279.33 μmol), B2Pin2 (106.40 mg, 418.99 μmol), potassium acetate (54.83 mg, 558.66 μmol), and anhydrous dioxane (3.0 mL) was added Pd(dppf)Cl2 (20.44 mg, 27.93 μmol). The mixture was heated to 100°C under nitrogen and stirred for 1 hour. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure. The residue was purified by normal phase column chromatography (petroleum ether:ethyl acetate = 0:1) to obtain the title compound 28B (80.0 mg).

[0577] MS m / z(ESI):370.2[M+H] + .

[0578] Step 3: Preparation of 3-[3-[3-[3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-7-[1-[(1-methylcyclobutyl)amino]ethyl]-9-(trifluoromethyl)pyrido[1,2-a]pyrimidin-4-one (Compound 28)

[0579] Compound 6E (20 mg, 44.32 μmol), 28B (24.55 mg, 66.49 μmol), Pd(dppf)Cl2 (3.24 mg, 4.43 μmol), and K2CO3 (12.23 mg, 88.65 μmol) were added to a mixture of 1,4-dioxane (2 mL) and water (0.4 mL), and the atmosphere was replaced with nitrogen. The mixture was heated to 90°C under nitrogen and stirred for 2.0 hours. After completion of the reaction, the mixture was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was separated on a preparative HPLC column (Welch Xtimate C18, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 28 (17 mg).

[0580] MS m / z(ESI):567.3[M+H] + .

[0581] 1 H NMR(400MHz,DMSO-d6)δ9.26(s,1H),8.67(s,1H),8.58(s,1H),8.30(s,1H),7.85(s,1H), 7.74–7.66(m,1H),7.46(t,J=8.0Hz,1H),7.28(d,J=7.1Hz,1H),4.19–4.13(m,1H),4.12–4 .04(m,1H),3.25(s,3H),3.17(s,3H),3.09(d,J=10.4Hz,2H),2.83–2.76(m,2H),1.90(d,J =9.6Hz,1H),1.76(t,J=9.1Hz,2H),1.67–1.40(m,4H),1.32(d,J=6.2Hz,3H),1.13(s,3H).

[0582] Example 29: Preparation of 3-[3-[3-[3-methoxy-1-(4-methyl-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-8-methyl-6-[[(2R)-2-methylmorpholin-4-yl]methyl]chromen-4-one (Compound 29)

[0583] Compound 25G (20.73 mg, 51.92 μmol), 28B (28.76 mg, 77.88 μmol), Pd(dppf)Cl2 (3.8 mg, 5.19 μmol), and K2CO3 (14.33 mg, 103.84 μmol) were added to a mixture of 1,4-dioxane (2 mL) and water (0.4 mL), and the atmosphere was replaced with nitrogen. The mixture was heated to 90°C under nitrogen and stirred for 2.0 hours. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was separated on a preparative HPLC column (Welch Xtimate C18, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 29 (8 mg).

[0584] MS m / z(ESI):515.3[M+H] + .

[0585] 1 H NMR(400MHz,DMSO-d6)δ8.64(s,1H),8.31(s,1H),7.94(s,1H),7.67(s,1H),7.58 (s,1H),7.47(t,J=8.9Hz,2H),7.30(d,J=7.0Hz,1H),4.09(p,J=7.2,6.3Hz,1H),3 .78(d,J=9.3Hz,1H),3.62–3.49(m,4H),3.26(s,3H),3.17(s,3H),3.12–3.07(m, 2H),2.81(d,J=9.3Hz,2H),2.18–1.38(m,4H),1.24(s,3H),1.04(d,J=5.7Hz,3H).

[0586] Example 30: Preparation of (R)-4-(2-cyclopropyl-6-(7-((2-methylmorpholinyl)methyl)-4-oxo-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-3-yl)pyridin-4-yl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)benzonitrile (Compound 30)

[0587] Step 1: Preparation of (R)-7-((2-methylmorpholinyl)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (30A)

[0588] Compound 19D (251.0 mg, 956.0 μmol), (R)-2-methylmorpholine hydrochloride (170.0 mg, 1.24 mmol), potassium carbonate (263.8 mg, 1.91 mmol), and potassium iodide (158.7 mg, 956.0 μmol) were added to DMF (5.0 mL) in sequence. The mixture was stirred at room temperature for 1.0 hour. After the reaction, the crude product was purified by reverse phase column chromatography (chromatographic column: The title compound 30A (220.0 mg) was obtained after purification using a flash silica gel column; mobile phase: acetonitrile / water = 55:45).

[0589] MS m / z(ESI):328.3[M+H] + .

[0590] Step 2: Preparation of (R)-3-iodo-7-((2-methylmorpholinyl)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (30B)

[0591] At room temperature, compound 30A (210.0 mg, 641.6 μmol), cerium ammonium nitrate (680.1 mg, 1.28 mmol), and iodine (325.7 mg, 1.28 mmol) were added to acetonitrile (30.0 mL) in sequence. The reaction mixture was then stirred for 6 hours. After the reaction was completed, a saturated aqueous sodium sulfite solution (10 mL) was added, and the mixture was extracted with dichloromethane (50 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure to obtain a crude product; the crude product was subjected to reverse phase column chromatography (chromatographic column: Flash silica gel column; mobile phase: acetonitrile / water = 50:50) to give the title compound 30B (160.0 mg).

[0592] MS m / z(ESI):454.2[M+H]+.

[0593] Step 3: Preparation of (R)-4-(2-cyclopropyl-6-(7-((2-methylmorpholinyl)methyl)-4-oxo-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-3-yl)pyridin-4-yl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)benzonitrile (30)

[0594] Compound 30B (20.0 mg, 44.1 μmol), 19B (18.6 mg, 40.1 μmol), BINAP (10.0 mg, 16.0 μmol), and cuprous iodide (7.6 mg, 40.1 μmol) were added to 1,4-dioxane (2.0 mL), and the atmosphere was replaced with nitrogen. Under a nitrogen atmosphere, Pd(dppf)Cl2·DCM (6.5 mg, 8.0 μmol) was added, and the mixture was heated to 100°C and stirred for 12 hours. The crude product was purified by reverse phase column chromatography (column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 50:50) to give the title compound 30 (4.5 mg).

[0595] MS m / z(ESI):627.45[M+H] + .

[0596] 1 H NMR(400MHz,DMSO-d6)δ9.25(s,1H),9.19(s,1H),8.51(s,1H),8.41(s,1H),8.31–8 .15(m,2H),8.04(s,1H),7.89(d,J=8.1Hz,1H),7.01(s,1H),3.70–3.65(m,2H),3.5 2(s,3H),2.79(d,J=11.1Hz,1H),2.75–2.65(m,2H),2.18–2.08(m,2H),2.00(d,J=9 .3Hz,2H),1.84(t,J=10.6Hz,1H),1.04(d,J=6.1Hz,3H),1.00(s,2H),0.98(s,2H).

[0597] Example 31: Preparation of (R)-3-(4-(4-chloro-2-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-6-cyclopropylpyridin-2-yl)-8-methyl-6-((2-methylmorpholinyl)methyl)-4H-chromen-4-one (Compound 31)

[0598] Compound 25H (25.2 mg, 57.9 μmol), 31A (10.0 mg, 29.0 μmol), and cuprous iodide (11.0 mg, 57.9 μmol) were added to 1,4-dioxane (2.0 mL), and the atmosphere was replaced with nitrogen. Pd(dppf)Cl2·DCM (9.45 mg, 11.6 μmol) and BINAP (10.8 mg, 17.4 μmol) were added, and the mixture was heated to 100°C under nitrogen and stirred for 7.0 hours. The crude product was purified by reverse phase column chromatography (column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 70:30) to give the title compound 31 (2.5 mg).

[0599] MS m / z(ESI):582.69[M+H] + .

[0600] 1 H NMR (400MHz, DMSO-d6) δ9.04(s,1H),8.51(s,1H),7.92(s,1H),7.88(d,J=1.5Hz,1H),7.85(dd,J= 8.3,2.3Hz,1H),7.78(d,J=2.2Hz,1H),7.73(d,J=8.4Hz,1H),7.67(s,1H),6.95(d,J=1.6Hz,1H), 3.76(d,J=10.6Hz,2H),3.57(s,3H),3.35(s,4H),2.67(dd,J=26.9,10.8Hz,3H),2.15–1.96(m,2H ),1.78(t,J=10.6Hz,1H),1.04(d,J=6.2Hz,3H),0.98(s,2H),0.97(s,2H),0.87(t,J=6.6Hz,1H).

[0601] Example 32: Preparation of (R)-4-(2-cyclopropyl-6-(8-methyl-6-((2-methylmorpholinyl)methyl)-4-oxo-4H-chromen-3-yl)pyridin-4-yl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)benzonitrile (Compound 32)

[0602] Compound 19A (20.00 mg, 59.56 μmol), 25H (51.95 mg, 119.12 μmol), Pd(dppf)Cl2·DCM (9.65 mg, 11.91 μmol), BINAP (14.83 mg, 23.82 μmol), and CuI (11.34 mg, 59.56 μmol) were added to a mixture of 1,4-dioxane (2 mL), and the atmosphere was replaced with nitrogen. The resulting mixture was heated to 100°C under nitrogen and stirred for 12.0 hours. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was separated by preparative HPLC (Welch Xtimate C18 column, 150 mm length, 30 mm inner diameter, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% in 18 minutes) to obtain the title compound 32 (9 mg).

[0603] MS m / z(ESI):573.3[M+H] + .

[0604] 1 H NMR(400MHz,DMSO-d6)δ9.04(s,1H),8.52(s,1H),8.24–8.19(m,2H),7.88(d,J= 8.2Hz,3H),7.66–7.63(m,1H),7.00(d,J=1.5Hz,1H),3.76–3.71(m,1H),3.54(s, 2H),3.53–3.46(m,2H),3.40(s,3H),2.65(dd,J=26.8,11.1Hz,2H),2.49(s,3H) ,2.11–2.02(m,2H),1.80–1.73(m,1H),1.02(d,J=6.3Hz,3H),1.00–0.94(m,4H).

[0605] Example 33: Preparation of 3-(6-cyclopropyl-4-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-7-fluoro-6-(((2-methoxyethyl)amino)methyl)-8-methyl-4H-benzo-4-one (Compound 33)

[0606] Step 1: Preparation of 7-fluoro-6-[(2-methoxyethylamino)methyl]-8-methyl-3-trimethylstannyl-chromen-4-one (33A)

[0607] Compound 20F (40 mg, 102.26 μmol) and hexamethyltin (335.02 mg, 1.02 mmol, 212.04 μL) were added to anhydrous dioxane (3.0 mL), followed by Pd(PPh3)4 (11.81 mg, 10.23 μmol). The resulting mixture was heated to 100°C under nitrogen and stirred for 1 hour. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure. The residue was purified by normal phase column chromatography (petroleum ether:ethyl acetate = 0:1) to afford the title compound 33A (40.0 mg).

[0608] MS m / z(ESI):430.1[M+H] + .

[0609] Step 2: Preparation of 2-chloro-6-cyclopropyl-4-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridine (33C)

[0610] Under argon atmosphere, to a solution of compound 33B (320 mg, 1.0 mmol) in tetrahydrofuran (5.0 mL) were added ferrous acetylacetonate (50.8 mg, 0.2 mmol) and cyclopropylmagnesium bromide (1 M in THF, 3.0 mL, 3.0 mmol) in sequence. The resulting mixture was stirred at room temperature overnight under argon. After completion of the reaction, the mixture was cooled to 0°C, quenched with saturated aqueous ammonium chloride, extracted with dichloromethane, and the organic phase concentrated and purified by preparative reverse-phase column chromatography (chromatographic column: The title compound 33C (6.7 mg) was obtained by separation using a C18 flash silica gel column; mobile phase: acetonitrile / water = 5%-98%, 15 min.

[0611] MS m / z(ESI):325.1[M+H] +

[0612] Step 3: Preparation of 3-(6-cyclopropyl-4-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-7-fluoro-6-(((2-methoxyethyl)amino)methyl)-8-methyl-4H-benzo-4-one (Compound 33)

[0613] Compound 33A (40 mg, 90.47 μmol), 33C (14.69 mg, 45.24 μmol), Pd(dppf)Cl2·DCM (14.66 mg, 18.09 μmol), CuI (17.23 mg, 90.47 μmol), and BINAP (22.53 mg, 36.19 μmol) were added to 1,4-dioxane (2 mL), and the atmosphere was replaced with nitrogen. The resulting mixture was heated to 100°C under nitrogen and stirred for 12.0 hours. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was separated by preparative HPLC (Welch Xtimate C18 column; column length 150 mm, inner diameter 30 mm, particle size 5 μm; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% in 18 minutes) to obtain the title compound 33 (3 mg).

[0614] MS m / z(ESI):554.3[M+H] + .

[0615] 1H NMR (400MHz, DMSO-d6) δ9.00 (s, 1H), 8.46 (s, 1H), 8.10 (d, J = 8.1Hz, 1H), 7.92 (s ,1H),7.34(s,1H),5.32(t,J=4.9Hz,1H),3.85(s,2H),3.76(d,J=14.2Hz,2H),3. 25(s,3H),2.71–2.67(m,2H),2.37(s,3H),2.22–2.12(m,2H),2.07(s,3H),2.04 –1.98(m,2H),1.48–1.43(m,1H),1.09–1.05(m,2H),0.97(dq,J=6.2,2.9Hz,2H).

[0616] Example 34: Preparation of (S)-4-(2-cyclopropyl-6-(6-((2-isopropyl-4-methylpiperazin-1-yl)methyl)-8-methyl-4-oxo-4H-chromen-3-yl)pyridin-4-yl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)benzonitrile (Compound 34)

[0617] Step 1: Preparation of (3S)-3-isopropyl-4-[(8-methyl-4-oxo-chromen-6-yl)methyl]piperazine-1-carboxylic acid tert-butyl ester (34A)

[0618] Compound 14F (0.4 g, 1.92 mmol) was dissolved in DMF (3.0 mL). To the reaction solution were added tert-butyl (3S)-3-isopropylpiperazine-1-carboxylate (875.50 mg, 3.83 mmol), potassium carbonate (793.71 mg, 5.75 mmol), and potassium iodide (63.08 mg, 0.38 mmol). The reaction solution was stirred at 50°C for 3.0 hours. After TLC monitoring of the reaction completion, the crude product was separated on a preparative HPLC column (Welch Xtimate C18, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 34A (600 mg).

[0619] MS m / z(ESI):401.3[M+H] + .

[0620] Step 2: Preparation of 6-[[(2S)-2-isopropylpiperazin-1-yl]methyl]-8-methyl-chromen-4-one (34B)

[0621] Compound 34A (0.6 g, 1.50 mmol) was dissolved in DCM (5.0 mL). Dioxane hydrochloride solution (6 mL, 4 M) was added to the reaction mixture, and the reaction mixture was stirred at room temperature for 1.0 hour. After TLC monitoring, the reaction mixture was concentrated under reduced pressure to give the crude product, title compound 34B (450 mg). This product was used directly in the next reaction without purification.

[0622] MS m / z(ESI):301.2[M+H]+.

[0623] Step 3: Preparation of 6-[[[(2S)-2-isopropyl-4-methyl-piperazin-1-yl]methyl]-8-methyl-chromen-4-one (34C)

[0624] Compound 34B (100 mg, 332.90 μmol) was dissolved in formaldehyde (10.00 mg, 332.90 μmol, 1.5 mL). Formic acid (610.00 mg, 13.25 mmol, 0.5 mL) was added to the reaction solution, and the reaction solution was stirred at 90°C for 1.0 hour. After the reaction was complete as monitored by TLC, the crude product was separated by preparative HPLC (Welch Xtimate C18 column, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 34C (50 mg).

[0625] MS m / z(ESI):315.2[M+H] + .

[0626] Step 4: Preparation of 1-[2-hydroxy-5-[[[(2S)-2-isopropyl-4-methyl-piperazin-1-yl]methyl]-3-methyl-phenyl]-3-pyrrolidin-1-yl-prop-2-en-1-one (34D)

[0627] Compound 34C (0.1 g, 318.05 μmol) and tetrahydropyrrole (113.10 mg, 1.59 mmol) were added to methanol (2 mL). The resulting mixture was heated to 50°C and stirred for 1 hour. After completion of the reaction, the mixture was cooled to room temperature and concentrated under reduced pressure to afford the crude title product 34D (120 mg). This product was used directly in the next step without further purification.

[0628] MS m / z(ESI):386.3[M+H]+.

[0629] Step 5: Preparation of 3-iodo-6-[[[(2S)-2-isopropyl-4-methyl-piperazin-1-yl]methyl]-8-methyl-chromen-4-one (34E)

[0630] Compound 34D (0.12 g, 311.25 μmol), iodine (158.00 mg, 622.50 μmol), and pyridine (4.92 mg, 62.25 μmol, 5.01 μL) were added to chloroform (2 mL), and the resulting mixture was stirred at room temperature for 1 hour. After completion of the reaction, the mixture was cooled to room temperature and concentrated under reduced pressure to obtain a crude product. The crude product was then separated by preparative HPLC (Welch Xtimate C18 column, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 34E (32 mg).

[0631] MS m / z(ESI):441.1[M+H] + .

[0632] Step 6: Preparation of (S)-4-(2-cyclopropyl-6-(6-((2-isopropyl-4-methylpiperazin-1-yl)methyl)-8-methyl-4-oxo-4H-chromen-3-yl)pyridin-4-yl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)benzonitrile (34)

[0633] Compound 34E (15 mg, 34.07 μmol), 19B (31.62 mg, 68.13 μmol), Pd(dppf)Cl2·DCM (5.52 mg, 6.81 μmol), CuI (6.49 mg, 34.07 μmol), and BINAP (8.48 mg, 13.63 μmol) were added to dioxane (1 mL), and the atmosphere was replaced with nitrogen. The resulting mixture was heated to 100°C under nitrogen and stirred for 12.0 hours. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was separated by preparative HPLC (chromatographic column: Welch Xtimate C18, column length 150 mm, inner diameter 30 mm, particle size 5 μm; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% in 18 minutes) to obtain the title compound 34 (5 mg).

[0634] MS m / z(ESI):614.3[M+H] + .

[0635] 1H NMR (400MHz, DMSO-d6) δ9.04(s,1H),8.20(d,J=6.0Hz,2H),7.92(s,2H),7.89(s,1H),7.61(s,2H),6.96(s,1H),3.45(s, 3H), 3.16 (d, J = 13.1Hz, 2H), 2.60 (s, 3H), 2.27 (s, 2H), 2.14 (s, 3H), 2.05 (s, 4H), 1.97 (s, 3H), 0.92 (s, 6H), 0.84 (s, 4H).

[0636] Example 35: Preparation of cis-3-(6-cyclopropyl-4-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-8-methyl-6-(((R)-2-methylmorpholinyl)methyl)-4H-chromen-4-one (Compound 35)

[0637] Step 1: Preparation of 2-chloro-4-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridine-1-oxide (35B)

[0638] Trifluoroacetic anhydride (4.0 mL) was added to a solution of compound 35A (400.0 mg, 1.52 mmol) in dichloromethane (4.0 mL). Hydrogen peroxide (4.0 mL) was slowly added dropwise at room temperature, and then stirring was continued and monitored until the starting material disappeared. After the reaction was completed, the reaction solution was concentrated and the crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column (mobile phase: acetonitrile / water = 45:55) to give the title compound 35B (300.0 mg).

[0639] MS m / z(ESI):279.74[M+H] +

[0640] Step 2: Preparation of 2,6-dichloro-4-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridine (35C)

[0641] Compound 35B (300.0 mg, 1.08 mmol) was added to phosphorus oxychloride (3.0 mL), and the reaction solution was stirred at 70°C for 1 hour. After the reaction was completed, the reaction solution was concentrated to dryness, and the crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 35:65) to give the title compound 35C (200.0 mg).

[0642] MS m / z(ESI):297.06 / 299.06[M+H] + .

[0643] Step 3: Preparation of cis-2-chloro-6-cyclopropyl-4-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridine (35D)

[0644] Compound 35C (200.0 mg, 673.0 μmol), cyclopropylboronic acid (86.7 mg, 1.01 mmol), and potassium phosphate (54.5 mg, 256.9 μmol) were added to a mixture of water (1.0 mL) and 1,4-dioxane (4.0 mL). The atmosphere was replaced with nitrogen. Pd(dppf)Cl2 (49.3 mg, 67.3 μmol) was added, and the mixture was heated to 100°C under nitrogen and stirred for 12.0 hours. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated to obtain a crude product, which was then separated on a preparative HPLC column (Welch Xtimate C18, 150 mm length, 30 mm inner diameter, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: 5% to 95% mobile phase B in 24 minutes) to afford the title compound 35D (142.0 mg).

[0645] MS m / z(ESI):303.1 / 305.1[M+H] + .

[0646] Step 4: Preparation of cis-2-cyclopropyl-4-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-6-(trimethylstannyl)pyridine (35E)

[0647] Compound 35D (30.0 mg, 99.1 μmol) and hexamethyltin (48.7 mg, 148.6 μmol) were added to 1,4-dioxane (2.0 mL), and the atmosphere was replaced with nitrogen. Pd(PPh3)4 (11.5 mg, 9.9 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen and stirred for 2.0 hours. The reaction mixture was concentrated in vacuo to afford the crude title compound 35E (40.0 mg), which was not further purified.

[0648] MS m / z(ESI):433.1 / 431.1 / 429.1[M+H] + .

[0649] Step 5: Preparation of cis-3-(6-cyclopropyl-4-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-8-methyl-6-(((R)-2-methylmorpholinyl)methyl)-4H-chromen-4-one (35)

[0650] Compound 25G (40.0 mg, 100.2 μmol), 35E (43.2 mg, 100.2 μmol), and cesium fluoride (33.5 mg, 220.4 μmol) were added to 1,4-dioxane (2.0 mL), and the nitrogen atmosphere was replaced. Di(tri-tert-butylphosphine)palladium (10.3 mg, 20.0 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen protection and stirred for 1.0 hour. After the reaction was completed, the crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 80:20) to give the title compound 35 (20.0 mg).

[0651] MS m / z(ESI):540.56[M+H] + .

[0652] 1 H NMR (400MHz, DMSO-d6) δ9.02(s,1H),8.37(s,1H),8.05(d,J=1.6Hz,1H),7.92(d,J=2.0Hz,1H),7.67–7.61(m,1H),7. 29(d,J=1.7Hz,1H),3.79–3.72(m,1H),3.56(d,J=3.0Hz,2H),3.51(dd,J=11.3,2.2Hz,2H),3.27(s,3H),2.88(d,J=4. 0Hz,2H),2.72–2.68(m,1H),2.66–2.59(m,4H),2.51(s,3H),2.16(dq,J=8.2,4.2,3.6Hz,1H),2.08(td,J=11.3,3.2Hz ,1H),1.82–1.74(m,1H),1.12(d,J=5.0Hz,3H),1.09–1.06(m,2H),1.04(d,J=6.3Hz,3H),0.98(dt,J=8.3,3.1Hz,2H).

[0653] Example 36: Preparation of (R)-4-(2-cyclopropyl-6-(8-cyclopropyl-6-((2-methylmorpholinyl)methyl)-4-oxo-4H-chromen-3-yl)pyridin-4-yl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)benzonitrile (36)

[0654] Step 1: Preparation of (R)-1-(3-cyclopropyl-2-hydroxy-5-((2-methylmorpholinyl)methyl)phenyl)ethan-1-one (36B)

[0655] Compound 36A (600.0 mg, 1.6 mmol), cyclopropylboronic acid (412.0 mg, 4.8 mmol), and potassium phosphate (684.6 mg, 3.2 mmol) were added to 1,4-dioxane (10.0 mL) and water (2.5 mL), and the nitrogen atmosphere was replaced. Pd(dppf)Cl2 (117.1 mg, 159.9 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen protection and stirred for 16.0 hours. After the reaction was completed, the pH was adjusted to acidic with dilute hydrochloric acid (1.0 M), and the mixture was extracted three times with ethyl acetate (30.0 mL). The organic phase was concentrated, and the crude product was purified by reverse phase column chromatography (chromatographic column: The title compound 36B (200.0 mg) was purified by flash silica gel column; mobile phase: acetonitrile / water = 50:50).

[0656] MS m / z(ESI):290.17[M+H] + .

[0657] Step 2: Preparation of (R)-8-cyclopropyl-3-iodo-6-((2-methylmorpholinyl)methyl)-4H-chromen-4-one (36C)

[0658] Compound 36B (200.0 mg, 691.16 μmol) was added to DMF-DMA (6.0 mL) and heated to 100°C with stirring for 1 hour. After the reaction, the reaction solution was concentrated to obtain the crude product. The crude product and iodine (350.8 mg, 1.38 mmol) were added to dichloromethane (6.0 mL), followed by pyridine (273.4 mg, 3.46 mmol) and stirred at room temperature for 1.0 hour. After the reaction, the crude product was purified by normal phase column chromatography (petroleum ether / ethyl acetate = 20:80) to obtain the title compound 36C (70.0 mg).

[0659] MS m / z(ESI):426.05[M+H] + .

[0660] Step 3: Preparation of (R)-4-(2-cyclopropyl-6-(8-cyclopropyl-6-((2-methylmorpholinyl)methyl)-4-oxo-4H-chromen-3-yl)pyridin-4-yl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)benzonitrile (36)

[0661] Compound 36C (40.3 mg, 94.8 μmol), 19B (40.0 mg, 86.2 μmol), and cesium fluoride (28.8 mg, 189.6 μmol) were added to 1,4-dioxane (2.0 mL), and the nitrogen atmosphere was replaced. Di(tri-tert-butylphosphine)palladium (8.8 mg, 17.2 μmol) was added, and the mixture was heated to 100°C under nitrogen protection and stirred for 1.0 hour. After the reaction was completed, the mixture was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 75:25) to give the title compound 36 (20.0 mg).

[0662] MS m / z(ESI):599.53[M+H] + .

[0663] 1 H NMR(400MHz,DMSO-d6)δ9.09(s,1H),8.54(s,1H),8.27–8.18(m,2H),7.96–7.87(m,3H),7.35 (d,J=2.0Hz,1H),7.02(d,J=1.6Hz,1H),3.75(d,J=10.8Hz,1H),3.56(s,2H),3.52–3.49(m,2 H),3.42(s,3H),2.72–2.67(m,1H),2.61(d,J=11.4Hz,1H),2.40(td,J=8.4,4.3Hz,1H),2.11 –2.04(m,2H),1.14–1.09(m,2H),1.04(d,J=6.3Hz,3H),1.02–0.97(m,4H),0.89–0.84(m,3H).

[0664] Example 37: Preparation of 4-(2-(6-(((1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)methyl)-8-methyl-4-oxo-4H-chromen-3-yl)-6-cyclopropylpyridin-4-yl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)benzonitrile (37)

[0665] Step 1: Preparation of potassium (((1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)methyl)trifluoroborate (37B)

[0666] Compound 37A (1 g, 10.09 mmol), potassium (bromomethyl)trifluoroborate (2.43 g, 12.11 mmol), potassium bicarbonate (2.02 g, 20.18 mmol), and KI (167.46 mg, 1.01 mmol) were added to tetrahydrofuran (10 mL) and heated to 80°C with stirring for 12 hours. After completion of the reaction, the mixture was cooled to room temperature and concentrated to obtain a crude product. The crude product was dissolved in acetone, pulped, and filtered. The filtrate was concentrated to obtain the title compound 37B (2.21 g). This product was used directly in the next reaction without purification.

[0667] MS m / z(ESI):162.1[M+H-KF] + .

[0668] Step 2: Preparation of 8-methyl-6-[[[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]methyl]-4H-chromen-4-one (37C)

[0669] Compound 4A (300 mg, 1.25 mmol), 37B (549.78 mg, 2.51 mmol), Xphos Pd G2 (98.63 mg, 125.49 μmol), Xphos (119.72 mg, 250.98 μmol), and cesium carbonate (815.68 mg, 2.51 mmol) were added to a mixture of 1,4-dioxane (5 mL) and water (1 mL), and the atmosphere was replaced with nitrogen. The mixture was heated to 100°C under nitrogen and stirred for 2.0 hours. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated. The crude product was separated by preparative HPLC (Welch Xtimate C18 column, 150 mm length, 30 mm inner diameter, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% in 18 minutes) to give the title compound 37C (100 mg).

[0670] MS m / z(ESI):272.2[M+H] + .

[0671] Step 3: Preparation of 1-[2-hydroxy-3-methyl-5-[[[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]methyl]phenyl]-3-pyrrolidin-1-yl-prop-2-en-1-one (37D)

[0672] Compound 37C (100 mg, 368.58 μmol) and tetrahydropyrrole (131.07 mg, 1.84 mmol) were added to methanol (2 mL). The mixture was heated to 50°C and stirred for 1 hour. After completion of the reaction, the mixture was cooled to room temperature and concentrated under reduced pressure to obtain the crude product of the title compound 37D (126 mg). This product was used directly in the next step without further purification.

[0673] MS m / z(ESI):343.2[M+H] + .

[0674] Step 4: Preparation of 3-iodo-8-methyl-6-[[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]methyl]-4H-chromen-4-one (37E)

[0675] Compound 37D (126 mg, 367.96 μmol), iodine (93.39 mg, 367.96 μmol), and pyridine (5.82 mg, 73.59 μmol, 5.93 μL) were added to chloroform (5 mL), and the mixture was stirred at room temperature for 1 hour. After completion of the reaction, the mixture was cooled to room temperature and concentrated under reduced pressure to obtain a crude product. The crude product was separated by preparative HPLC (Welch Xtimate C18 column, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 37E (45 mg).

[0676] MS m / z(ESI):398.1[M+H] + .

[0677] Step 5: Preparation of 4-(2-(6-(((1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)methyl)-8-methyl-4-oxo-4H-chromen-3-yl)-6-cyclopropylpyridin-4-yl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)benzonitrile (37)

[0678] Compound 37E (41.08 mg, 103.41 μmol), 19B (40 mg, 86.18 μmol), bis(tri-tert-butylphosphine)palladium (8.84 mg, 17.24 μmol), and CsF (12.53 mg, 189.59 μmol) were added to a mixture of 1,4-dioxane (2 mL), and the atmosphere was replaced with nitrogen. The resulting mixture was heated to 100°C under nitrogen and stirred for 3.0 hours. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was separated on a preparative HPLC column (Welch Xtimate C18, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 37 (10 mg).

[0679] MS m / z(ESI):571.3[M+H] + .

[0680] 1 H NMR(400MHz, DMSO-d6)δ9.04(s,1H),8.52(s,1H),8.24–8.18(m,2H),7.93(d,J=2.1Hz,1H),7.90–7.87 (m,2H),7.67(d,J=1.9Hz,1H),7.00(d,J=1.6Hz,1H),4.36(s,1H),3.94(d,J=7.5Hz,1H),3.81(d,J=6. 5Hz,2H),3.54(dd,J=7.4,1.8Hz,1H),3.47(s,1H),3.40(s,3H),2.77–2.72(m,1H),2.43(d,J=9.9Hz,1 H),2.07(s,3H),1.84(d,J=9.7Hz,1H),1.61(d,J=9.6Hz,1H),1.54–1.44(m,1H),0.97(d,J=8.3Hz,4H).

[0681] Example 38: Preparation of 4-[2-cyclopropyl-6-[8-methyl-6-[[(1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]methyl]-4-oxo-chromen-3-yl]-4-pyridinyl]-3-(4-methyl-1,2,4-triazol-3-yl)benzonitrile (38)

[0682] Step 1: Preparation of potassium (((1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)methyl)trifluoroborate (38B)

[0683] Compound 38A (1 g, 10.09 mmol), potassium (bromomethyl)trifluoroborate (2.43 g, 12.11 mmol), potassium bicarbonate (2.02 g, 20.18 mmol), and KI (167.46 mg, 1.01 mmol) were added to tetrahydrofuran (10 mL) and heated to 80°C with stirring for 12 hours. After completion of the reaction, the mixture was cooled to room temperature and concentrated to obtain a crude product. The crude product was dissolved in acetone, pulped, and filtered. The filtrate was concentrated to obtain the title compound 38B (2.21 g). This product was used directly in the next reaction without purification.

[0684] MS m / z(ESI):162.1[M+H-KF] + .

[0685] Step 2: Preparation of 8-methyl-6-[[(1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]methyl]-4H-chromen-4-one (38C)

[0686] Compound 4A (200 mg, 836.59 μmol), 38B (366.52 mg, 1.67 mmol), Xphos Pd G2 (65.76 mg, 83.66 μmol), Xphos (79.81 mg, 167.32 μmol), and cesium carbonate (543.78 mg, 1.67 mmol) were added to a mixture of 1,4-dioxane (5 mL) and water (1 mL). The atmosphere was replaced with nitrogen. The mixture was heated to 100°C under nitrogen and stirred for 2.0 hours. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was separated by preparative HPLC (Welch Xtimate C18 column, 150 mm length, 30 mm inner diameter, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% in 18 minutes) to obtain the title compound 38C (80 mg).

[0687] MS m / z(ESI):272.2[M+H] + .

[0688] Step 3: Preparation of 1-[2-hydroxy-3-methyl-5-[[(1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]methyl]phenyl]-3-pyrrolidin-1-yl-prop-2-en-1-one (38D)

[0689] Compound 38C (80 mg, 294.87 μmol) and tetrahydropyrrole (104.86 mg, 1.47 mmol) were added to methanol (2 mL). The resulting mixture was heated to 50°C and stirred for 1 hour. After completion of the reaction, the mixture was cooled to room temperature and concentrated under reduced pressure to afford the crude title compound 38D (100 mg). This product was used directly in the next step without further purification.

[0690] MS m / z(ESI):343.2[M+H] + .

[0691] Step 4: Preparation of 3-iodo-8-methyl-6-[[(1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]methyl]-4H-chromen-4-one (38E)

[0692] Compound 38D (100 mg, 292.03 μmol), iodine (74.12 mg, 292.03 μmol), and pyridine (4.62 mg, 58.41 μmol, 4.71 μL) were added to chloroform (2 mL), and the resulting mixture was stirred at room temperature for 1 hour. After completion of the reaction, the mixture was cooled to room temperature and concentrated under reduced pressure to obtain a crude product. The crude product was separated by preparative HPLC (Welch Xtimate C18 column, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 38E (40 mg).

[0693] MS m / z(ESI):398.1[M+H] + .

[0694] Step 5: Preparation of 4-[2-cyclopropyl-6-[8-methyl-6-[[(1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]methyl]-4-oxo-chromen-3-yl]-4-pyridinyl]-3-(4-methyl-1,2,4-triazol-3-yl)benzonitrile (38)

[0695] Compound 38E (40 mg, 86.18 μmol), 19B (29.10 mg, 73.25 μmol), bis(tri-tert-butylphosphine)palladium (8.84 mg, 17.24 μmol), and CsF (12.53 mg, 189.59 μmol) were added to 1,4-dioxane (2 mL), and the atmosphere was replaced with nitrogen. The resulting mixture was heated to 100°C under nitrogen and stirred for 3.0 hours. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was separated on a preparative HPLC column (Welch Xtimate C18, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 38 (8 mg).

[0696] MS m / z(ESI):571.3[M+H] + .

[0697] 1 H NMR(400MHz, DMSO-d6)δ9.03(s,1H),8.52(s,1H),8.24–8.19(m,2H),7.93(d,J=2.1Hz,1H),7.90–7.87(m,2 H),7.67(d,J=2.0Hz,1H),7.00(d,J=1.6Hz,1H),4.36(t,J=1.9Hz,1H),3.94(d,J=7.5Hz,1H),3.85–3.77(m ,2H),3.54(dd,J=7.5,1.9Hz,1H),3.47(s,1H),3.40(s,3H),2.74(dd,J=9.9,1.8Hz,1H),2.49(s,3H),2.43 (d,J=9.9Hz,1H),1.84(dd,J=9.6,2.1Hz,1H),1.64–1.59(m,1H),1.16(d,J=14.0Hz,1H),1.01–0.95(m,4H).

[0698] Example 39: Preparation of cis-3-(6-cyclopropyl-4-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-7-fluoro-6-((2-methoxyethyl)amino)methyl)-8-methyl-4H-chromen-4-one (Compound 39)

[0699] 20F (20.0 mg, 51.0 μmol), 35E (20.0 mg, 46.4 μmol) and cesium fluoride (15.5 mg, 102.1 μmol) were added to 1,4-dioxane (2.0 mL) and the argon atmosphere was replaced. Di(tri-tert-butylphosphine)palladium (4.8 mg, 9.3 μmol) was added and the resulting mixture was heated to 100°C under argon protection and stirred for 1.0 hour. After the reaction was completed, the mixture was chromatographed on a reverse phase column (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 80:20) to give the title compound 39 (5.0 mg).

[0700] MS m / z(ESI):532.71[M+H] + .

[0701] 1 H NMR (400MHz, DMSO-d6) δ8.99(s,1H),8.34(s,1H),8.11(d,J=8.1Hz,1H),8.00(d,J=1.7Hz ,1H),7.27(d,J=1.6Hz,1H),3.86(s,2H),3.43(s,2H),3.25(s,3H),3.24(s,3H),2.86(s, 2H),2.70(t,J=5.7Hz,2H),2.58(d,J=7.7Hz,3H),2.38(d,J=1.9Hz,3H),2.18–2.10(m,1H ),2.00(q,J=7.4Hz,1H),1.10(d,J=5.1Hz,3H),1.05(t,J=3.6Hz,2H),0.97–0.92(m,2H).

[0702] Example 40: Preparation of cis-3-(6-cyclopropyl-4-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-7-(((R)-2-methylmorpholino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 40)

[0703] 30B (20.0 mg, 44.1 μmol), 35E (19.0 mg, 44.1 μmol) and cesium fluoride (13.4 mg, 88.3 μmol) were added to 1,4-dioxane (2.0 mL) and the argon atmosphere was replaced. Di(tri-tert-butylphosphine)palladium (4.5 mg, 8.8 μmol) was added and the resulting mixture was heated to 100°C under argon protection and stirred for 1.0 hour. The crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 80:20) to give the title compound 40 (2.5 mg).

[0704] MS m / z(ESI):594.41[M+H] + .

[0705] 1 H NMR(400MHz, DMSO-d6)δ9.22(d,J=2.8Hz,2H),8.40–8.37(m,1H),8.34(s,1H),8.22(d,J=1.6Hz,1H),7. 29(d,J=1.6Hz,1H),3.75(d,J=11.1Hz,1H),3.66(d,J=5.1Hz,2H),3.51(s,2H),3.23(s,3H),2.87(s,2H) ,2.77(d,J=11.2Hz,1H),2.71(d,J=11.3Hz,1H),2.60(s,1H),2.16(d,J=9.8Hz,2H),2.02–1.96(m,2H), 1.82(t,J=10.6Hz,1H),1.10(d,J=5.0Hz,3H),1.07(s,2H),1.03(d,J=6.2Hz,3H),0.85(t,J=6.4Hz,2H).

[0706] Example 41: 3-(6-cyclopropyl-4-(cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-8-methyl-6-(((R)-2-methylmorpholinyl)methyl)-4H-chromen-4-one, (R)-3-(6-cyclopropyl-4-(cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)- Preparation of 8-methyl-6-(((R)-2-methylmorpholinyl)methyl)-4H-chromen-4-one and (S)-3-(6-cyclopropyl-4-(cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-8-methyl-6-(((R)-2-methylmorpholinyl)methyl)-4H-chromen-4-one (Compounds 41, 41-1, and 41-2)

[0707] Step 1: Preparation of cyclopropyl(2,6-dichloropyridin-4-yl)methanol (Compound 41B)

[0708] Compound 41A (2.3 g, 13.07 mmol) was added to tetrahydrofuran (23.0 mL). The reaction mixture was cooled to 0°C, and a tetrahydrofuran solution of cyclopropylmagnesium bromide (17.0 mL, 17.0 mmol, 1.0 M) was added dropwise. After the addition was complete, the reaction mixture was transferred to room temperature and reacted for 4 hours. After the reaction was completed, the reaction mixture was cooled to 0°C in an ice bath and then quenched by adding saturated aqueous ammonium chloride. Ethyl acetate was added for extraction, and the organic phase was dried and concentrated. The crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 60:40) to give the title compound 41B (1.67 g).

[0709] MS m / z(ESI):218.0 / 220.0[M+H] + .

[0710] Step 2: Preparation of (2-chloro-6-cyclopropylpyridin-4-yl)(cyclopropyl)methanol (41C)

[0711] 41B (1.5 g, 6.88 mmol), cyclopropylboronic acid (886.2 mg, 10.3 mmol), and potassium phosphate (2.92 g, 13.76 mmol) were added to a mixture of water (10.0 mL) and 1,4-dioxane (40.0 mL), and the atmosphere was replaced with nitrogen. Pd(dppf)Cl2 (503.5 mg, 687.8 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen and stirred for 12.0 hours. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain a crude product, which was then purified by reverse phase column chromatography (chromatographic column: Flash silica gel column; mobile phase: acetonitrile / water = 50:50) to give the title compound 41C (1.0 g).

[0712] MS m / z(ESI):224.0 / 226.0[M+H] + .

[0713] Step 3: Preparation of (2-chloro-6-cyclopropylpyridin-4-yl)(cyclopropyl)methanone (41D)

[0714] 41C (1.0 g, 4.47 mmol) was dissolved in anhydrous dichloromethane (20.0 mL). Dess-Martin periodinane (2.84 g, 6.71 mmol) was added to the solution in portions under an ice bath at 0°C. After the addition was complete, the reaction solution was slowly heated to room temperature and stirred for 2.0 hours. After the reaction was complete, the reaction residue was filtered off and rinsed with dichloromethane. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 50:50) to give the title compound 41D (800.0 mg).

[0715] MS m / z(ESI):222.0 / 224.0[M+H] + .

[0716] Step 4: Preparation of (2-chloro-6-cyclopropylpyridin-4-yl)(cyclopropyl)(4-methyl-4H-1,2,4-triazol-3-yl)methanol (41E)

[0717] 4-Methyl-4H-1,2,4-triazole (93.7 mg, 1.13 mmol) was dissolved in DME (10.0 mL). The reaction mixture was cooled to -40°C, and a solution of n-butyllithium in n-hexane (1.6 M, 0.71 mL, 1.13 mmol) was added dropwise. After the addition was complete, the reaction mixture was stirred at -40°C for 1.0 hour. A solution of 41D (125.0 mg, 564.0 μmol) in DME (3.0 mL) was then added dropwise. After the addition was complete, the reaction mixture was brought to room temperature and allowed to react for 1.0 hour. After the reaction was completed, the reaction mixture was cooled to 0°C in an ice bath, and saturated aqueous ammonium chloride was added and stirred for 10 minutes. After stirring, the mixture was extracted three times with ethyl acetate (20.0 mL). The resulting organic phase was dried and concentrated, and the crude product was washed twice with petroleum ether (100.0 mL) to obtain the title compound 41E (105.0 mg).

[0718] MS m / z(ESI):305.1 / 307.1[M+H] + .

[0719] Step 5: Preparation of 2-chloro-4-(chloro(cyclopropyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)-6-cyclopropylpyridine (41F)

[0720] To a solution of compound 41E (70 mg, 229.7 μmol) in dichloromethane (2.0 mL) was added thionyl chloride (273.2 mg, 2.3 mmol) and DIEA (296.8 mg, 2.3 mmol) in an ice bath. The mixture was stirred at room temperature for 2.0 h. After completion of the reaction, the reaction solution was washed with saturated aqueous ammonium chloride, extracted with dichloromethane, and the organic phase was concentrated in vacuo to afford the crude title compound 41F (60.0 mg), which did not require further purification.

[0721] MS m / z(ESI):323.0 / 325.0[M+H] + .

[0722] Step 6: Preparation of 2-chloro-6-cyclopropyl-4-(cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridine (41G)

[0723] Zinc powder (241.0 mg, 3.71 mmol) was added to a solution of 41F (60.0 mg, 185.6 mmol) in glacial acetic acid (8.0 mL) and stirred at room temperature for 12.0 h. After the reaction, the reaction solution was filtered and the filtrate was concentrated in vacuo. The crude product was separated by a reverse phase separation column (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 50:50) to give the title compound 41G (20.0 mg).

[0724] MS m / z(ESI):289.1 / 291.1[M+H] + .

[0725] Step 7: Preparation of 2-cyclopropyl-4-(cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)-6-(trimethylstannyl)pyridine (41H)

[0726] 41G (30.0 mg, 103.89 μmol) and hexamethyltin (68.0 mg, 207.8 μmol) were added to 1,4-dioxane (3.0 mL), and the atmosphere was replaced with nitrogen. Tetrakis(triphenylphosphine)palladium (24.0 mg, 20.8 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen and stirred for 18.0 hours. The mixture was concentrated in vacuo to afford the crude title compound 41H (25.0 mg), which was not further purified.

[0727] MS m / z(ESI):419.1 / 417.1 / 415.1[M+H] + .

[0728] Step 8: Preparation of 3-(6-cyclopropyl-4-(cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-8-methyl-6-(((R)-2-methylmorpholinyl)methyl)-4H-chromen-4-one (Compound 41)

[0729] Compound 25G (26.3 mg, 65.9 μmol), 41H (25.0 mg, 59.9 μmol), and cesium fluoride (20.0 mg, 131.9 μmol) were added to 1,4-dioxane (2.0 mL), and the nitrogen atmosphere was replaced. Di(tri-tert-butylphosphine)palladium (6.2 mg, 12.0 μmol) was added, and the mixture was heated to 100°C under nitrogen protection and stirred for 1.0 hour. After the reaction was completed, the mixture was chromatographed on a reverse phase column (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 80:20) to give the title compound 41 (6.5 mg).

[0730] MS m / z(ESI):526.52[M+H] + .

[0731] 1 H NMR (400MHz, DMSO-d6) δ8.98(s,1H),8.38(s,1H),8.01(d,J=1.5Hz,1H),7.91(d,J=2.1Hz,1H),7.63(d,J=1.3Hz,1H) ,7.23(d,J=1.5Hz,1H),3.73(d,J=10.8Hz,1H),3.61(d,J=9.8Hz,1H),3.56–3.49(m,4H),3.46(s,3H),2.70–2.59(m, 2H),2.09(ddd,J=11.0,7.3,3.9Hz,2H),2.04–1.97(m,2H),1.76(t,J=10.5Hz,1H),1.68–1.63(m,1H),1.48(t,J=7.2 Hz,2H),1.03(dd,J=6.9,3.2Hz,4H),0.95(dd,J=8.1,3.0Hz,2H),0.85(t,J=6.6Hz,2H),0.60(dd,J=14.3,8.8Hz,2H).

[0732] Step 9: Preparation of (R)-3-(6-cyclopropyl-4-(cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-8-methyl-6-(((R)-2-methylmorpholinyl)methyl)-4H-chromen-4-one and (S)-3-(6-cyclopropyl-4-(cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-8-methyl-6-(((R)-2-methylmorpholinyl)methyl)-4H-chromen-4-one (Compounds 41-1 and 41-2)

[0733] Compound 41 was isolated and purified by supercritical fluid chromatography (column: REGIS (S,S) WHELK-O1, 250 mm length, 25 mm inner diameter, 10 μm particle size; mobile phase A: ethanol (containing 0.1% ammonia), mobile phase B: supercritical carbon dioxide; gradient: mobile phase B from 60% to 60%; flow rate: 80 mL / min) to afford the title compounds 41-1 and 41-2. The two title products were further analyzed using the following chiral HPLC method.

[0734] Chiral HPLC analysis method:

[0735] Chromatographic column: (S,S) Whelk-01, column length: 100 mm, inner diameter: 4.6 mm, particle size: 5 μm; mobile phase: A: CO2; B: ethanol (containing 0.05% diethylamine); gradient: mobile phase B from 50% to 50% in 5 minutes; flow rate: 2.5 mL / min; column temperature: 40°C; ABPR: 100 bar

[0736] 41-1:

[0737] The chiral HPLC peak time was 2.804 min;

[0738] MS m / z(ESI):526.3[M+H] +

[0739] 1 H NMR (400MHz, DMSO-d6) δ8.98(s,1H),8.38(s,1H),8.01(d,J=1.5Hz,1H),7.91(d,J=2.1Hz,1H),7.63(d,J=1.3Hz,1H) ,7.23(d,J=1.5Hz,1H),3.73(d,J=10.8Hz,1H),3.61(d,J=9.8Hz,1H),3.56–3.49(m,4H),3.46(s,3H),2.70–2.59(m, 2H),2.09(ddd,J=11.0,7.3,3.9Hz,2H),2.04–1.97(m,2H),1.76(t,J=10.5Hz,1H),1.68–1.63(m,1H),1.48(t,J=7.2 Hz,2H),1.03(dd,J=6.9,3.2Hz,4H),0.95(dd,J=8.1,3.0Hz,2H),0.85(t,J=6.6Hz,2H),0.60(dd,J=14.3,8.8Hz,2H).

[0740] 41-2:

[0741] The chiral HPLC peak time was 3.833 min;

[0742] MS m / z(ESI):526.3[M+H] +

[0743] 1H NMR (400MHz, DMSO-d6) δ8.98(s,1H),8.38(s,1H),8.01(d,J=1.5Hz,1H),7.91(d,J=2.1Hz,1H),7.63(d,J=1.3Hz,1H) ,7.23(d,J=1.5Hz,1H),3.73(d,J=10.8Hz,1H),3.61(d,J=9.8Hz,1H),3.56–3.49(m,4H),3.46(s,3H),2.70–2.59(m, 2H),2.09(ddd,J=11.0,7.3,3.9Hz,2H),2.04–1.97(m,2H),1.76(t,J=10.5Hz,1H),1.68–1.63(m,1H),1.48(t,J=7.2 Hz,2H),1.03(dd,J=6.9,3.2Hz,4H),0.95(dd,J=8.1,3.0Hz,2H),0.85(t,J=6.6Hz,2H),0.60(dd,J=14.3,8.8Hz,2H).

[0744] Example 42: Preparation of 3-(6-cyclopropyl-4-((R)-1,2,2,2-tetrafluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)pyridin-2-yl)-8-methyl-6-(((R)-2-methylmorpholinyl)methyl)-4H-chromen-4-one and 3-(6-cyclopropyl-4-((S)-1,2,2,2-tetrafluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)pyridin-2-yl)-8-methyl-6-(((R)-2-methylmorpholinyl)methyl)-4H-chromen-4-one (Compound 42-1 and Compound 42-2)

[0745] Step 1: Preparation of (2-chloropyridin-4-yl)(4-methyl-4H-1,2,4-triazol-3-yl)methanol (42B)

[0746] 4-Methyl-4H-1,2,4-triazole (1.53 g, 18.37 mmol) was dissolved in DME (40.0 mL). The reaction mixture was cooled to -40°C, and a solution of n-butyllithium in n-hexane (1.6 M, 11.48 mL, 18.37 mmol) was added dropwise. After the addition was complete, the reaction mixture was stirred at -40°C for 1.0 hour. A solution of compound 42A (2.0 g, 14.13 mmol) in DME (20.0 mL) was then added dropwise. After the addition was complete, the reaction mixture was transferred to room temperature and reacted for 1.0 hour. After the reaction was completed, the reaction mixture was cooled to 0°C in an ice bath, and saturated aqueous ammonium chloride was added and stirred for 10 minutes. After stirring, the mixture was extracted three times with ethyl acetate (20.0 mL). The resulting organic phase was dried and concentrated, and the crude product was washed twice with petroleum ether (100.0 mL) to obtain the title compound 42B (1.1 g).

[0747] MS m / z(ESI):225.0 / 227.0[M+H] + .

[0748] Step 2: Preparation of (2-chloropyridin-4-yl)(4-methyl-4H-1,2,4-triazol-3-yl)methanone (42C)

[0749] 42B (100.0 mg, 445.1 μmol) was dissolved in anhydrous dichloromethane (4.0 mL). Dess-Martin periodinane (283.2 mg, 667.7 μmol) was added to the solution in portions under an ice bath at 0°C. After the addition was complete, the reaction solution was slowly heated to room temperature and stirred for 2.0 hours. After the reaction was complete, the reaction residue was filtered off and rinsed with dichloromethane. The organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated to dryness under reduced pressure to obtain a crude product. The crude product was purified by reverse phase column chromatography (chromatographic column: Flash silica gel column; mobile phase: acetonitrile / water = 50:50) to give the title compound 42C (80.0 mg).

[0750] MS m / z(ESI):223.0 / 225.0[M+H] + .

[0751] Step 3: Preparation of 1-(2-chloropyridin-4-yl)-2,2,2-trifluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethan-1-ol (42D)

[0752] 42C (310.0 mg, 1.39 mmol) and (trifluoromethyl)trimethylsilane (247.0 μL, 1.67 mmol) were added to tetrahydrofuran (4.8 mL). After cooling to 0°C, a THF solution of tetrabutylammonium fluoride (1.0 M, 0.7 mL, 0.7 mmol) was added dropwise to the reaction solution. After the addition was complete, the reaction solution was transferred to room temperature and reacted for 3.0 hours. After the reaction was completed, the reaction solution was cooled to 0°C in an ice bath, and then saturated aqueous ammonium chloride was added to quench the reaction. The reaction was extracted three times with ethyl acetate. The organic phases were combined, dried, and concentrated. The crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 60:40) to give the title compound 42D (270.0 mg).

[0753] MS m / z(ESI):293.0 / 295.0[M+H] + .

[0754] Step 4: Preparation of 2-chloro-4-(1,2,2,2-tetrafluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)pyridine (42E)

[0755] 42D (300.0 mg, 1.03 mmol) was dissolved in dichloromethane (6.0 mL). After cooling to 0°C, DAST (0.2 mL, 1.54 mmol) was added dropwise to the reaction solution. After the addition was complete, the reaction solution was transferred to room temperature and reacted for 2.0 hours. After the reaction was completed, the reaction solution was cooled to 0°C in an ice bath, and then saturated sodium bicarbonate aqueous solution was added and stirred for 10 minutes. After stirring, the solution was extracted three times with dichloromethane (3.0 mL). The resulting organic phase was dried and concentrated, and the crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 50:50) to give the title compound 42E (227.0 mg).

[0756] MS m / z(ESI):295.0 / 297.0[M+H] + .

[0757] Step 5: Preparation of 2-chloro-4-(1,2,2,2-tetrafluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)pyridine 1-oxide (42F)

[0758] TFAA (3.0 mL) was added to a solution of 42E (227.0 mg, 0.77 mmol) in dichloromethane (3.0 mL). Hydrogen peroxide (6.0 mL) was slowly added dropwise at room temperature. After the addition was complete, stirring was continued at room temperature and monitored until the starting material disappeared. After the reaction was completed, the reaction solution was concentrated and the crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 35:65) to give the title compound 42F (100.0 mg).

[0759] MS m / z(ESI):311.0[M+H] +

[0760] Step 6: Preparation of 2,6-dichloro-4-(1,2,2,2-tetrafluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)pyridine (42G)

[0761] 42F (100.0 mg, 0.32 mmol) was added to phosphorus oxychloride (3.0 mL), and the reaction solution was stirred at 80°C for 1 hour. After the reaction was completed, the reaction solution was completely concentrated to dryness, and the crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 45:55) to give the title compound 42G (90.0 mg).

[0762] MS m / z(ESI):329.0 / 331[M+H] + .

[0763] Step 7: Preparation of 2-chloro-6-cyclopropyl-4-(1,2,2,2-tetrafluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)pyridine (Compound 42H)

[0764] 42G (90.0 mg, 273.5 μmol), cyclopropylboronic acid (35.2 mg, 0.41 mmol), and potassium phosphate (116.0 mg, 547.0 μmol) were added to a mixture of water (0.5 mL) and 1,4-dioxane (2.0 mL). The atmosphere was replaced with nitrogen. Pd(dppf)Cl2 (20.0 mg, 27.4 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen and stirred for 12.0 hours. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was separated by preparative HPLC (Welch Xtimate C18 column, 150 mm length, 30 mm inner diameter, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% in 24 minutes) to obtain the title compound 42H (45.0 mg).

[0765] MS m / z(ESI):335.0 / 337.0[M+H] + .

[0766] Step 8: Preparation of (R)-2-chloro-6-cyclopropyl-4-(1,2,2,2-tetrafluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)pyridine and (S)-2-chloro-6-cyclopropyl-4-(1,2,2,2-tetrafluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)pyridine (42H-1 and 42H-2)

[0767] 42H (970.0 mg) was isolated and purified by supercritical fluid chromatography (column: DAICEL CHIRALPAK IC, 250 mm length, 30 mm inner diameter, 10 μm particle size; mobile phase A: isopropanol (containing 0.1% aqueous ammonia), mobile phase B: supercritical carbon dioxide; gradient: mobile phase B from 80% to 80%; flow rate: 80 mL / min) to afford the title compounds 42H-1 (409 mg) and 42H-2 (438 mg) as colorless oils. The two title products were further analyzed by the following chiral HPLC method.

[0768] Chiral HPLC analysis method:

[0769] Chromatographic column: Chiralpak IC-3, column length: 100 mm, inner diameter: 4.6 mm, particle size: 3 μm; mobile phase: A: CO2; B: isopropanol (containing 0.05% diethylamine); gradient: mobile phase B from 5% to 80% in 5 minutes, maintained at 80% for 0.5 minutes, and then eluted with 5% mobile phase B for 1.5 minutes; flow rate: 2.5 mL / min; column temperature: 25°C; ABPR: 1500 psi42H-1:

[0770] The chiral HPLC peak time was 2.295 min;

[0771] MS m / z(ESI):335.0 / 337.0[M+H] +

[0772] 42H-2:

[0773] The chiral HPLC peak time was 2.564 min;

[0774] MS m / z(ESI):335.0 / 337.0[M+H] +

[0775] Step 9: Preparation of (R)-2-cyclopropyl-4-(1,2,2,2-tetrafluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)-6-(trimethyltinyl)pyridine and (S)-2-cyclopropyl-4-(1,2,2,2-tetrafluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)-6-(trimethyltinyl)pyridine (42I-1 and 42I-2)

[0776] 42H-1 (25.0 mg, 74.7 μmol) and hexamethyltin (36.7 mg, 112.0 μmol) were added to 1,4-dioxane (2.5 mL), and the atmosphere was replaced with nitrogen. Tetrakis(triphenylphosphine)palladium (8.63 mg, 7.47 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen and stirred for 3.0 hours. After completion of the reaction, the reaction mixture was concentrated in vacuo to afford the crude title compound 42I-1 (34.0 mg), which was not further purified.

[0777] MS m / z(ESI):465.1 / 463.1 / 461.1[M+H] + .

[0778] 42H-2 (25.0 mg, 74.7 μmol) and hexamethyltin (36.7 mg, 112.0 μmol) were added to 1,4-dioxane (2.5 mL), and the atmosphere was replaced with nitrogen. Tetrakis(triphenylphosphine)palladium (8.63 mg, 7.47 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen and stirred for 3.0 hours. After completion of the reaction, the reaction mixture was concentrated in vacuo to afford the crude title compound 42I-2 (34.0 mg), which was not further purified.

[0779] MS m / z(ESI):465.1 / 463.1 / 461.1[M+H] + .

[0780] Step 3: Preparation of 3-(6-cyclopropyl-4-((R)-1,2,2,2-tetrafluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)pyridin-2-yl)-8-methyl-6-(((R)-2-methylmorpholinyl)methyl)-4H-chromen-4-one and 3-(6-cyclopropyl-4-((S)-1,2,2,2-tetrafluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)pyridin-2-yl)-8-methyl-6-(((R)-2-methylmorpholinyl)methyl)-4H-chromen-4-one (42-1 and 42-2)

[0781] 42I-1 (34.0 mg, 73.4 μmol), 25G (35.2 mg, 88.1 μmol), and cesium fluoride (24.5 mg, 161.5 μmol) were added to 1,4-dioxane (3.0 mL), and the nitrogen atmosphere was replaced. Di(tri-tert-butylphosphine)palladium (7.5 mg, 14.7 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen protection and stirred for 1.0 hour. After the reaction was completed, the mixture was chromatographed on a reverse phase column (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 80:20) to give the title compound 42-1 (9.3 mg).

[0782] MS m / z(ESI):572.15[M+H] + .

[0783] 1 H NMR (400MHz, DMSO-d6) δ9.12(s,1H),8.77(s,1H),8.16(d,J=1.6Hz,1H),7.90(d,J=2.1Hz,1H),7.6 4(s,1H),7.42(d,J=1.6Hz,1H),3.73(d,J=10.1Hz,1H),3.56–3.47(m,4H),3.42(d,J=1.6Hz,3H),2. 67(d,J=10.8Hz,1H),2.61(d,J=11.4Hz,1H),2.49(s,3H),2.29(dt,J=8.1,3.6Hz,1H),2.06(td,J= 11.2, 3.1Hz, 1H), 1.75 (t, J = 10.5Hz, 1H), 1.13 (s, 2H), 1.03 (d, J = 5.7Hz, 2H), 1.01 (d, J = 4.1Hz, 3H).

[0784] 42I-2 (34.0 mg, 73.4 μmol), 25G (35.2 mg, 88.1 μmol), and cesium fluoride (24.5 mg, 161.5 μmol) were added to 1,4-dioxane (3.0 mL), and the nitrogen atmosphere was replaced. Di(tri-tert-butylphosphine)palladium (7.5 mg, 14.7 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen protection and stirred for 1.0 hour. After the reaction was completed, the mixture was chromatographed on a reverse phase column (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 80:20) to give the title compound 42-2 (21.7 mg).

[0785] MS m / z(ESI):572.32[M+H] + .

[0786] 1 H NMR (400MHz, DMSO-d6) δ9.12(s,1H),8.77(s,1H),8.16(d,J=1.6Hz,1H),7.90(d,J=2.1Hz,1H),7. 64(s,1H),7.42(d,J=1.6Hz,1H),3.73(d,J=10.8Hz,1H),3.52(dd,J=15.9,2.8Hz,4H),3.42(d,J= 1.7Hz,3H),2.67(d,J=11.0Hz,1H),2.61(d,J=11.3Hz,1H),2.49(s,3H),2.28(dq,J=8.2,4.7,4.0 Hz,1H),2.06(td,J=11.3,3.1Hz,1H),1.75(t,J=10.5Hz,1H),1.13(d,J=5.0Hz,2H),1.02(m,5H).

[0787] Example 43: Preparation of (R)-3-(6-cyclopropyl-4-(cyclopropylfluoro(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-8-methyl-6-(((R)-2-methylmorpholinyl)methyl)-4H-chromen-4-one and (S)-3-(6-cyclopropyl-4-(cyclopropylfluoro(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-8-methyl-6-(((R)-2-methylmorpholinyl)methyl)-4H-chromen-4-one (Compound 43-1, Compound 43-2)

[0788] Step 1: Preparation of 2-chloro-6-cyclopropyl-4-(cyclopropylfluoro(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridine (43A)

[0789] 41E (35.0 mg, 114.8 μmol) was dissolved in DCM (2.0 mL). The reaction mixture was cooled to 0°C, and DAST (37.2 mg, 229.7 μmol) was added dropwise. After the addition was complete, the reaction mixture was brought to room temperature and allowed to react for 2.0 hours. After the reaction was completed, the reaction mixture was cooled to 0°C in an ice bath, and then saturated aqueous sodium bicarbonate solution was added and stirred for 10 minutes. After stirring, the mixture was extracted three times with dichloromethane (2.0 mL). The resulting organic phase was dried and concentrated, and the crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 50:50) to give the title compound 43A (30.0 mg).

[0790] MS m / z(ESI):307.1 / 309.1[M+H] +.

[0791] Step 2: Preparation of (R)-2-chloro-6-cyclopropyl-4-(cyclopropylfluoro(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridine and (S)-2-chloro-6-cyclopropyl-4-(cyclopropylfluoro(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridine (43A-1 and 43A-2)

[0792] 43A (186.0 mg) was isolated and purified by supercritical fluid chromatography (column: DAICEL CHIRALPAK IC, 250 mm length, 30 mm inner diameter, 10 μm particle size; mobile phase A: ethanol (containing 0.1% ammonia), mobile phase B: supercritical carbon dioxide; gradient: mobile phase B from 80% to 80%; flow rate: 80 mL / min) to afford the title compounds 43A-1 (77 mg) and 43A-2 (77 mg) as colorless oils. The two title products were further analyzed by the following chiral HPLC method.

[0793] Chiral HPLC analysis method:

[0794] Chromatographic column: Chiralpak IC-3 column, 100 mm length, 4.6 mm inner diameter, 3 μm particle size; mobile phase: A: CO2; B: ethanol (containing 0.05% DEA); gradient: 5% to 80% mobile phase B in 5 minutes, maintained at 80% for 0.5 minutes, and then eluted with 5% mobile phase B for 1.5 minutes; flow rate: 2.5 mL / min; column temperature: 35°C; ABPR: 1500 psi.

[0795] 43A-1:

[0796] The chiral HPLC peak time was 1.700 min;

[0797] MS m / z(ESI):307.1 / 309.1[M+H] +

[0798] 43A-2:

[0799] The chiral HPLC peak time was 1.946 min;

[0800] MS m / z(ESI):307.1 / 309.1[M+H] +

[0801] Step 3: Preparation of (R)-2-cyclopropyl-4-(cyclopropylfluoro(4-methyl-4H-1,2,4-triazol-3-yl)methyl)-6-(trimethyltinyl)pyridine and (S)-2-cyclopropyl-4-(cyclopropylfluoro(4-methyl-4H-1,2,4-triazol-3-yl)methyl)-6-(trimethyltinyl)pyridine (43B-1 and 43B-2)

[0802] 43A-1 (20.0 mg, 65.2 μmol) and hexamethyltin (32.0 mg, 97.8 μmol) were added to 1,4-dioxane (2.0 mL), and the atmosphere was replaced with nitrogen. Tetrakis(triphenylphosphine)palladium (7.5 mg, 6.5 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen and stirred for 3.0 hours. The mixture was concentrated in vacuo to afford the crude title compound 43B-1 (28.0 mg), which was not further purified.

[0803] MS m / z(ESI):437.1 / 435.1 / 433.1[M+H] + .

[0804] 43A-2 (20.0 mg, 65.2 μmol) and hexamethyltin (32.0 mg, 97.8 μmol) were added to 1,4-dioxane (2.0 mL), and the atmosphere was replaced with nitrogen. Tetrakis(triphenylphosphine)palladium (7.5 mg, 6.5 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen and stirred for 3.0 hours. The mixture was concentrated in vacuo to afford the crude title compound 43B-2 (28.0 mg), which was not further purified.

[0805] MS m / z(ESI):437.1 / 435.1 / 433.1[M+H] + .

[0806] Step 4: Preparation of (R)-3-(6-cyclopropyl-4-(cyclopropylfluoro(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-8-methyl-6-(((R)-2-methylmorpholinyl)methyl)-4H-chromen-4-one and (S)-3-(6-cyclopropyl-4-(cyclopropylfluoro(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-8-methyl-6-(((R)-2-methylmorpholinyl)methyl)-4H-chromen-4-one (43-1 and 43-2)

[0807] 43B-1 (28.0 mg, 64.3 μmol), 25G (30.8 mg, 77.2 μmol), and cesium fluoride (21.5 mg, 141.6 μmol) were added to 1,4-dioxane (3.0 mL), and the nitrogen atmosphere was replaced. Di(tri-tert-butylphosphine)palladium (6.6 mg, 12.9 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen protection and stirred for 1.0 hour. After the reaction was completed, the mixture was chromatographed on a reverse phase column (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 80:20) to give the title compound 43-1 (15.0 mg).

[0808] MS m / z(ESI):544.58[M+H] + .

[0809] 1 H NMR (400MHz, DMSO-d6) δ9.05(s,1H),8.57(s,1H),7.99–7.92(m,1H),7.90(d,J=2.1Hz,1H),7.63(s,1H),7.19(d,J=1. 6Hz,1H),3.73(d,J=11.0Hz,1H),3.52(dd,J=12.7,4.6Hz,4H),3.40–3.38(m,3H),2.67(d,J=10.9Hz,1H),2.61(d,J=11 .2Hz,1H),2.49(s,3H),2.12(dddd,J=40.4,19.0,9.6,3.4Hz,3H),1.75(t,J=10.5Hz,1H),1.32–1.25(m,1H),1.00(dd, J=10.9,4.7Hz,4H),0.85(t,J=7.3Hz,2H),0.77(dt,J=9.9,6.2Hz,1H),0.68–0.57(m,2H),0.48(dd,J=9.8,5.4Hz,1H).

[0810] 43B-2 (28.0 mg, 64.3 μmol), 25G (30.8 mg, 77.2 μmol), and cesium fluoride (21.5 mg, 141.6 μmol) were added to 1,4-dioxane (3.0 mL), and the nitrogen atmosphere was replaced. Di(tri-tert-butylphosphine)palladium (6.6 mg, 12.9 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen protection and stirred for 1.0 hour. After the reaction was completed, the mixture was chromatographed on a reverse phase column (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 80:20) to give the title compound 43-2 (16.0 mg).

[0811] MS m / z(ESI):544.44[M+H] + .

[0812] 1 H NMR (400MHz, DMSO-d6) δ9.07(s,1H),8.59(s,1H),7.96(d,J=1.6Hz,1H),7.91(d,J=2.1Hz,1H),7.68–7.63(m,1H) ,7.21(d,J=1.6Hz,1H),3.75(ddd,J=11.3,3.3,1.5Hz,1H),3.58–3.48(m,4H),3.41(d,J=1.7Hz,3H),2.69(dt,J=1 1.1,1.9Hz,1H),2.66–2.60(m,1H),2.50(s,3H),2.25–2.05(m,3H),1.81–1.73(m,1H),1.10(dq,J=7.3,4.3Hz,2H) ,1.04(d,J=6.3Hz,3H),1.02–0.98(m,2H),0.79(qd,J=8.4,7.3,4.1Hz,1H),0.70–0.60(m,2H),0.53–0.47(m,1H).

[0813] Example 44: Preparation of (R)-3-(6-cyclopropyl-4-(1,2,2,2-tetrafluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)pyridin-2-yl)-7-(((2-methoxyethyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one and (S)-3-(6-cyclopropyl-4-(1,2,2,2-tetrafluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)pyridin-2-yl)-7-(((2-methoxyethyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 44-1, Compound 44-2)

[0814] 42I-1 (34.0 mg, 73.4 μmol), 19F (37.6 mg, 88.1 μmol) and cesium fluoride (25.6 mg, 168.9 μmol) were added to 1,4-dioxane (3.0 mL) and the nitrogen atmosphere was replaced. Di(tri-tert-butylphosphine)palladium (7.5 mg, 14.7 μmol) was added and the resulting mixture was heated to 100°C under nitrogen protection and stirred for 1.0 hour. After the reaction was completed, the mixture was chromatographed on a reverse phase column (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 80:20) to give the title compound 44-1 (17.0 mg).

[0815] MS m / z(ESI):600.27[M+H] + .

[0816] 1 H NMR(400MHz, DMSO-d6)δ9.29(s,1H),9.27(s,1H),8.76(s,1H),8.52(d,J=1.9Hz,1H),8.31(s,1H),7.43(s,1H),3.91(s,2H),3.44–3.42(m, 3H), 3.40 (d, J = 5.5Hz, 3H), 3.24 (s, 3H), 2.68 (t, J = 5.5Hz, 2H), 2.32 (dd, J = 8.3, 4.0Hz, 1H), 1.19–1.12 (m, 2H), 1.05 (dd, J = 8.0, 3.1Hz, 2H).

[0817] 42I-2 (34.0 mg, 73.4 μmol), 19F (37.6 mg, 88.1 μmol) and cesium fluoride (25.6 mg, 168.9 μmol) were added to 1,4-dioxane (3.0 mL) and the nitrogen atmosphere was replaced. Di(tri-tert-butylphosphine)palladium (7.5 mg, 14.7 μmol) was added and the resulting mixture was heated to 100°C under nitrogen protection and stirred for 1.0 hour. After the reaction was completed, the mixture was chromatographed on a reverse phase column (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 80:20) to give the title compound 44-2 (20.2 mg).

[0818] MS m / z(ESI):600.17[M+H] + .

[0819] 1 H NMR (400MHz, DMSO-d6) δ9.35 (s, 1H), 9.33 (d, J = 1.8Hz, 1H), 8.81 (s, 1H), 8.58 ( d,J=1.9Hz,1H),8.37(s,1H),7.48(d,J=1.6Hz,1H),3.97(s,2H),3.48(d,J=1.7 Hz,3H),3.46(d,J=5.5Hz,2H),3.41(s,1H),3.30(s,3H),2.74(t,J=5.6Hz,2H), 2.36(td,J=7.8,4.0Hz,1H), 1.21(q,J=4.4Hz,2H), 1.11(dd,J=8.0,3.1Hz,2H).

[0820] Example 45: Preparation of cis-3-(6-cyclopropyl-4-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-7-((2-methoxyethyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 45)

[0821] 19F (39.6 mg, 92.77 μmol), 35E (40.0 mg, 92.77 μmol), and cesium fluoride (31.0 mg, 204.1 μmol) were added to 1,4-dioxane (2.0 mL), and the nitrogen atmosphere was replaced. Di(tri-tert-butylphosphine)palladium (9.5 mg, 18.6 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen protection and stirred for 1.5 hours. After the reaction was completed, the mixture was chromatographed on a reverse phase column (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 75:25) to give the title compound 45 (11.0 mg).

[0822] MS m / z(ESI):568.45[M+H] + .

[0823] 1 H NMR(400MHz,DMSO-d6)δ9.26(d,J=7.5Hz,1H),9.21(d,J=7.3Hz,1H),8.49(s,1H),8.34 (s,1H),8.23(s,1H),7.28(s,1H),3.92(s,2H),3.42(t,J=5.6Hz,2H),3.25(s,3H),3.23 (s,3H),2.93–2.83(m,2H),2.70(t,J=5.7Hz,2H),2.61(d,J=7.7Hz,3H),2.17(tt,J=8. 2,4.6Hz,1H),1.10(d,J=5.2Hz,3H),0.98(dq,J=7.2,3.6Hz,2H),0.85(d,J=6.5Hz,3H).

[0824] Example 46: Preparation of 3-(6-cyclopropyl-4-(1,2,2,2-tetrafluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)pyridin-2-yl)-7-(((2-(difluoromethoxy)ethyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (46)

[0825] Step 1: Preparation of 7-(((2-(difluoromethoxy)ethyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (46A)

[0826] To a solution of 2-(difluoromethoxy)ethanamine (101.52 mg, 913.88 μmol), potassium carbonate (420.39 mg, 3.05 mmol), and potassium iodide (20.23 mg, 121.85 μmol) in anhydrous DMF (3.0 mL) was slowly added 19D (160 mg, 609.26 μmol). The mixture was stirred at 25°C for 1 hour. After completion of the reaction, the crude product was separated by preparative HPLC (Welch Xtimate C18 column, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to afford the title compound 46A (120.0 mg).

[0827] MS m / z(ESI):338.1[M+H] + .

[0828] Step 2: Preparation of 7-(((2-(difluoromethoxy)ethyl)amino)methyl)-3-iodo-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (46B)

[0829] 46A (120 mg, 355.82 μmol) and ceric ammonium nitrate (377.30 mg, 711.65 μmol) were added to acetonitrile (2 mL), followed by elemental iodine (180.62 mg, 711.65 μmol), and stirred at 25°C for 2.0 hours. After completion, the reaction was quenched with saturated aqueous sodium sulfite solution, extracted with dichloromethane, and the organic phase was concentrated under reduced pressure to give the crude product, which was purified by normal phase column chromatography (petroleum ether:ethyl acetate = 1:3) to give the title compound 46B (35 mg).

[0830] MS m / z(ESI):464.0[M+H] + .

[0831] Step 3: Preparation of 2-cyclopropyl-4-(1,2,2,2-tetrafluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)-6-(trimethylstannyl)pyridine (Compound 42I)

[0832] 42H (25.0 mg, 74.69 μmol) and hexamethyltin (36.71 mg, 112.04 μmol) were added to 1,4-dioxane (2.0 mL), and the atmosphere was replaced with nitrogen. Tetrakis(triphenylphosphine)palladium (8.63 mg, 7.47 μmol) was added under a nitrogen atmosphere. The resulting mixture was heated to 100°C under nitrogen and stirred for 3.0 hours. The crude product was concentrated in vacuo without further purification to afford the title compound 42I (34.0 mg, 98.3% yield).

[0833] MS m / z(ESI):465.0 / 463.0 / 461.0[M+H] + .

[0834] Step 4: Preparation of 3-(6-cyclopropyl-4-(1,2,2,2-tetrafluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)pyridin-2-yl)-7-(((2-(difluoromethoxy)ethyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (46)

[0835] 42I (20 mg, 43.19 μmol), 46B (20.00 mg, 43.19 μmol), bis(tri-tert-butylphosphine)palladium (4.43 mg, 8.64 μmol), and CsF (6.28 mg, 95.02 μmol) were added to 1,4-dioxane (2 mL), and the atmosphere was replaced with nitrogen. The resulting mixture was heated to 100°C under a nitrogen atmosphere and stirred for 3.0 hours. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was separated on a preparative HPLC column (Welch Xtimate C18, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 46 (7 mg).

[0836] MS m / z(ESI):636.2[M+H] + .

[0837] 1H NMR(400MHz,DMSO-d6)δ9.31(s,2H),8.78(s,1H),8.55(s,1H),8.33(d,J= 1.5Hz,1H),7.45(d,J=1.6Hz,1H),6.68(s,1H),3.96(s,2H),3.91(t,J=5.6 Hz,2H),3.44(d,J=1.7Hz,3H),3.38–3.38(m,1H),2.80(t,J=5.6Hz,2H),2 .37–2.31(m,1H),1.18(dd,J=8.5,5.2Hz,2H),1.08(dd,J=8.0,3.1Hz,2H).

[0838] Example 47: Preparation of (R)-3-(6-cyclopropyl-4-(cyclopropylfluoro(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-7-((2-methoxyethyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one and (S)-3-(6-cyclopropyl-4-(cyclopropylfluoro(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-7-((2-methoxyethyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compounds 47-1 and 47-2)

[0839] 43B-1 (35.0 mg, 80.44 μmol), 19F (41.2 mg, 96.5 μmol), and cesium fluoride (26.9 mg, 177.0 μmol) were added to 1,4-dioxane (3.0 mL), and the nitrogen atmosphere was replaced. Di(tri-tert-butylphosphine)palladium (8.3 mg, 16.1 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen protection and stirred for 1.0 hour. After the reaction was completed, the mixture was chromatographed on a reverse phase column (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 80:20) to give the title compound 47-1 (10.0 mg).

[0840] MS m / z(ESI):572.36[M+H] + .

[0841] 1H NMR(400MHz,DMSO-d6)δ9.25(d,J=5.7Hz,2H),8.56(s,1H),8.50(d,J=1.8Hz,1H),8.11 (d,J=1.5Hz,1H),7.19(d,J=1.6Hz,1H),3.91(s,2H),3.41(t,J=5.5Hz,2H),3.38(d,J= 1.6Hz,3H),3.24(s,3H),2.68(t,J=5.4Hz,2H),2.21(td,J=8.0,4.1Hz,1H),2.16–2.07(m,1H),1.10(q,J=4.5Hz ,2H),1.00(dd,J=8.0,3.1Hz,2H),0.88–0.74(m,2H),0.61(dd,J=12.6,6.6Hz,2H),0.48(dt,J=10.2,4.7Hz,1H).

[0842] 43B-2 (35.0 mg, 80.44 μmol), 19F (41.2 mg, 96.5 μmol), and cesium fluoride (26.9 mg, 177.0 μmol) were added to 1,4-dioxane (3.0 mL), and the nitrogen atmosphere was replaced. Di(tri-tert-butylphosphine)palladium (8.3 mg, 16.1 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen protection and stirred for 1.0 hour. After the reaction was completed, the mixture was chromatographed on a reverse phase column (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 80:20) to give the title compound 47-2 (14.0 mg).

[0843] MS m / z(ESI):572.36[M+H] + .

[0844] 1H NMR (400MHz, DMSO-d6) δ9.26(d,J=1.9Hz,1H),9.24(s,1H),8.56(s,1H),8.50(d,J=1.9Hz,1H),8.11(d, J=1.5Hz,1H),7.19(d,J=1.6Hz,1H),3.91(s,2H),3.41(t,J=5.5Hz,2H),3.38(d,J=1.6Hz,3H),3.24(s, 3H),2.68(t,J=4.6Hz,2H),2.22(dq,J=8.1,4.1,3.5Hz,1H),2.17–2.07(m,1H),1.13–1.06(m,2H),1.00 (dd,J=8.1,3.0Hz,2H),0.90–0.72(m,2H),0.63(dtd,J=17.1,10.1,9.4,4.5Hz,2H),0.52–0.44(m,1H).

[0845] Example 48: Preparation of Compound 48

[0846] Step 1: Preparation of (S)-7-(((2-methoxypropyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (48A)

[0847] To a solution of (S)-2-methoxypropan-1-amine (108.61 mg, 1.22 mmol), potassium carbonate (420.39 mg, 3.05 mmol), and potassium iodide (20.23 mg, 121.85 μmol) in anhydrous DMF (3.0 mL) was slowly added compound 19D (160 mg, 609.26 μmol). The resulting mixture was stirred at 25°C for 1 hour. After completion of the reaction, the crude product was separated by preparative HPLC (column: Welch Xtimate C18, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to afford the title compound 48A (150.0 mg).

[0848] MS m / z(ESI):316.2[M+H] + .

[0849] Step 2: Preparation of (S)-3-iodo-7-(((2-methoxypropyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (48B)

[0850] 48A (150 mg, 475.75 μmol) and cerium ammonium nitrate (521.63 mg, 951.50 μmol) were added to acetonitrile (5 mL), followed by elemental iodine (241.50 mg, 951.50 μmol). The mixture was stirred at 25°C for 2.0 hours. After completion of the reaction, saturated aqueous sodium sulfite solution was added to quench the reaction, followed by extraction with dichloromethane. The organic phase was concentrated under reduced pressure to obtain a crude product, which was then separated by normal phase column chromatography (petroleum ether:ethyl acetate = 1:3) to afford the title compound 48B (160 mg).

[0851] MS m / z(ESI):442.1[M+H] + .

[0852] Step 3: Preparation of compound 48

[0853] 48B (20 mg, 45.35 μmol), 42I-2 (21.04 mg, 45.35 μmol), bis(tri-tert-butylphosphine)palladium (4.65 mg, 9.07 μmol), and CsF (15.15 mg, 99.73 μmol) were added to 1,4-dioxane (2 mL), and the atmosphere was replaced with nitrogen. The resulting mixture was heated to 100°C under a nitrogen atmosphere and stirred for 3.0 hours. After completion of the reaction, the mixture was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was separated on a preparative HPLC column (Welch Xtimate C18, 150 mm length, 30 mm ID, 5 μm particle size; mobile phase A: water (containing 0.225% NH3), mobile phase B: acetonitrile; gradient: mobile phase B from 5% to 95% over 18 minutes) to obtain the title compound 48 (3 mg).

[0854] MS m / z(ESI):614.2[M+H] + .

[0855] 1 H NMR(400MHz,DMSO-d6))δ9.30(s,1H),9.28(s,1H),8.76(s,1H),8.54(s,1H),8.32(s,1H), 7.43(s,1H),5.44–5.24(m,1H),3.92(s,2H),3.42(s,3H),3.39(s,1H),3.24(s,3H),2.36– 2.30(m,1H),2.04–1.98(m,1H),1.52–1.44(m,1H),1.18–1.13(m,2H),1.08(d,J=6.1Hz,3H),1.02(s,2H).

[0856] Example 49: Preparation of (S)-3-(6-cyclopropyl-4-(cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-7-(((2-(difluoromethoxy)ethyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one and (R)-3-(6-cyclopropyl-4-(cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-7-(((2-(difluoromethoxy)ethyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 49-1, Compound 49-2)

[0857] Step 1: Preparation of 2-cyclopropyl-4-(cyclopropylfluoro(4-methyl-4H-1,2,4-triazol-3-yl)methyl)-6-(trimethylstannyl)pyridine (Compound 49A)

[0858] 43A (200.0 mg, 651.9 μmol) and hexamethyltin (320.4 mg, 977.9 μmol) were added to 1,4-dioxane (5.0 mL), and the atmosphere was replaced with nitrogen. Tetrakis(triphenylphosphine)palladium (75.4 mg, 65.2 μmol) was added under a nitrogen atmosphere. The resulting mixture was heated to 100°C under nitrogen and stirred for 3.0 hours. The crude product was concentrated in vacuo without further purification to afford the title compound 49A (281.0 mg).

[0859] MS m / z(ESI):437.1[M+H] + .

[0860] Step 2: Preparation of 3-(6-cyclopropyl-4-(cyclopropylfluoro(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-7-(((2-(difluoromethoxy)ethyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 49B)

[0861] 49A (281.0 mg, 647.7 μmol), 46B (300.0 mg, 647.7 μmol) and cesium fluoride (216.5 mg, 1.43 mmol) were added to 1,4-dioxane (20.0 mL) and the nitrogen atmosphere was replaced. Under a nitrogen atmosphere, di(tri-tert-butylphosphine)palladium (66.5 mg, 129.6 μmol) was added and the resulting mixture was heated to 100°C under nitrogen protection and stirred for 4.0 hours. The crude product was purified by reverse phase column chromatography (chromatographic column: The residue was separated by flash silica gel column; mobile phase: acetonitrile / water = 80:20) to give the title compound 49B (260.0 mg).

[0862] MS m / z(ESI):608.5[M+H] + .

[0863] Step 3: Preparation of 3-(6-cyclopropyl-4-(cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-7-(((2-(difluoromethoxy)ethyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 49)

[0864] To a solution of 49B (240.0 mg, 395.0 μmol) in acetonitrile (2.4 mL) were added water (24.0 mL) and trifluoroacetic acid (0.48 mL) in sequence, followed by the addition of zinc powder (385.2 mg, 5.9 mmol) in portions. The resulting mixture was heated to 35°C and stirred for 2.0 hours. After the reaction, the mixture was filtered and concentrated to obtain a crude product which was purified by reverse phase column chromatography (column: The residue was separated by flash silica gel column; mobile phase: acetonitrile / water = 80:20) to give the title compound 49 (63.0 mg).

[0865] MS m / z(ESI):590.5[M+H] + .

[0866] Step 4: Preparation of (S)-3-(6-cyclopropyl-4-(cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-7-(((2-(difluoromethoxy)ethyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one and (R)-3-(6-cyclopropyl-4-(cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-7-(((2-(difluoromethoxy)ethyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 49-1, Compound 49-2)

[0867] Compound 49 (63.0 mg) was purified and separated by supercritical fluid chromatography (column: DAICEL CHIRALPAK IC, 250 mm length, 30 mm inner diameter, 10 μm particle size; mobile phase A: isopropanol (containing 0.1% ammonia), mobile phase B: supercritical carbon dioxide; gradient: mobile phase B from 5% to 95%; flow rate: 25 mL / min) to afford title compounds 49-1 (14.2 mg) and 49-2 (13.8 mg). The two title products were further analyzed by the following chiral HPLC method.

[0868] Chiral HPLC analysis method:

[0869] Chromatographic column: Chiralpak IC-3 column, 100 mm length, 4.6 mm inner diameter, 3 μm particle size; mobile phase: A: n-hexane, B: ethanol (containing 0.05% DEA); gradient: mobile phase B from 45% to 45% in 12 minutes; flow rate: 2.5 mL / min; column temperature: 25°C; ABPR: 1500 psi49-1:

[0870] The chiral HPLC peak time was 6.872 min;

[0871] MS m / z(ESI):590.29[M+H] + .

[0872] 1 H NMR (400MHz, DMSO-d6) δ9.27(d,J=1.8Hz,1H),9.21(s,1H),8.49(d,J=1.9Hz,1H),8.39(s,1H),8.20(d,J =1.4Hz,1H),7.23(d,J=1.5Hz,1H),6.67(t,J=76.4Hz,1H),3.92(s,2H),3.89(t,J=5.5Hz,2H),3.62(d,J= 9.8Hz,1H),3.45(s,3H),2.77(t,J=5.7Hz,2H),2.11(tt,J=8.3,4.7Hz,1H),1.71–1.61(m,1H),1.06(t,J =3.5Hz,2H),0.98(dt,J=8.5,3.4Hz,2H),0.84(d,J=8.5Hz,1H),0.71–0.54(m,2H),0.39(d,J=4.6Hz,2H).

[0873] 49-2:

[0874] The chiral HPLC peak time was 8.712 min;

[0875] MS m / z(ESI):590.29[M+H] +

[0876] 1H NMR (400MHz, DMSO-d6) δ9.27(d,J=1.8Hz,1H),9.21(s,1H),8.49(d,J=1.9Hz,1H),8.39(s,1H),8.20(d ,J=1.4Hz,1H),7.23(d,J=1.6Hz,1H),6.67(t,J=76.4Hz,1H),3.92(s,2H),3.89(t,J=5.5Hz,2H),3.62( d,J=9.8Hz,1H),3.45(s,3H),3.38(s,1H),2.77(t,J=5.7Hz,2H),2.11(tt,J=8.2,4.7Hz,1H),1.73–1. 60(m,1H),1.06(d,J=4.9Hz,2H),0.98(dt,J=8.4,3.4Hz,2H),0.68–0.55(m,2H),0.39(d,J=4.6Hz,2H).

[0877] Example 50: Preparation of cis-3-(6-methoxy-4-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-7-((2-methoxyethyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 50) Synthetic Route:

[0878] Step 1: Preparation of cis-2-chloro-6-methoxy-4-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridine (Compound 50A)

[0879] 35C (100.0 mg, 336.5 μmol), potassium trimethylsilanol (86.3 mg, 673.0 μmol) and sodium methoxide (175.1 mg, 3.36 mmol) were added to methanol (4.0 mL). The mixture was heated to 100°C and stirred for 16.0 hours. The crude product was purified by reverse phase column chromatography (chromatographic column: The residue was separated by flash silica gel column; mobile phase: acetonitrile / water = 50:50) to give the title compound 50A (60.0 mg).

[0880] MS m / z(ESI):293.5[M+H] + .

[0881] Step 2: Preparation of cis-2-methoxy-4-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-6-(trimethylstannyl)pyridine (Compound 50B)

[0882] 50A (11.7 mg, 40.0 μmol) and hexamethyltin (26.2 mg, 79.9 μmol) were added to 1,4-dioxane (1.0 mL), and the atmosphere was replaced with nitrogen. Tetrakis(triphenylphosphine)palladium (4.62 mg, 4.0 μmol) was added under a nitrogen atmosphere. The resulting mixture was heated to 100°C under nitrogen and stirred for 12.0 hours. The crude product was concentrated in vacuo without further purification to afford the title compound 50B (16.0 mg).

[0883] MS m / z(ESI):422.0[M+H] + .

[0884] Step 3: Preparation of cis-3-(6-methoxy-4-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-7-((2-methoxyethyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 50)

[0885] 50B (16.0 mg, 38.0 μmol), 19F (19.4 mg, 45.5 μmol) and cesium fluoride (12.7 mg, 83.5 μmol) were added to 1,4-dioxane (3.0 mL) and the nitrogen atmosphere was replaced. Under a nitrogen atmosphere, di(tri-tert-butylphosphine)palladium (3.9 mg, 7.6 μmol) was added and the resulting mixture was heated to 100°C under nitrogen protection and stirred for 4.0 hours. The crude product was purified by reverse phase column chromatography (chromatographic column: The residue was separated by flash silica gel column; mobile phase: acetonitrile / water = 80:20) to give the title compound 50 (5.9 mg).

[0886] MS m / z(ESI):558.4[M+H] + .

[0887] 1 H NMR (400MHz, DMSO-d6) δ9.40 (s, 1H), 9.28 (s, 1H), 8.50 (d, J = 1.8Hz, 1H), 8.34 (s, 1H) ),8.17(d,J=1.4Hz,1H),6.75(d,J=1.4Hz,1H),3.98(s,3H),3.91(s,2H),3.42(t,J= 5.6Hz,2H),3.25(s,3H),3.22(s,3H),2.84(d,J=4.6Hz,2H),2.68(t,J=5.5Hz,2H),2 .59(s,2H),2.00(q,J=7.0,6.6Hz,1H),1.09(d,J=5.3Hz,3H),0.85(t,J=6.5Hz,1H).

[0888] Example 51: Preparation of Compound 51

[0889] Synthesis route:

[0890] 43B-2 (15.3 mg, 35.2 μmol), 36C (15.0 mg, 35.2 μmol) and cesium fluoride (11.8 mg, 77.6 mmol) were added to 1,4-dioxane (3.0 mL) and the nitrogen atmosphere was replaced. Under a nitrogen atmosphere, di(tri-tert-butylphosphine)palladium (3.6 mg, 7.0 μmol) was added and the resulting mixture was heated to 100°C under nitrogen protection and stirred for 4.0 hours. The crude product was purified by reverse phase column chromatography (chromatographic column: The residue was separated by flash silica gel column; mobile phase: acetonitrile / water = 80:20) to give the title compound 51 (8.0 mg).

[0891] MS m / z(ESI):570.32[M+H] + .

[0892] 1 H NMR (400MHz, DMSO-d6) δ9.09(s,1H),8.58(s,1H),7.95(d,J=1.5Hz,1H),7.88(d,J=2.0Hz,1H),7.32(d,J=2.0Hz,1H),7.20(d,J=1.6 Hz,1H),3.73(d,J=10.4Hz,1H),3.53(s,3H),3.50–3.46(m,1H),3.39(d,J=1.6Hz,3H),2.66(d,J=11.2Hz,1H),2.59(d,J=11.2Hz,1H) ,2.37(ddd,J=13.9,8.7,5.4Hz,1H),2.19(tt,J=8.3,4.7Hz,1H),2.12–1.99(m,2H),1.74(t,J=10.5Hz,1H),1.14–1.06(m,4H),1.02 (d,J=6.2Hz,3H),0.99(dd,J=8.1,3.0Hz,2H),0.89–0.82(m,2H),0.81–0.73(m,1H),0.61(dd,J=11.8,6.1Hz,2H),0.52–0.44(m,1H).

[0893] Example 52: Preparation of 8-cyclopropyl-3-(6-cyclopropyl-4-((S)-cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-6-(((R)-2-methylmorpholinyl)methyl)-4H-chromen-4-one and 8-cyclopropyl-3-(6-cyclopropyl-4-((R)-cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-6-(((R)-2-methylmorpholinyl)methyl)-4H-chromen-4-one (Compound 52-1, Compound 52-2)

[0894] Step 1: Preparation of 8-cyclopropyl-3-(6-cyclopropyl-4-(cyclopropylfluoro(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-6-((((R)-2-methylmorpholinyl)methyl)-4H-chromen-4-one (Compound 52A)

[0895] 49A (425.0 mg, 976.7 μmol), 36C (415.4 mg, 976.7 μmol), and cesium fluoride (326.4 mg, 2.15 mmol) were added to 1,4-dioxane (20.0 mL), and the nitrogen atmosphere was replaced. Under a nitrogen atmosphere, di(tri-tert-butylphosphine)palladium (100.2 mg, 195.4 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen protection and stirred for 4.0 hours. The crude product was purified by reverse phase column chromatography (chromatographic column: The residue was separated by flash silica gel column; mobile phase: acetonitrile / water = 80:20) to give the title compound 52A (280.0 mg).

[0896] MS m / z(ESI):570.6[M+H] + .

[0897] Step 2: Preparation of 8-cyclopropyl-3-(6-cyclopropyl-4-(cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-6-(((R)-2-methylmorpholinyl)methyl)-4H-chromen-4-one (Compound 52)

[0898] To a solution of 52A (280.0 mg, 491.5 μmol) in acetonitrile (2.8 mL) was added water (28.0 mL) and trifluoroacetic acid (0.56 mL) in sequence, followed by the addition of zinc powder (319.5 mg, 4.92 mmol) in portions. The resulting mixture was heated to 35°C and stirred for 2.0 hours. After the reaction was complete, the mixture was filtered and concentrated to obtain a crude product which was purified by reverse phase column chromatography (column: The residue was separated by flash silica gel column; mobile phase: acetonitrile / water = 80:20) to give the title compound 52 (135.0 mg).

[0899] MS m / z(ESI):552.3[M+H] + .

[0900] Step 3: Preparation of 8-cyclopropyl-3-(6-cyclopropyl-4-((S)-cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-6-(((R)-2-methylmorpholinyl)methyl)-4H-chromen-4-one and 8-cyclopropyl-3-(6-cyclopropyl-4-((R)-cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-6-(((R)-2-methylmorpholinyl)methyl)-4H-chromen-4-one (Compound 52-1, Compound 52-2)

[0901] Compound 52 (135.0 mg) was purified and separated by supercritical fluid chromatography (DAICEL CHIRALPAK IC column, 250 mm length, 30 mm inner diameter, 10 μm particle size; mobile phase A: isopropanol (containing 0.1% ammonia), mobile phase B: supercritical carbon dioxide; gradient: mobile phase B from 5% to 95%; flow rate: 25 mL / min) to afford the title compounds 52-1 (35.0 mg) and 52-2 (36 mg). The two title products were further analyzed by the following chiral HPLC method.

[0902] Chiral HPLC analysis method:

[0903] Chromatographic column: Chiralpak IC-3 column, 100 mm length, 4.6 mm inner diameter, 3 μm particle size; mobile phase: A: n-hexane, B: ethanol (containing 0.05% DEA); gradient: mobile phase B from 50% to 50% in 12 minutes; flow rate: 2.5 mL / min; column temperature: 25°C; ABPR: 1500 psi52-1:

[0904] The chiral HPLC peak time was 6.232 min;

[0905] MS m / z(ESI):552.3[M+H] +

[0906] 1H NMR (400MHz, DMSO-d6) δ9.01(s,1H),8.39(s,1H),8.02(d,J=1.4Hz,1H),7.89(d,J=2.0Hz,1H),7.31(d,J=2.0Hz,1H),7.23(d,J=1.5Hz,1H),3 .73(d,J=10.4Hz,1H),3.61(d,J=9.7Hz,1H),3.52(d,J=12.7Hz,4H),3.46(s,3H),3.36(d,J=8.3Hz,1H),2.66(d,J=10.6Hz,1H),2.60(d,J=11 .2Hz,1H),2.37(td,J=8.8,4.5Hz,1H),2.13–2.00(m,2H),1.75(t,J=10.5Hz,1H),1.65(h,J=5.3,4.6Hz,1H),1.12–1.07(m,2H),1.04(d,J=2. 9Hz, 1H), 1.02 (d, J = 6.3Hz, 3H), 0.95 (dd, J = 8.1, 2.9Hz, 2H), 0.84 (dt, J = 5.3, 3.0Hz, 2H), 0.60 (dd, J = 14.8, 8.7Hz, 2H), 0.38 (d, J = 4.8Hz, 2H).

[0907] 52-2:

[0908] The chiral HPLC peak time was 5.542 min;

[0909] MS m / z(ESI):552.3[M+H] +

[0910] 1H NMR (400MHz, DMSO-d6) δ9.01(s,1H),8.38(s,1H),8.02(d,J=1.5Hz,1H),7.89(d,J=2.1Hz,1H),7.31(d,J=2.1Hz,1H),7.23(d,J=1.5 Hz,1H),3.73(d,J=10.1Hz,1H),3.61(d,J=9.8Hz,1H),3.52(d,J=13.6Hz,4H),3.46(s,3H),3.37(s,1H),2.69–2.58(m,2H),2.38(td, J=8.5,4.2Hz,1H),2.13–2.01(m,2H),1.78–1.71(m,1H),1.66(tt,J=8.0,4.1Hz,1H),1.12–1.09(m,1H),1.09–1.07(m,1H),1.06–1. 04(m,1H),1.02(d,J=6.3Hz,3H),0.95(dd,J=8.2,3.0Hz,2H),0.89–0.79(m,2H),0.59(dt,J=17.9,9.1Hz,2H),0.38(p,J=4.7Hz,2H).

[0911] Example 53: Preparation of 3-(6-cyclopropyl-4-((R)-cyclopropylfluoro(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-6-(((R)-2-methylmorpholinyl)methyl)-8-(trifluoromethyl)-4H-chromen-4-one (Compound 53)

[0912] Step 1: Preparation of (R)-4-((2-methylmorpholinyl)methyl)-2-(trifluoromethyl)phenol (53C)

[0913] 53A (2.1 g, 8.71 mmol), 25E ​​(2.89 g, 13.07 mmol), and potassium carbonate (2.4 g, 17.43 mmol) were added to a mixture of water (4.0 mL) and 1,4-dioxane (20.0 mL), and the atmosphere was replaced with nitrogen. Under a nitrogen atmosphere, Xphos Pd G2 (684.9 mg, 871.4 μmol) and Xphos (831.3 mg, 1.74 mmol) were added. The resulting mixture was heated to 100°C under nitrogen and stirred for 12 hours. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain a crude product, which was then purified by reverse phase column chromatography (chromatographic column: The title compound 53C (600.0 mg) was separated using a flash silica gel column; mobile phase: acetonitrile / water = 45:55).

[0914] MS m / z(ESI):276.2[M+H] +

[0915] Step 2: Preparation of (R)-2-iodo-4-((2-methylmorpholinyl)methyl)-6-(trifluoromethyl)phenol (53D)

[0916] 53C (600.0 mg, 2.18 mmol), N-iodosuccinimide (735.6 mg, 3.27 mmol) and p-toluenesulfonic acid (563.1 mg, 3.27 mmol) were added to acetonitrile (10.0 mL). The mixture was heated to 100°C and stirred for 3.0 hours. After the reaction was completed, the crude product was purified by reverse phase column chromatography (chromatographic column: The title compound 53D (290.0 mg) was separated using a flash silica gel column; mobile phase: acetonitrile / water = 50:50).

[0917] MS m / z(ESI):402.2[M+H] + .

[0918] Step 3: Preparation of (R)-1-(2-hydroxy-5-((2-methylmorpholinyl)methyl)-3-(trifluoromethyl)phenyl)ethan-1-one (53E)

[0919] 53D (290.0 mg, 722.9 μmol) and tributyl(1-ethoxyethylene)tin (391.6 mg, 1.08 mmol) were added to 1,4-dioxane (10.0 mL), and the nitrogen atmosphere was replaced. Tetrakis(triphenylphosphine)palladium (83.6 mg, 72.3 μmol) was added under a nitrogen atmosphere, and the resulting mixture was heated to 100°C under nitrogen protection and stirred for 16.0 hours. The crude product was purified by reverse phase column chromatography (chromatographic column: The title compound 53E (100.0 mg) was obtained after purification using a flash silica gel column; mobile phase: acetonitrile / water = 70:30).

[0920] MS m / z(ESI):318.1[M+H] +

[0921] Step 4: Preparation of (R)-3-(dimethylamino)-1-(2-hydroxy-5-((2-methylmorpholinyl)methyl)-3-(trifluoromethyl)phenyl)prop-2-en-1-one (Compound 53F)

[0922] 53E (100.0 mg, 315.1 μmol) was added to DMF-DMA (5.0 mL), and the reaction mixture was heated to 100°C and stirred for 1 hour. After the reaction, the reaction mixture was directly distilled under reduced pressure to obtain the crude product, which was obtained without further purification to obtain the title compound 53F (117.0 mg).

[0923] MS m / z(ESI):373.1[M+H] +

[0924] Step 5: Preparation of (R)-3-iodo-6-((2-methylmorpholinyl)methyl)-8-(trifluoromethyl)-4H-chromen-4-one (53G)

[0925] 53F (117.0 mg, 315.1 mmol) and iodine (80.0 mg, 315.1 mmol) were added to dichloromethane (5.0 mL), followed by pyridine (24.9 mg, 315.1 μmol). The mixture was stirred at room temperature for 1.0 hour. The crude product was purified by normal phase column chromatography (dichloromethane / methanol = 95:5) to give the title compound 53G (29.0 mg).

[0926] MS m / z(ESI):454.1[M+H] + .

[0927] Step 6: Preparation of 3-(6-cyclopropyl-4-((R)-cyclopropylfluoro(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-6-(((R)-2-methylmorpholinyl)methyl)-8-(trifluoromethyl)-4H-chromen-4-one (53)

[0928] 53G (22.0 mg, 48.5 μmol), 49A (31.6 mg, 72.8 μmol) and cesium fluoride (16.2 mg, 106.8 μmol) were added to 1,4-dioxane (2.0 mL) and the nitrogen atmosphere was replaced. Under a nitrogen atmosphere, di(tri-tert-butylphosphine)palladium (5.0 mg, 9.7 μmol) was added and the resulting mixture was heated to 100°C under nitrogen protection and stirred for 2.0 hours. The crude product was purified by reverse phase column chromatography (chromatographic column: Flash silica gel column; mobile phase: acetonitrile / water = 75:25) to give the title compound 53 (6.5 mg).

[0929] MS m / z(ESI):598.23[M+H] + .

[0930] 1H NMR (400MHz, DMSO-d6) δ9.11(s,1H),8.59(s,1H),8.37(d,J=2.0Hz,1H),8.14(d,J=2.0Hz,1H),7.89(d,J=1.6Hz,1H),7.2 6(d,J=1.6Hz,1H),3.79–3.75(m,1H),3.69(s,2H),3.58–3.52(m,2H),3.41(d,J=1.6Hz,3H),2.72(d,J=11.4Hz,1H),2.65 (d,J=11.3Hz,1H),2.22(dq,J=8.0,4.0,3.2Hz,1H),1.82(t,J=10.6Hz,1H),1.13(q,J=4.2Hz,2H),1.05(d,J=6.3Hz,3H), 1.00(dd,J=8.1,2.9Hz,2H),0.88–0.85(m,2H),0.79(q,J=5.0,4.5Hz,1H),0.69–0.61(m,2H),0.49(q,J=5.5,4.9Hz,1H).

[0931] Example 54: Preparation of 3-(6-cyclopropyl-4-(S)-cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-7-(((S)-2-methoxypropyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one and 3-(6-cyclopropyl-4-((R)-cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-7-(((S)-2-methoxypropyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 54-1, Compound 54-2)

[0932] Step 1: Preparation of 3-(6-cyclopropyl-4-(cyclopropylfluoro(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-7-((((S)-2-methoxypropyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 54A)

[0933] 49A (300.0 mg, 689.5 μmol), 48B (304.2 mg, 689.5 μmol) and cesium fluoride (230.4 mg, 1.52 mmol) were added to 1,4-dioxane (20.0 mL) and the nitrogen atmosphere was replaced. Under a nitrogen atmosphere, di(tri-tert-butylphosphine)palladium (70.7 mg, 137.9 μmol) was added and the resulting mixture was heated to 100°C under nitrogen protection and stirred for 4.0 hours. The crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 80:20) to obtain the title compound 54A (200.0 mg).

[0934] MS m / z(ESI):586.6[M+H] + .

[0935] Step 2: Preparation of 3-(6-cyclopropyl-4-(cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-7-(((S)-2-methoxypropyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 54)

[0936] To a solution of 54A (170.0 mg, 290.3 μmol) in acetonitrile (1.7 mL) was added water (17.0 mL) and trifluoroacetic acid (0.34 mL) in sequence, followed by the addition of zinc powder (283.1 mg, 4.35 mmol) in portions. The resulting mixture was heated to 35°C and stirred for 2.0 hours. After the reaction was complete, the mixture was filtered and concentrated to obtain a crude product which was purified by reverse phase column chromatography (column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 80:20) to give the title compound 54 (31.0 mg).

[0937] MS m / z(ESI):568.4[M+H] + .

[0938] Step 3: Preparation of 3-(6-cyclopropyl-4-(S)-cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-7-(((S)-2-methoxypropyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one and 3-(6-cyclopropyl-4-((R)-cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)-7-(((S)-2-methoxypropyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 54-1, Compound 54-2)

[0939] Compound 54 (31.0 mg) was purified and separated by supercritical fluid chromatography (column: DAICEL CHIRALPAK IC, 250 mm length, 30 mm inner diameter, 10 μm particle size; mobile phase A: isopropanol (containing 0.1% ammonia), mobile phase B: supercritical carbon dioxide; gradient: mobile phase B from 5% to 95%; flow rate: 25 mL / min) to afford title compounds 54-1 (12.0 mg) and 54-2 (12 mg). The two title products were further analyzed by the following chiral HPLC method.

[0940] Chiral HPLC analysis method:

[0941] Chromatographic column: Chiralpak IC-3 column, 100 mm length, 4.6 mm inner diameter, 3 μm particle size; mobile phase: A: n-hexane, B: ethanol (containing 0.05% DEA); gradient: mobile phase B from 50% to 50% in 12 minutes; flow rate: 2.5 mL / min; column temperature: 25°C; ABPR: 1500 psi54-1:

[0942] The chiral HPLC peak time was 4.010 min;

[0943] MS m / z(ESI):568.45[M+H] +

[0944] 1 H NMR (400MHz, DMSO-d6) δ9.26 (s, 1H), 9.20 (s, 1H), 8.49 (d, J = 1.9Hz, 1H), 8.38 (s, 1H), 8.21 (d, J=1.4Hz,1H),7.22(d,J=1.4Hz,1H),3.90(s,2H),3.62(d,J=9.8Hz,1H),3.45(s,3H),3.41–3.3 6(m,1H),3.24(s,3H),2.59–2.51(m,3H),2.15–2.07(m,1H),1.66(s,1H),1.08(d,J=6.2Hz,3H ),1.05(d,J=4.3Hz,2H),0.97(dd,J=7.9,3.2Hz,2H),0.67–0.54(m,2H),0.39(d,J=4.6Hz,2H).

[0945] 54-2:

[0946] The chiral HPLC peak time was 8.096 min;

[0947] MS m / z(ESI):568.45[M+H] +

[0948] 1 H NMR (400MHz, DMSO-d6) δ9.26(d,J=1.8Hz,1H),9.21(s,1H),8.49(d,J=1.9Hz,1H),8.38(s,1H),8.21 (d,J=1.4Hz,1H),7.22(d,J=1.5Hz,1H),3.90(s,2H),3.62(d,J=9.8Hz,1H),3.45(s,3H),3.42–3.36( m,1H),3.24(s,3H),2.59–2.52(m,3H),2.10(td,J=8.1,4.1Hz,1H),1.72–1.61(m,1H),1.08(d,J=6.1 Hz,3H),1.05(d,J=4.7Hz,2H),0.98(dt,J=8.3,3.4Hz,2H),0.68–0.54(m,2H),0.39(d,J=4.7Hz,2H).

[0949] Example 55: Preparation of 3-(4-(cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)-6-(trifluoromethyl)pyridin-2-yl)-7-((((S)-2-methoxypropyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 55)

[0950] Step 1: Preparation of ethyl 2-chloro-6-(trifluoromethyl)isonicotinate (Compound 55B)

[0951] 55A (2.0 g, 8.87 mmol) was added to triethyl orthoformate (3.29 g, 22.1 mmol), and the reaction mixture was heated to 120°C and stirred for 6.0 h. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product which was purified by column chromatography (chromatographic column: Flash silica gel column; mobile phase: petroleum ether / ethyl acetate = 90:10) to give the title compound 55B (2.03 g).

[0952] MS m / z(ESI):254.6[M+H] + .

[0953] Step 2: Preparation of (2-chloro-6-(trifluoromethyl)pyridin-4-yl)methanol (Compound 55C)

[0954] Under ice bath, sodium borohydride (605.6 mg, 16.0 mmol) was added to a solution of 55B (2.03 g, 8.0 mmol) in ethanol (10.0 mL). The mixture was slowly warmed to room temperature and stirred for 12.0 hours. After completion of the reaction, the reaction was quenched with saturated aqueous ammonium chloride and extracted three times with ethyl acetate. The organic phase was dried and concentrated to obtain a crude product, which was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (chromatographic column: Flash silica gel column; mobile phase: petroleum ether / ethyl acetate = 90:10) to give the title compound 55C (1.53 g).

[0955] MS m / z(ESI):212.4[M+H] + .

[0956] Step 3: Preparation of 2-chloro-6-(trifluoromethyl)isonicotinaldehyde (55D)

[0957] 55C (1.53 g, 7.23 mmol) was dissolved in anhydrous dichloromethane (20.0 mL). Dess-Martin periodinane (4.6 g, 10.85 mmol) was added to the solution in portions under an ice bath at 0°C. After the addition was complete, the reaction solution was slowly heated to room temperature and stirred for 2.0 hours. After the reaction was complete, the reaction residue was filtered off and rinsed with dichloromethane. The organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated to dryness under reduced pressure to obtain the crude product. The product was purified by column chromatography (chromatographic column: Flash silica gel column; mobile phase: petroleum ether / ethyl acetate = 90:10) to give the title compound 55D (1.0 g).

[0958] MS m / z(ESI):210.4[M+H] + .

[0959] Step 4: Preparation of (2-chloro-6-(trifluoromethyl)pyridin-4-yl)(4-methyl-4H-1,2,4-triazol-3-yl)methanol (55E)

[0960] 4-Methyl-4H-1,2,4-triazole (515.5 mg, 6.2 mmol) was dissolved in ethylene glycol dimethyl ether (30.0 mL). After the reaction solution was cooled to -40°C, a solution of n-butyl lithium in n-hexane (1.6 M, 3.88 mL, 6.2 mmol) was added dropwise to the reaction solution. After the addition was complete, the reaction solution was stirred at -40°C for 1.0 hour. Then, a solution of 55D (1.0 g, 4.77 mmol) dissolved in ethylene glycol dimethyl ether (10.0 mL) was added dropwise. After the addition was complete, the reaction solution was transferred to room temperature and reacted for 1.0 hour. After the reaction was completed, the reaction solution was cooled to 0°C in an ice bath, and then a saturated aqueous ammonium chloride solution was added and stirred for ten minutes. After stirring, the reaction solution was extracted three times with ethyl acetate (20.0 mL). The resulting organic phase was dried and concentrated to obtain a crude product, which was then passed through a reverse phase separation column (chromatographic column: The title compound 55E (450.0 mg) was obtained after purification using a flash silica gel column; mobile phase: acetonitrile / water = 50:50).

[0961] MS m / z(ESI):293.5[M+H] + .

[0962] Step 5: Preparation of (2-chloro-6-(trifluoromethyl)pyridin-4-yl)(4-methyl-4H-1,2,4-triazol-3-yl)methanone (55F)

[0963] 55E (580.0 mg, 1.98 mmol) was dissolved in anhydrous 1,2-dichloroethane (20.0 mL), and manganese dioxide (1.76 g, 19.8 mmol) was added to the solution. After the addition, the reaction mixture was heated to 50°C and stirred for 2 hours. After the reaction, the residue was filtered and rinsed with dichloromethane. The organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated to dryness under reduced pressure to obtain the crude product. The product was used in the next step without further purification, resulting in the title compound 55F (500.0 mg).

[0964] MS m / z(ESI):291.6[M+H] + .

[0965] Step 6: Preparation of (2-chloro-6-(trifluoromethyl)pyridin-4-yl)(cyclopropyl)(4-methyl-4H-1,2,4-triazol-3-yl)methanol (Compound 55G)

[0966] 55F (500.0 mg, 1.72 mmol) was added to tetrahydrofuran (18.0 mL). After the reaction mixture was cooled to 0°C, a THF solution of cyclopropylmagnesium bromide (3.44 mL, 3.44 mmol, 1.0 M) was added dropwise to the reaction mixture. After the addition was complete, the reaction mixture was transferred to room temperature and reacted for 4.0 hours. After the reaction was completed, the reaction mixture was cooled to 0°C in an ice bath and then quenched by adding saturated aqueous ammonium chloride. The crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 60:40) to obtain the title compound 55G (500.0 mg).

[0967] MS m / z(ESI):333.7[M+H] + .

[0968] Step 7: Preparation of 2-chloro-4-(cyclopropylfluoro(4-methyl-4H-1,2,4-triazol-3-yl)methyl)-6-(trifluoromethyl)pyridine (Compound 55H)

[0969] 55G (500.0 mg, 1.5 mmol) was dissolved in dichloromethane (20.0 mL). After the reaction solution was cooled to 0°C, DAST (363.3 mg, 2.25 mmol) was added dropwise to the reaction solution. After the addition was complete, the reaction solution was transferred to room temperature and reacted for 2.0 hours. After the reaction was completed, the reaction solution was cooled to 0°C in an ice bath, and then saturated sodium bicarbonate aqueous solution was added and stirred for ten minutes. After stirring, the solution was extracted three times with dichloromethane (30.0 mL). The resulting organic phase was dried and concentrated, and the crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 60:40) to give the title product 55H (350.0 mg).

[0970] MS m / z(ESI):335.7[M+H] + .

[0971] Step 8: Preparation of 2-chloro-4-(cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)-6-(trifluoromethyl)pyridine (Compound 55I)

[0972] To a solution of 55H (200.0 mg, 597.5 μmol) in acetonitrile (2.0 mL) was added water (20.0 mL) and trifluoroacetic acid (0.8 mL) in sequence, and then zinc powder (388.4 mg, 5.98 mmol) was added portionwise. The resulting mixture was heated to 35°C and stirred for 2.0 hours. After the reaction was completed, the mixture was filtered and concentrated to obtain a crude product which was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 80:20) to obtain the title compound 55I (60.0 mg).

[0973] MS m / z(ESI):317.6[M+H] + .

[0974] Step 9: Preparation of 4-(cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)-2-(trifluoromethyl)-6-(trimethylstannyl)pyridine (Compound 55J)

[0975] 55I (24.0 mg, 75.8 μmol) and hexamethyltin (37.2 mg, 113.6 μmol) were added to 1,4-dioxane (2.0 mL), and the atmosphere was replaced with nitrogen. Under a nitrogen atmosphere, Pd(dtbpf)Cl2 (4.9 mg, 7.6 μmol) was added, and the resulting mixture was heated to 100°C under nitrogen and stirred for 1.0 hour. The crude product was concentrated in vacuo without further purification to afford the title compound 55J (33.0 mg).

[0976] MS m / z(ESI):446.0[M+H] + .

[0977] Step 10: Preparation of 3-(4-(cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)-6-(trifluoromethyl)pyridin-2-yl)-7-((((S)-2-methoxypropyl)amino)methyl)-9-(trifluoromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (Compound 55)

[0978] 55J (33.0 mg, 74.1 μmol), 48B (32.7 mg, 74.1 μmol) and cesium fluoride (24.7 mg, 163.1 μmol) were added to 1,4-dioxane (3.0 mL) and the nitrogen atmosphere was replaced. Under a nitrogen atmosphere, di(tri-tert-butylphosphine)palladium (7.6 mg, 14.8 μmol) was added and the resulting mixture was heated to 100°C under nitrogen protection and stirred for 4.0 hours. The crude product was purified by reverse phase column chromatography (chromatographic column: The residue was purified by flash silica gel column; mobile phase: acetonitrile / water = 80:20) to give the title compound 55 (9.5 mg).

[0979] MS m / z(ESI):596.23[M+H] + .

[0980] 1H NMR(400MHz,DMSO-d6)δ9.31(s,1H),9.20(s,1H),8.76(s,1H),8.57(s,1H ),8.43(s,1H),7.84(d,J=1.4Hz,1H),3.95(d,J=14.4Hz,3H),3.53(s,3H), 3.32–3.27(m,1H),3.24(s,3H),2.60–2.53(m,2H),2.12–1.90(m,1H),1.71 –1.62(m,1H),1.09(d,J=6.1Hz,3H),0.70–0.58(m,2H),0.51–0.37(m,2H).

[0981] Biological activity and related properties test examples

[0982] Test Example 1: Cbl-b activity experiment

[0983] Experimental purpose: To test the inhibitory activity of compounds on the interaction between Cbl-b protein and UbcH5B-Ub

[0984] Experimental Methods: Eu-Ubquitin (Cisbio) was incubated with UbcH5B (ENZO) and E1 (ENZO) at 37°C for 4 hours to prepare Eu-Ubquitin-UbcH5B. Eu-Ubquitin-UbcH5B was aliquoted and stored at -80°C. Cbl-b activity assays were performed in 384-well plates (Perkin Elmer). 100 nL of a 3-fold serial dilution of compound (final concentration 10 μM to 0.5 nM, starting at 10 μM, 3-fold dilutions, 10 points, 10 points at 0.5 nM) was incubated with 5 μL of 50 nM Biotin-Cbl-b protein (Sigma) at room temperature for 1 hour in a reaction buffer consisting of 50 mM HEPES pH 7.0 (Gibco), 100 mM NaCl (Sigma), 0.01% Triton X-100 (Sigma), 0.01% BSA (Sigma), and 1 mM DTT (Invitrogen). 5 μL of a Src cocktail (40 nM Src (R&D), 2 mM ATP (Sigma), 10 mM MgCl2 (Sigma)) was added to the reaction plate and incubated at room temperature for 3 hours. 10 μL of detection solution (12.5 nM Strepdividin-XL665 (Cisbio), 500 nM Eu-Ubquitin-UbcH5B, 120 nM EDTA (Invitrogen), 0.004% BSA (Sigma)) was added to the reaction plate and incubated overnight at room temperature. The HTRF signal (665 nm / 615 nm) was read on Envision (Perkin Elmer). IC was calculated using IDBS XLfit. 50 .

[0985] The experimental results are shown in Table 1.

[0986] Table 1

[0987] Test Example 2: Jurkat T activation experiment

[0988] Experimental purpose: To test the effect of compounds on the activation of IL-2 release in Jurkat T cells

[0989] Experimental method: 96-well cell plates (Corning) were coated with 2 μg / mL Anti-Human CD3 Clone OKT3 (BD) at 37°C for 4 hours. A 3-fold serial dilution of the compound (final concentration 10 μM-4.6 nM, starting concentration 10 μM, 3-fold dilution, 8 points, the 8th point is 4.6 nM) was added to 220 μL of 1.11x10 6 / mL Jurkat T cells (ATCC) were incubated for 1 hour, 5 μL 45 μg / mL Anti-Human CD28 Clone CD28.2 (BD) was added, mixed evenly, and 100 μL was transferred to the aforementioned CD3-coated cell plate. The cells were cultured in a 37°C cell culture incubator for 48 hours, and the supernatant was collected and the IL-2 release was detected using an IL-2 ELISA kit (BD). EC was analyzed using Prism. 50 .

[0990] The experimental results are shown in Table 2.

[0991] Table 2

[0992] Test Example 3: Pharmacokinetics (PK) test in rats

[0993] Objective: To determine the plasma concentration of the test compound at different time points after injection or oral administration using LC / MS / MS in rats. This study aims to investigate the pharmacokinetic behavior of the compound in rats and evaluate its pharmacokinetic characteristics.

[0994] Experimental Methods: Six healthy male SD rats (Beijing Weitonglihua Laboratory Animal Technology Co., Ltd.) were randomly divided into two dose groups, each with three rats. One group received tail vein administration at a dose of 1 mg / kg, and the other received oral administration at a dose of 5 mg / kg. The tail vein administration group used a complete solvent of 5% NMP + 10% PEG400 + 85% (10% solutol), while the oral administration group used a complete solvent of 5% NMP + 20% PEG400 + 75% (10% VETPGS) or a suspension solvent of 0.5% HPMC / 0.1% Tween 80 in water (w / v / v). The individual dose was calculated based on the rat's body weight. Blood was collected by jugular vein puncture at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h after administration in the tail vein administration group and at 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h after administration in the oral administration group. About 200 μL of whole blood was collected at each time point and placed in a 1.5 mL centrifuge tube anticoagulated with EDTA-2K. The tube was then centrifuged at 8000 r / min for 5 min, and the plasma was transferred and stored at -80°C.

[0995] A 20 μL rat plasma sample was taken and protein was precipitated with 300 μL of acetonitrile (containing the internal standard compound verapamil (Sigma)). After vortexing for 0.5 min, the sample was centrifuged at 14,000 rpm for 5 min. The supernatant was diluted 2-fold with water containing 0.1% (v / v) FA and quantified on an AB Sciex Triple Quad 6500+ system. A standard curve and quality control samples were also used for sample concentration determination. For the 10x diluted sample, 2 μL was added to 18 μL of blank plasma. After vortexing for 0.5 min, protein was precipitated with 300 μL of acetonitrile (containing the internal standard compound). All other steps were performed as for the undiluted sample. Drug concentrations in plasma were determined by LC-MS / MS, with a minimum detection limit of 1 ng / mL. Key PK parameters were calculated using non-compartmental methods using WinNonlin software (Phoenix version 8.3).

[0996] The experimental results are shown in Table 3.

[0997] Table 3

[0998] Note: - indicates not determined

[0999] Test Example 4: Inhibitory effects of the compounds disclosed herein on cytochrome P450 enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4

[1000] Experimental purpose: To test the inhibitory effect of compounds on cytochrome P450 enzymes

[1001] 1. Test materials and equipment

[1002] 1. Reagents

[1003] 2. Liver microsomes

[1004] 2. Experimental steps

[1005] 1. Prepare a 10 mM stock solution of the test compound in DMSO and serially dilute it with DMSO to the following concentrations: 0, 4, 20, 100, 400, 2000, and 10,000 μM. The test compound concentrations in the final incubation system are 0, 0.02, 0.1, 0.5, 2, 10, and 50 μM. The volume ratio of organic solvent introduced into the test system along with the test compound is 0.5%. The final concentration of the positive inhibitor in the reaction system is shown in the table below.

[1006] Working solution concentration of positive inhibitor

[1007] Final concentration of positive inhibitor in the reaction system

[1008] 2. Preparation of Substrate Stock Solution

[1009] The preparation of the substrate stock solution is shown in the table below. After preparation, store the stock solution in a -20°C refrigerator. Thaw at room temperature before use.

[1010] Substrate stock information

[1011] 3. Preparation of phosphate buffer (100 mM, pH 7.4)

[1012] First, weigh 7.098g of disodium hydrogen phosphate and add it to 500mL of pure water and ultrasonically dissolve it, creating Solution A. Weigh 3.400g of potassium dihydrogen phosphate and add it to 250mL of pure water and ultrasonically dissolve it, creating Solution B. Place Solution A on a stirrer and slowly add Solution B until the pH reaches 7.4. Store the phosphate buffer at 4°C until needed.

[1013] 4. Preparation of 10mM NADPH

[1014] Before the test, weigh an appropriate amount of NADPH and prepare a working solution with a concentration of 10 mM using phosphate buffer. The final concentration of NADPH in the test system is 1 mM.

[1015] 5. Preparation of the Incubation System

[1016] The incubation system was prepared as shown in the table below and preheated in a 37°C water bath for 15 minutes before use.

[1017] 6. Test methods

[1018] The entire incubation process was performed in a 96-well deep-well plate. 179 μL of the incubation system was added to the plate, followed by 1 μL of the compound solution or vehicle (DMSO). The incubation system was preheated to 37°C for 15 minutes before initiating the reaction with 20 μL of 10 mM NADPH solution. After initiating the reaction with NADPH, the reaction was incubated at 37°C for 45 minutes. Experimental samples were prepared in duplicate.

[1019] After a 45-minute incubation, the reaction was terminated by adding 400 μL of ice-cold methanol (10 ng / mL glipizide and 10 ng / mL propranolol). After vortexing, the plate was centrifuged at 4000 g and 4°C for 10 minutes. 100 μL of the supernatant was transferred to a new 96-well plate and mixed with 100 μL of purified water for LC-MS / MS analysis.

[1020] 3. Data Analysis

[1021] The generated metabolites were analyzed by LC-MS / MS. The reduction in metabolite production in the drug-treated group compared to the blank solvent control group was compared by comparing the peak area ratio of the sample to the internal standard, and the IC was calculated based on the percentage of residual activity using GraphPad Prism 8.0. 50 value.

[1022] The remaining activity percentage was calculated using the following formula:

[1023] Remaining activity percentage (%) = ratio of metabolite peak area to internal standard peak area 受试物 / Ratio of metabolite peak area to internal standard peak area 空白溶剂 ×100%.

[1024] The test results are shown in Table 4.

[1025] Table 4 Inhibitory effects of the compounds disclosed herein on cytochrome P450 enzymes

[1026] Note: - indicates not determined

[1027] Test Example 5: Evaluation of the Time-Dependent Inhibition (TDI) Effect of the Compounds of the Present Disclosure on Cytochrome P450 Enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4

[1028] Experimental purpose: To test the effect of compounds on the TDI of cytochrome P450 enzymes

[1029] 1. Test materials and equipment

[1030] 1. Reagents

[1031] 2. Liver microsomes

[1032] 3. Test equipment

[1033] 2. Test steps

[1034] 1. Preparation of test compound solution

[1035] The test compound was prepared into a 10 mM DMSO stock solution, and diluted with DMSO to 5 mM and 1 mM solutions respectively for later use.

[1036] 2. Preparation of 100 mM phosphate buffered saline (PBS, pH 7.4)

[1037] First, weigh 7.098g of disodium hydrogen phosphate and add it to 500mL of pure water and ultrasonically dissolve it, creating Solution A. Weigh 3.400g of potassium dihydrogen phosphate and add it to 250mL of pure water and ultrasonically dissolve it, creating Solution B. Place Solution A on a stirrer and slowly add Solution B until the pH reaches 7.4. Store the phosphate buffer at 4°C until needed.

[1038] 3. Preparation of Mixed Inhibitors and Mixed Probe Substrates

[1039] Preparation of mixed positive inhibitors: Use DMSO to prepare stock solutions of furafylline (10 mM), tinic acid (5 mM), paroxetine (5 mM), ticlopidine (10 mM) and verapamil (30 mM), respectively, and then dilute with DMSO to prepare a mixed solution of furafylline (1 mM), tinic acid (0.5 mM), paroxetine (0.5 mM), ticlopidine (1 mM) and verapamil (3 mM).

[1040] Preparation of mixed probe substrate stock solution: Prepare 50 mM phenacetin (acetonitrile), 20 mM diclofenac sodium (water), 50 mM S-mephenytoin (acetonitrile), 20 mM dextromethorphan (acetonitrile), and midazolam (1 mg / ml) (methanol stock solution). Then, take 1.25 μL phenacetin, 1.56 μL diclofenac sodium, 1.25 μL S-mephenytoin, 1.56 μL dextromethorphan, and 4.07 μL midazolam in 490 μL PBS to obtain a mixed probe substrate stock solution.

[1041] The final concentrations of the mixed positive inhibitor and mixed probe substrate in the reaction system are shown in the table below.

[1042] Probe substrate and positive inhibitor information

[1043] 4. Preparation of 10mM NADPH

[1044] Before the test, weigh an appropriate amount of NADPH and prepare a working solution with a concentration of 10 mM using phosphate buffer. The final concentration of NADPH in the test system is 1 mM.

[1045] 5. Preparation of the Incubation System

[1046] The preparation of the primary incubation system is shown in the table below.

[1047] The preparation of the secondary incubation system is shown in the table below.

[1048] 6. Test methods

[1049] The entire incubation process was performed in a 96-well plate. A mixture of 5 μL of liver microsomes and 84 μL of PBS was first added to the plate, followed by 1 μL of the test compound solution, vehicle (DMSO), or mixed positive inhibitor stock solution. This mixture was preheated at 37°C for 10 minutes before initiating the reaction with 10 μL of 10 mM NADPH solution or PBS. After initiating the reaction with NADPH solution or PBS (i.e., the primary incubation system), the reaction was incubated at 37°C for 30 minutes. Test samples were prepared in duplicate. Ten minutes prior, a mixture of 80 μL of the mixed probe substrate stock solution and 10 μL of NADPH was placed in a separate 96-well plate. At 30 minutes, 10 μL of the primary incubation system was added to the mixture to create the secondary incubation system, which was then incubated for an additional 45 minutes. The reaction was terminated by adding 400 μL of glacial acetonitrile containing internal standards (10 ng / mL glipizide and 10 ng / mL propranolol). After vortex mixing, centrifuge the deep-well plate at 4000g and 4°C for 10 minutes. Transfer 100 μL of the supernatant to a new 96-well plate and add 100 μL of pure water to mix before LC-MS / MS analysis.

[1050] 3. Data Analysis

[1051] The generated metabolites were analyzed by LC-MS / MS. The reduction in metabolite production in the drug-treated group was compared with that in the blank solvent control group by comparing the peak area ratio of the sample to the internal standard.

[1052] Relative activity (% of NC) = metabolite production in the test group or positive control group / metabolite production in the blank control group × 100

[1053] (Note: A represents the activity in the presence or absence of the test compound / positive inhibitor and NADPH, (A inactivator / A vehicle ) no NADPH Represents the relative activity of the test group or positive control group and the blank control group in the absence of NADPH, (A inactivator / A vehicle ) +NADPH Represents the relative activity of the test group or positive control group and the blank control group in the presence of NADPH)

[1054] The test results are shown in Table 5.

[1055] Table 5 TDI effect of the compounds disclosed herein on cytochrome P450 enzymes

[1056] Test Example 6: Application of automated patch clamp technology to evaluate the effects of the disclosed compounds on hERG potassium channel currents

[1057] Experimental purpose: To test the effect of compounds on hERG potassium channel current

[1058] 1. Materials and Instruments

[1059] 2. Test methods

[1060] 1. Cell Lines and Cell Culture

[1061] The CHO cell line stably expressing hERG ion channel was purchased from B'SYS GmbH, Switzerland. The cell line was cultured in a medium containing 10% FBS, 100 U / mL penicillin-streptomycin, 100 μg / mL hygromycin and 100 μg / mL Geneticin. TM When the cell density reaches 40% to 80% of the bottom area of ​​the culture dish, trypsin substitute TrypLE TM Express cell digestion solution was used for digestion and passage, and cells were passaged three times a week. (Note: The cell passage number used in the safety evaluation test was <55).

[1062] 2. Solution Preparation

[1063] 1) NMDG 60 Extracellular solution (in mM): 80 sodium chloride, 60 NMDG, 4 potassium chloride, 2 calcium chloride, 1 magnesium chloride, 5 polydextrose, 10 HEPES (adjusted to pH 7.4 with hydrochloric acid, osmotic pressure 289 mOsm / kg).

[1064] 2) NMDG 60 cell sealing solution (in mM): 80 sodium chloride, 60 NMDG, 4 potassium chloride, 10 calcium chloride, 1 magnesium chloride, 5 polydextrose, 10 HEPES (pH adjusted to 7.4 with hydrochloric acid, osmotic pressure 313 mOsm / kg).

[1065] 3) Chip filling solution (in mM): 140 sodium chloride, 4 potassium chloride, 5 polydextrose, 10 HEPES (pH adjusted to 7.4 with sodium hydroxide, osmotic pressure of 289 mOsm / kg).

[1066] 4) Standard external solution (in mM): 140 sodium chloride, 4 potassium chloride, 2 calcium chloride, 1 magnesium chloride, 5 polydextrose, 10 HEPES (adjust pH to 7.4 with sodium hydroxide, osmotic pressure 298 mOsm / kg).

[1067] 5) KF110 intracellular solution (in mM): 10 EGTA, 10 HEPES, 10 KCl, 10 NaCl, 110 KF2 (pH adjusted to 7.2 with KOH, osmotic pressure 280-300 mOsm / kg).

[1068] 3. Preparation of test compound solution

[1069] 1) Dissolve the test compound in DMSO and prepare a stock solution with a final concentration of 10 mM.

[1070] 2) The stock solution was diluted with DMSO in a 1:3 gradient to form three other intermediate concentration solutions, with concentrations of 3.33 mM, 1.11 mM, and 0.37 mM, respectively. The dilution operation was performed using an NMS Apricot Personal Pipettor pipetting workstation.

[1071] 3) Prior to the start of the experiment, the stock solution and intermediate solution of the test compound were diluted 1000-fold with NMDG 60 extracellular solution to produce a series of working solutions with concentrations of 20 μM, 6.66 μM, 2.22 μM, and 0.74 μM. Simultaneously, the 10 mM stock solution was diluted 166.67-fold with NMDG 60 extracellular solution to produce a 60 μM working solution. The DMSO content in the working solution was 0.2%-0.6% (v / v). (Note: During dosing, the working solution was added at a 1:1 volume ratio to the chip wells containing the same volume of NMDG 60 extracellular solution. Therefore, the actual dosing concentrations were 30 μM, 10 μM, 3.33 μM, 1.11 μM, and 0.37 μM, with a final DMSO content of 0.1%-0.3%).

[1072] 4) After preparing the working solution, visually inspect it for precipitation or turbidity. If so, this may be due to poor solubility of the compound in physiological solutions. Further sonication in a water bath for 30 minutes may be recommended to improve solution clarity.

[1073] 5) Determine the potential inhibitory effect of the test substance on hERG channels at five concentrations of 30 μM, 10 μM, 3.33 μM, 1.11 μM, and 0.37 μM, fit the dose-effect curve, and calculate the corresponding IC 50 .

[1074] 4. Test operation

[1075] 4.1 Preparation before the test

[1076] 1) Run "Home All Axes" on the SyncroPatch 384i system to calibrate the robot arm.

[1077] 2) Run the "LH_Startup" method to clean the instrument and fill the tubing with intracellular solution before the experiment begins.

[1078] 3) Place the prepared NMDG 60 extracellular solution and compound working solution in the corresponding positions on the instrument, and the experiment is ready.

[1079] 4.2 Cell treatment

[1080] 1) Take the adherent cells from two T175 culture flasks and discard the upper layer of culture medium.

[1081] 2) Rinse twice with 8 mL of phosphate buffered saline containing 2 mM EDTA using a 10 mL pipette at room temperature to remove excess culture medium.

[1082] 3) Add 3 mL of TrypLE to the culture flask TM Express, gently shake to cover the entire cell surface with solution.

[1083] 4) Remove half of the digestion solution so that only a thin layer remains on the cell surface.

[1084] 5) Incubate the cells at 37°C for 8-10 minutes. Gently shake the cells under a microscope to observe their floating state. Stop incubation until the cells are completely digested.

[1085] 6) Prepare 10 mL of F-12 (HAM) medium containing 15 mM HEPES in a 50 mL centrifuge tube and add 10 mL of Standard External Solution to create a 1:1 mixture. Add 3 mL of this mixture to each culture flask and incubate in a refrigerator at 4-8°C for 5 minutes to terminate digestion.

[1086] 7) Use a pipette to gently blow the cells 3-5 times to disperse the cells and transfer them to a 10 cm cell culture dish.

[1087] 8) Count the cells using a Countess cell counter and dilute the cells with cold Standard solution to ensure a final density of 5-7.5*10 5 cells / mL.

[1088] 9) Transfer the diluted cell suspension into a 10 cm low-adsorption cell culture dish and incubate at 4-10°C for 10 minutes.

[1089] 10) Gently blow the cells to mix them evenly. Transfer the cells to the SyncroPatch 384i system's dedicated Teflon plate and place it in the cell incubation tank of the automated patch clamp system. Incubate at 15°C and 200 rpm for 30 minutes before starting the experiment.

[1090] 4.3 Recording electrophysiological signals using the SyncroPatch 384i system

[1091] 1) The chip was filled with chip filling solution, and the bottom was filled with KF110 intracellular solution containing 15 μM aescin as a perforating agent to form the initial internal and external liquid environments on both sides of the chip and compensate for the junction potential.

[1092] 2) Add the cell suspension to the chip and apply a gripping pressure of -150 mBar to allow the cells to adhere to the microwells at the bottom of the chip, with each microwell containing only a single cell. The bottom of the cell is now exposed to the intracellular fluid on the other side of the chip. The pressure should be maintained at -50 mBar throughout the experiment to prevent the cells from falling out of the microwells.

[1093] 3) Add NMDG 60 cell sealing solution, set the clamping potential to -90mV, and compensate the slow capacitive current C under this condition. slow and cell membrane capacitance.

[1094] 4) Set the clamp voltage to -90mV for 500ms, the current sampling frequency to 500Hz, and the filtering frequency to 3kHz. The leakage current detection conditions are -90mV and a duration of 500ms.

[1095] 5) hERG current test method:

[1096] A 4.8-second depolarization was applied to depolarize the membrane potential from -90 mV to +30 mV. A repolarizing voltage was then applied momentarily to reduce the membrane potential to -50 mV for 5.2 seconds to eliminate channel inactivation, allowing the observation of the hERG tail current. The peak value of the tail current was the magnitude of the hERG current. The sampling interval for this stimulation pattern was 15 seconds.

[1097] 6) hERG currents used to detect test compounds were recorded continuously for 120 seconds before administration to assess the stability of hERG currents generated by the test cells. Only cells that were stable within the acceptable range of the evaluation criteria were considered reliable for subsequent test results.

[1098] 7) Testing the inhibitory effect of the test compound on hERG current: First, wash the cells six times with NMDG 60 extracellular solution containing 0.1% DMSO. A stable hERG current is measured, which serves as the baseline. The baseline current is the average of five stable sampling points. After the hERG current stabilizes, a solution containing the test compound is perfused around the cells. Wait 10 minutes to allow the compound to fully interact with the cells, and the hERG current is recorded simultaneously. After the current stabilizes, five stable hERG current values ​​are read, and the average is taken as the final current value at the specified concentration. If a steady state is not reached within 10 minutes, the last five recorded current peaks are used as the reading. Cisapride is used as the positive drug in the experiment, and six concentrations are measured simultaneously to verify the stability of the test cells and the accuracy of the test results. After the compound is tested, 450 nM dofetilide is added to all test cells to completely inhibit their current, serving as a complete positive control for these cells.

[1099] For all test compounds including positive drugs, the inhibitory effects of multiple samples at different concentrations on hERG current were detected in at least two independent test wells (n>=2) to fit the IC 50 curve.

[1100] 4.4 Data quality control standards

[1101] Only data that meet the following criteria can be used for subsequent analysis:

[1102] 1) The initial sealing resistance is greater than 100MΩ;

[1103] 2) The series resistance is less than 25MΩ;

[1104] 3) The leakage current under the test voltage is less than 50% of the current value under this condition;

[1105] 4) The tail current is greater than the platform current of the prepulse, and the initial tail current value is greater than 150pA;

[1106] 5) The attenuation rate of the tail current is less than 30%.

[1107] 3. Data Analysis

[1108] The data is output by Data Control 384 software. Only data that meets the above standards can be analyzed according to the following steps:

[1109] 1) After perfusing the blank solvent or compound or positive drug gradient solution, the average value of the 5 consecutive current values ​​obtained was calculated and used as the "tail current size" 空白 ", "Tail current size 化合物 ” and “tail current size 阳性对照 ”;

[1110] 2) The current suppression percentage is calculated using the following formula:

[1111] The dose-effect curve was fitted and the IC was calculated using Graphpad Prism 8.0 software. 50 The results are shown in Table 6.

[1112] Table 6 Effects of the compounds disclosed herein on hERG potassium channel currents

[1113] Test Example 7: Pharmacokinetics test in mice

[1114] Experimental purpose: Using mice as test animals, the LC-MS / MS method was used to determine the drug concentration in plasma at different times after injection or oral administration of the test compound, to study the pharmacokinetic behavior of the compound in mice and evaluate its pharmacokinetic characteristics.

[1115] Experimental Methods: Six healthy Balbc female mice (purchased from Beijing Weitonglihua Laboratory Animal Technology Co., Ltd.) were randomly divided into two groups of three. One group received a tail vein injection at a dose of 5 mg / kg, while the other group received an oral administration at a dose of 30 mg / kg. Mice had free access to food and water throughout the experiment. The tail vein administration group used a complete solvent of 5% NMP + 10% PEG400 + 85% (10% solutol), while the oral administration group used a complete solvent of 5% NMP + 20% PEG400 + 75% (10% VETPGS). On the day of the experiment, the corresponding compound was prepared and administered via a single tail vein injection of 5 ml / kg to the animals in the tail vein group; the oral administration group received a single oral injection of 10 ml / kg to the animals in the oral group. Animals were weighed before administration, and the administration volume was calculated based on their body weight. Samples were collected from the intravenous group at 0 (pre-dose), 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours. Samples were collected from the oral group at 0 (pre-dose), 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours. Approximately 100 μL of whole blood was collected via the jugular vein at each sampling time point for plasma preparation, which was stored at 80°C.

[1116] A 10 μL mouse plasma sample was taken and protein precipitated with 150 μL of acetonitrile (containing the internal standard verapamil, purchased from Sigma). After vortexing for 5 minutes, the sample was centrifuged for 5 minutes (14,000 rpm, 4°C). The supernatant was diluted 2-fold with water containing 0.1% formic acid (v / v) and quantified using an LC-MS / MS system (AB Sciex Triple Quad 6500+). A standard curve and quality control samples using female Balbc mouse plasma were also used for sample concentration determination. For the 20x diluted sample, 2 μL of the sample was added to 38 μL of blank mouse plasma. After vortexing for 1 minute, protein precipitation was performed with 600 μL of acetonitrile (containing the internal standard verapamil, purchased from Sigma). The remaining processing steps were the same as for the undiluted sample.

[1117] Drug concentrations in plasma samples were determined using LC-MS / MS, with a minimum detection limit of 1 ng / mL. All animals were euthanized by CO2 anesthesia after the final plasma sample was collected. Plasma concentrations and corresponding pharmacokinetic parameters were calculated using a non-compartmental model using Phoenix WinNonlin (version 8.3.4) pharmacokinetic software. The results are shown in Table 7:

[1118] Table 7: Pharmacokinetic properties of the compounds of the present disclosure in mice

Claims

1. A compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, in, Ring A is selected from Y1, Y2, Y3 and Y4 are independently selected from CR a or N; R a is selected from H, halogen, OH, NH2, CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkyl-NH-, (C1-C6 alkyl)2-N-, C3-C6 cycloalkyl or 4-7 membered heterocyclyl; k is selected from 0 or 1; R1, R2, R3 and R4 are independently selected from H, F, CF3, CH3, cyclopropyl or oxetanyl; or R1 and R2 together with the C atom to which they are attached form a cyclobutyl group, which is optionally substituted with F, CN, CH3 or -OCH3; or R1, R2, R3 and R4 together with the atom to which they are attached form a phenyl group, which is optionally substituted with halogen, CH3 or CN; R5 and R6 are independently selected from H, C1-C6 alkyl, C3-C6 cycloalkyl or 4-7 membered heterocyclic group, wherein the C1-C6 alkyl, C3-C6 cycloalkyl or 4-7 membered heterocyclic group is optionally replaced by R 5a or R5 and R6 and the N atom to which they are connected together form a 5-7 membered heterocyclic group, wherein the 5-7 membered heterocyclic group contains at least one N atom and one O atom, and the 5-7 membered heterocyclic group is optionally substituted by a C1-C6 alkyl group; R 5a is selected from OH, C1-C6 alkyl, C3-C6 cycloalkyl, 4-7 membered heterocyclyl or -SO2CH3, wherein the OH, C1-C6 alkyl, C3-C6 cycloalkyl, 4-7 membered heterocyclyl or -SO2CH3 is optionally replaced by R 5b replace; R 5b is selected from halogen, OH, CN, C1-C6 alkyl, C1-C6 alkoxy or C1-C6 haloalkyl; R7 and R8 are independently selected from H, deuterium, C1-C6 alkyl or C1-C6 haloalkyl, or R7 and R8 and the C atom to which they are attached together form a C3-C6 cycloalkyl or a 4-7 membered heterocyclic group; R9 and R 10 Independently selected from H, F, CH3, CF3 or cyclopropyl; The conditions are: (i) R5 and R6 are not (ii) when R5 and R6 together with the nitrogen atom to which they are attached form a 5-7 membered heterocyclic group, Not for 2. The compound according to claim 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein Y1, Y2, Y3, and Y4 are all selected from CH; or Y1 is selected from N, and Y2, Y3, and Y4 are independently selected from CR a ; or Y1 is selected from N, Y2 and Y3 are selected from CH, and Y4 is selected from CR a ; or, Y4 is selected from N, and Y1, Y2, Y3 are independently selected from CR a ; Or, Y4 is selected from N, and Y1, Y2, and Y3 are all selected from CH.

3. The compound according to claim 1 or 2, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein R a is selected from H, CN, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl; or, R a is selected from H, CN, C1-C6 haloalkyl or C3-C6 cycloalkyl; or, R a is selected from H, CN, CHF2, CF3, OCH3 or cyclopropyl; or, R a is selected from H, CN, CHF2, CF3 or cyclopropyl; or, R a is selected from H, CN, CF3 or cyclopropyl; or, R a is selected from H, CF3 or cyclopropyl; or, R a is selected from H or cyclopropyl; or, R a Selected from cyclopropyl.

4. The compound or stereoisomer thereof or pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein R6 is selected from H, and R5 is selected from C1-C6 alkyl, C3-C6 cycloalkyl or 4-7 membered heterocyclyl, wherein the C1-C6 alkyl, C3-C6 cycloalkyl or 4-7 membered heterocyclyl is optionally replaced by R 5a or, R6 is selected from H, and R5 is selected from CH3, CH2CH3, cyclopropyl, cyclobutyl or oxetanyl, wherein the CH3, CH2CH3, cyclopropyl, cyclobutyl or oxetanyl is optionally replaced by R 5a or, R6 is selected from H, and R5 is selected from CH3, CH2CH3 or cyclobutyl, wherein CH3, CH2CH3 or cyclobutyl is optionally replaced by R 5a or, R5 and R6 and the N atom to which they are connected together form Said Optionally substituted with C1-C6 alkyl; or, R5 and R6 together with the N atom to which they are attached form Said Optionally substituted with C1-C6 alkyl; or, R5 and R6 together with the N atom to which they are attached form 5. The compound according to any one of claims 1 to 4, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein R 5a is selected from OH, C1-C6 alkyl, C3-C6 cycloalkyl or SO2CH3, wherein the OH, C1-C6 alkyl, C3-C6 cycloalkyl or -SO2CH3 is optionally replaced by R 5b Replace; or, R 5a is selected from OH, CH3, CH2CH3, cyclopropyl, cyclobutyl or SO2CH3, wherein the OH, CH3, cyclopropyl, cyclobutyl, CH2CH3 or SO2CH3 is optionally replaced by R 5b Replace; or, R 5a is selected from OH, CH3, cyclopropyl or cyclobutyl, wherein the OH, CH3, cyclopropyl or cyclobutyl is optionally replaced by R 5b replace.

6. The compound according to any one of claims 1 to 5, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein R 5b is selected from F, OH, CN, CH3, OCH3, CF3 or CHF2; or, R 5b is selected from F, OH, CN, CH3, OCH3 or CF3; or, R 5b Selected from CH3, OH, OCH3 or CHF2.

7. The compound or stereoisomer thereof or pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein R6 is selected from H, and R5 is selected from Alternatively, R5 and R6 together with the N atom to which they are attached form Alternatively, R6 is selected from H, and R5 is selected from Alternatively, R5 and R6 together with the N atom to which they are attached form 8. The compound or stereoisomer thereof or pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, wherein k = 0, R1 and R2 are independently selected from H, F, CF3, cyclopropyl or Alternatively, k = 0, R1 is selected from H or F, and R2 is selected from H, F, CH3, CF3, cyclopropyl or Alternatively, k = 0, R1 is selected from H or F, and R2 is selected from F, CH3, CF3, cyclopropyl or or R2 is selected from CF3, cyclopropyl or or R2 is selected from CF3 or cyclopropyl; or k=0, R1 is F and R2 is selected from CF3 or cyclopropyl; or k=0, R1 is H and R2 is selected from cyclopropyl or or R2 is selected from cyclopropyl; or, k=0, R1 and R2 and the C atom to which they are connected together form Alternatively, k = 0, R1 and R2 together with the C atom to which they are connected form Alternatively, k = 0, R1 and R2 together with the C atom to which they are connected form 9. The compound or stereoisomer thereof or pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, wherein k=1, and R3 and R4 are independently selected from H or F, or R3 is H and R4 is F; or, k=1 and R1, R2, R3 and R4 and the C atom to which they are connected together form Alternatively, k = 1 and R1, R2, R3 and R4 together with the C atom to which they are attached form 10. A compound or a stereoisomer thereof or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 9, wherein R7 or R8 is independently selected from H, deuterium, CH3 or CF3, or R7 and R8 together with the C atom to which they are attached form a cyclopropyl group; or, R7 and R8 are independently selected from H or CH3; or, R7 and R8 are both H; or R7 is H and R8 is CH3.

11. The compound according to any one of claims 1 to 10, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein R9 is selected from H or F; or R9 is H.

12. The compound according to any one of claims 1 to 11, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein R 10is selected from H, CH3, CF3 or cyclopropyl; R 10 is selected from H, CH3 or CF3, or R 10 Selected from CH3 or CF3.

13. The compound or stereoisomer thereof or pharmaceutically acceptable salt thereof according to any one of claims 1 to 12, which is a compound of formula (II) or a stereoisomer thereof or pharmaceutically acceptable salt thereof, in, Y1, Y2, Y3, Y4, R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10 and k is as defined in any one of claims 1 to 12, provided that: (i) R5 and R6 are not and (ii) when R5 and R6 together with the N atom to which they are attached form a 5-7 membered heterocyclic group, Not for 14. The compound or stereoisomer thereof or pharmaceutically acceptable salt thereof according to any one of claims 1 to 12, which is a compound of formula (III) or a stereoisomer thereof or pharmaceutically acceptable salt thereof, in, Y1, Y2, Y3, Y4, R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10 and k is as defined in any one of claims 1 to 12, provided that: (i) R5 and R6 are not and (ii) when R5 and R6 together with the N atom to which they are attached form a 5-7 membered heterocyclic group, Not for 15. A compound selected from one of the following compounds or its stereoisomers or pharmaceutically acceptable salts thereof:

16. A pharmaceutical composition comprising the compound according to any one of claims 1 to 15 or its stereoisomer or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

17. A method for treating or preventing a disease or condition mediated by Cbl-b in a mammal, comprising administering to the mammal, preferably a human, in need thereof, a therapeutically effective amount of the compound or stereoisomer thereof or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 15 or the pharmaceutical composition according to claim 16, wherein the disease or condition mediated by Cbl-b is preferably a tumor or an autoimmune disease.

18. A compound according to any one of claims 1 to 15 or a stereoisomer thereof or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to claim 16 for use in preventing or treating a disease or condition mediated by Cbl-b in a mammal, preferably a human being, wherein the disease or condition mediated by Cbl-b is preferably a tumor or an autoimmune disease.

19. Use of the compound or stereoisomer or pharmaceutically acceptable salt of any one of claims 1 to 15 or the pharmaceutical composition of claim 16 in the preparation of a medicament for treating or preventing a disease or condition mediated by Cbl-b in a mammal, preferably a human being, wherein the disease or condition mediated by Cbl-b is preferably a tumor or an autoimmune disease.

20. Use of the compound according to any one of claims 1 to 15 or its stereoisomer or pharmaceutically acceptable salt thereof or the pharmaceutical composition according to claim 16 for treating or preventing a disease or condition mediated by Cbl-b in a mammal, preferably a human being, wherein the disease or condition mediated by Cbl-b is preferably a tumor or an autoimmune disease.

Citation Information

Patent Citations

  • 3-substituted piperidine compounds for Cbl-b inhibition and use of Cbl-b inhibitors in combination with cancer vaccines and / or oncolytic viruses

    CN114364667A

  • Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation

    WO2009053799A1

  • Inhibitors of CBL-b and methods of use thereof

    WO2019148005A1

  • Polycyclic compound as cbl-b inhibitor

    WO2023072273A1